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FOREWORD 
/
t is with great pleasure that I present this scientific monograph on the dynamic 
modelling of drug use. This publication provides a rich overview of the application 
of mathematical and statistical techniques in the field of drug use and it clearly 
points to the further potential for using models for analysing and understanding drug 
data. The monograph reveals a growing interest on the European and international 
stages for adding such complementary quantitative approaches to the already wide 
array of tools in the social and life sciences. In a field that is quickly moving and changing 
appearance, within the no-less dynamic European context, I believe that dynamic 
modelling will help decision-makers and scientists to better understand hidden processes 
of drug use, epidemiological trends and their relationships, and thus will contribute to 
sound decision-making on policies and interventions. 
This monograph reflects the efforts and expertise of many people. Above all, I want to 
thank the experts who committed their time and work to discuss the future of modelling 
drug use at two meetings in York, UK, in May and November 1997, and at a seminar in 
Lisbon, Portugal, in May 1998. In particular I would like to thank: Azzedine Boumghar 
Sandeep Chawla; Catherine Comiskey; Almudena De Silva Rivera; Martin Donoghoe 
Martin Frischer; Christine Godfrey; Richard Hartnoll; Gordon Hay; Mathew Hickman 
Johannes Jager; James Kahan; Ludwig Kraus; Mirjam Kretzschmar; Leif Lenke; Ed Leuw 
Roberto Mollica; Steve Parrot; Maarten Postma; Peter Reuter; Carla Rossi; Gianpaolo 
Scalia Tomba; Roland Simon; Matthew Sutton; Colin Taylor; Gernot Tragler; Lucas 
Wiessing; and Philip Young. Special thanks are due to: Vanessa Waby; Monica Blum; 
Sonia Collaço; and Manuela Gomes for their organisational help. 
Georges Estievenart 
Executive Director 
EMCDDA 

GENERAL 
INTRODUCTION 

G E N E R A L I N T R O D U C T I O N 
Lucas Wiessing and Richard Hartnoll 
One of the central tasks of the European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) is to analyse and make sense of data on drug use and its consequences in 
the European Union. This is a basic prerequisite for developing rational interventions 
and policies in response to drug problems. In this monograph, the potential role of 
modelling in this task is explored. Modelling is a way to simplify and understand complex 
processes or structures and is usually performed using mathematical and statistical 
techniques. It can increase the value of available data, for example by analysing key 
dimensions of large or complicated data sets. Modelling can also be used to estimate 
missing data, to forecast trends and to carry out virtual experiments on the likely outcomes 
of different scenarios. Drug use and problems involve complex information, and 
modelling may also help to enhance the interpretation of available but scarce data and 
to increase the understanding of unobservable processes and relationships. It can serve 
especially to describe the dynamics of drug use at a more abstract or aggregated (local, 
national, international) level. 
It is this high level of abstraction that may make modelling somewhat difficult to 'sell', 
especially to those professionals who are nearer to the individual drug user, as the 
results of modelling studies seldom relate to individual experiences. It is exactly this 
abstraction, however, that gives modelling a strength of its own, by detecting common 
features within available data sets or by clarifying the relationships between more abstract 
concepts such as 'law enforcement', 'price' and 'demand for drugs'. This often results 
in more generalisable knowledge than can be achieved through direct observation, 
although of course data collected through direct observation form an indispensable 
basis for building any useful models. 
Several problems arise when trying to analyse data in a way that is relevant to policy 
questions. Where there is a large amount of data covering different aspects of a complex 
situation it is hard to identify and analyse the key dimensions and relationships within 
the data. In other situations, despite a lack of data, there are a number of alternative 
scenarios of how different policy options may affect drug problems, and policy decisions 
will anyway be taken even if not well grounded on empirical knowledge. Modelling 
techniques, such as scenario analysis, can then at least give some formal guidance. 
To explore the potential for using modelling approaches in the drugs field, the EMCDDA 
organised two meetings of modellers and a larger seminar with other European drug 
experts during 1997 and 1998. This monograph contains a number of reviews of different 
aspects of modelling work in the drugs field written by the participating experts. It aims 
to provide a broad overview of quantitative approaches to understanding drug data as 
a knowledge base and a first step towards more focused modelling projects. 
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Structure of the monograph 
Part I of the monograph is introductory in nature. In Chapter 1, the use of modelling is 
discussed for macro-level, rather than individually based, epidemiology, and models 
are presented as complementary tools to direct empirical observation of data or 
indicators. A distinction is made between statistical models that are inductive and rely 
heavily on data, and mathematical models that are more deductive and serve to explore 
potential relationships in a more theoretical manner. It is stressed that the interpretation 
of modelling results is not straightforward and should take careful account of the validity 
of the model and its assumptions. A number of broader issues are discussed that either 
can be investigated with models or should be taken into account before modelling can 
be useful, notably a common understanding of policy objectives and case definitions. 
In Chapter 2, an overview is provided of the discussions and conclusions of the modelling 
experts who contributed to the monograph. The chapter starts with an overview of 
different policy questions. Varying ways of categorising models are then discussed, and 
the chapter concludes with an account of discussions about different priorities for future 
developments in modelling across Europe based on the seminar held in Lisbon in May 
1998. 
Three examples are given in Part II of models that integrate available data sources or 
indicators at macro level to describe and predict the spread of problem drug use in 
time and space. In Chapter 3, a geographic model is presented designed to predict the 
spread of drug use at macro level from larger cities to smaller towns. It is based on a 
small number of parameters such as those used in models of the spread of infectious 
diseases (length of epidemic cycle, probability of infection as a function of distance) 
and linked to a geographic information system (GIS) to enable the results to be visualised 
in maps. In Chapter 4, the use of data on trends is discussed in an interactive way, 
allowing for interdependences between production processes of the observed data. 
The importance is stressed of using simple aggregate models for studying policy options 
rather than complex models of individual spread. An overview is provided of classical 
and new mathematical models that use routine data, and examples of their application, 
to estimate the extent of problem drug use in different countries. Chapter 5 follows a 
similar approach to estimate trends and interdependences in indicators based on routine 
drug data. The model is simultaneously validated by new data while estimating and 
forecasting variations in problemsand need for services over time. Illustrative examples 
are set out for describing how such a model could be used to assess the effectiveness 
and efficiency of new drug laws and therapeutic approaches. 
The chapters in Part III take as their starting point available standard modelling techniques 
rather than available drug data sources or indicators. In Chapter 6, there is discussion 
of a method that has been very useful in generating predictions of AIDS and HIV, the 
back-calculation method. Based on discussions in the expert meetings held in York, it is 
proposed to use back calculation to estimate incidence or rates of initiation of heroin 
use from routine drug-treatment data. Knowing incidence rates would enable more 
direct evaluation of activities that aim to prevent drug users from starting to use heroin 
than is possible with prevalence estimates. In Chapter 7, compartmental models are 
discussed. As an example, a classical compartmental model for the spread of measles is 
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presented, illustrating the basic concepts of the infectious spread of a phenomenon 
which can be described quite satisfactorily with only a few parameters. The use of 
compartmental models is recommended for analysing drug careers, as has been done 
for several diseases, as well as for studying the processes that lead young people to 
initiate drug use. In Chapter 8, different dynamic models are discussed to estimate 
prevalence of drug use by describing the unobservable underlying processes. A series 
of basic issues are highlighted, among others the time frame and geographic boundaries 
of a prevalence-estimation exercise, the types and amounts of drugs used and the 
relation between definitions of drug use and the use of data sources. System-dynamic 
models are also presented, which have mostly been used to describe macro-scale drug 
phenomena and national policy scenarios, such as drug imports, drug treatments and 
law enforcement. They are relatively well suited for macro-level analysis as they model 
flows as aggregate measures rather than keeping track of individual persons or events. 
In Chapter 9, the use of factor analysis is discussed to confirm or explore underlying 
latent variables from observed variables. Four classes of observable variables are 
presented: frequency of use; amount used; amount of disruptive use (e.g. use at school 
or at work); and subjective perception of problems with use. It is argued that working 
with composite latent variables is often nearer to reality than interpreting use of each 
drug separately, as most drug users are poly-drug users and there are different and 
combined ways of using (e.g. moderate or heavy alcohol use in combination with 
other drugs). Structural equation modelsand linear structural relationship (LISREL) models 
that allow more flexibility but also introduce more complexity are also reviewed. The 
authors conclude that these models are difficult to manage and of lesser practical value, 
although they are potentially very useful to fit underlying theoretical concepts into 
models of drug prevalence. 
Part IV centres around modelling health consequences of drug use rather than types of 
models. In Chapter 10, the main disease parameters needed to model infectious diseases 
in injecting drug users are discussed. Concepts from modelling studies are introduced, 
such as 'core groups' and 'mixing patterns', that have proved crucial to understanding 
the spread of disease and that might prove equally important in understanding the 
spread of drug use. A picture of the historical development of sexual-transmission models 
is given and several classic models of infectious diseases among drug users are reviewed. 
In Chapter 11, a structured overview of how to develop multinational scenario analyses 
is given together with an example for AIDS. In this approach, different disciplines, 
including mathematical modelling, are integrated to develop insight and a basic 
description of a problem, as well as to forecast the most probable future course and 
alternative scenarios including the estimated effect of interventions. It is argued that 
scenario analysis is well suited to analysing drug problems, as these are serious and 
important, complex, multinational, multidisciplinar/ and in need of (quantified) policy 
decisions. Scenario analyses are closely related to cost-effectiveness analyses for the 
allocation of health-care resources and both types of analysis can be performed jointly. 
Part V of the monograph addresses economic aspects and modelling, starting with a 
focus on estimating drug-related health-care costs (Chapter 12). In general, a costing 
model aims to assess current and to project future health-care needs and financial 
requirements. The main step is to link an epidemiological sub-model which describes 
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the future development of disease to specifically formatted information on health-care 
needs (e.g. lifetime patient costs). The approach can be incidence- or prevalence-
based. The former links estimated lifetime health-care needs and their costs (a staged-
disease model of natural history is necessary) to epidemiological estimates of incidence 
in a certain year. This gives the potential future costs that can still be averted by 
prevention. The latter links current health-care needs and costs per patient (estimates 
of the prevalent patient mix are needed according to the stage of disease) to estimates 
of prevalence. This gives the health-care needs and costs of current disease with its 
immediate budgetary implications. It is recommended to extend the extensive existing 
work on HIV/AIDS to hepatitis as a first step, and subsequently to include other relevant 
drug-related diseases and consequences. In Chapter 13, the potential for modelling 
economic drug markets is described. It is argued that studies at individual level have 
the greatest potential, but the macro level is what policy-makers are most interested in 
and where most data are available. Studies at macro level (e.g. effect of enforcement), 
however, have not resulted in relevant outcomes so far, most probably due to a too-
high level of aggregation. For a good markets study, it is recommended that sufficient 
resources be available for collecting high-quality data on consumption, prices and 
purities. 
It is hoped that this monograph, and the newly formed European network of modellers 
behind it, will prove to be significant in stimulating the application of quantitative 
techniques to drug data. As good and comparable data on drugs are still rather scarce 
in Europe, progress is not expected to be very rapid. However, with increasing work on 
improving data sources and growing understanding of the basic knowledge needed for 
sound policy-making, mathematical and statistical modelling form an indispensable 
part of the set of tools that are available to understand and prevent the problems caused 
by the use of drugs. 
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WHAT IS MODELLING 
AND HOW CAN IT BE 
USED? 

INTRODUCTION 
M odelling can be a valuable complementary tool for policy decisions and can be especially useful at levels of larger aggregation (national, international). It is often, however, not well understood, both because non-modellers may have 
little understanding or interest in the mathematical presentations of modellers, and 
because modellers may have little understanding or interest in the practical consequences 
of their work and its relation to other disciplines, often being more interested in theoretical 
mathematical advances. Part I aims to discuss the potential for modelling in drug 
epidemiology in a manner accessible to non-modellers. 
In Chapter 7, the authors discuss modelling approaches together with empirical data 
collection or in other words 'indicators' of drug use and problems. The-emphasis is on 
the use of modelling and indicators as complementary tools for developing evidence-
based policy decisions. Working at the macro level adds further complexity as data 
quality is often low. This affects both the use of indicators, which permit only limited 
interpretation and need to be complemented with studies, and modelling, of which the 
validity of results often crucially depends on the quality of data. Some general aspects of 
modelling are discussed, such as the differences in interpreting results from data-driven 
and more theoretical models. Models and indicators can generate knowledge for decision-
making, but some general problems remain. These include lack of clarity in case definition 
and in the objectives of drug policies, particularly the distinction between non-problem 
and problem drug use. Lack of knowledge of the basic mechanisms of the spread and 
progression of drug use and problem drug use hinders and challenges modelling. Legal 
and moral dimensions also strongly hamper the formulation of clear scientific theory in 
several ways, of which the most obvious is their influence on basic data availability and 
quality 
Chapter 2 presents the discussions held at two meetings in York, UK, in 1997 and at a 
larger seminar in Lisbon, Portugal, in May 1998. A central issue when discussing the use 
of modelling is to start from the questions that should be answered rather than from the 
methods and techniques used. Questions by policy-makers tend to be simple and 
straightforward ('how many drug users are there?', 'what works?') but are not always 
easily answered. To be policy-relevant, questions and study objectives should in general 
relate to interventions or policy options, for example, what is the cost-effectiveness of 
one intervention compared to another? However, basic descriptive data must be available 
and may sometimes be generated with other types of models. Models have two broad 
types of application: the more quantitative estimations; and the more qualitative 
understanding of dynamic processes and relationships. 
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CHAPTER 1 
EPIDEMIOLOGY OF DRUG USE AT MACRO LEVEL: 
INDICATORS, MODELS AND POLICY-MAKING 
Lucas Wiessing, Richard Hartnoll and Carla Rossi 
Indicators and models may help in studying and understanding the epidemiology of 
drug use at macro level. Indicators of drug use are mostly based on available routine 
data and give indirect information on prevalence and trends over time. They can be 
used to cover large geographic areas with a limited budget; however, they are usually 
limited in quality and scope. Modelling is based on mathematical theory and can be 
used to integrate data from different indicators and other sources. It can be used to 
estimate prevalence and incidence or to increase understanding of drug processes by 
simulating experiments that are not possible in real life. The interpretation of modelling 
results, however, crucially depends on sufficient understanding of their basic assumptions 
and limitations. A whole continuum of modelling may exist, depending on the availability 
and use of data, from empirical analyses with high applicability to real life to theoretical 
hypothesis-generating exercises based on many assumptions. 
Compared to other areas, drug-use epidemiology has still made little use of modelling, 
partly because good-quality data are still scarce, but work on improving indicators and 
other data is in progress. In the drugs field, the application of evidence-based approaches 
is still hampered by the lack of a common understanding of priorities for study and 
intervention, a lack of knowledge of mechanisms of spread and progression to drug 
problems, and legal and moral discourses. Indicators and models are complementary 
and increasingly important tools for epidemiology at macro level and may help to 
clarify some of these issues. Although quality of data and thus possible inferences are 
often much more limited than in in-depth empirical studies, macro-level assessments 
are necessary to guide national and international policy decisions. 
One problem of drug epidemiology at national or international (macro) level is the 
sheer scale of activities undertaken. While data on drug use can be collected directly 
within a city or small region, no funding is usually available for massive studies covering 
large areas or a number of countries. Even if it were possible, setting up such a study 
would not be straightforward, given important background differences between countries 
and regions and the many stakeholders involved. Data available at macro level are 
often aggregated rather than individual-level data, based on routine sources, with all 
their limitations of analysis and interpretation. The question is therefore (how) can 
valid inferences still be made at macro level? This chapter briefly introduces indicators 
19 
WHAT IS MODELLING AND HOW CAN IT BE USED? 
and modelling, two different but complementary tools that are receiving increasing 
attention for policy-making at macro level, and points to some still unresolved problems 
in the drugs field that interfere with such evidence-based approaches. 
Indicators 
Epidemiologists aim at describing the spread of disease in a population to provide 
evidence for public-health-oriented interventions and policies. Basic epidemiological 
measures are prevalence (all existing cases at a certain moment in time) and incidence 
(all newly occurring cases in a certain time period). To understand causal factors that 
lead to disease, a risk-factor analysis is usually performed by comparing individual cases 
with non-cases. In drug epidemiology it is usually difficult to determine prevalence and 
incidence, due to the 'hidden' nature of drug use. Normal sources of data such as 
medical services may be incomplete while standard tools such as household surveys 
may give biased results, due to social stigma and low social integration of heavy drug 
users. Working at macro level adds to these problems the difficulty of collecting 
comparable, quality data from a large number of sources and countries. As a result, 
additional methods are necessary to estimate or at least give some idea of prevalence, 
incidence and trends in drug use over time. 
In domains like public health and the economy, the concept of indicators has been 
developed for large-scale data collection and fordifficult-to-measure phenomena. Rather 
than aiming at exact prevalence and incidence figures, indicators are based on available 
or routine data on disease, risk factors or consequences, and may provide indirect 
information on the exact magnitude of and trends in the disease. Public-health indicators 
rely on data sources such as mortality registers, population censuses, routine health-
service records, epidemiological surveillance data, sample surveys or disease registers. 
The idea is to select from these sources those variables that fulfil certain quality 
requirements (such as validity, reliability, etc.) to measure health and changes in health 
(WHO, 1999). 
In the field of drug use, work on indicators was started in London in the early 1970s, 
taken to European multi-city level by the Pompidou Group of the Council of Europe, 
further developed at European multinational level by the EMCDDA and is currently 
being implemented at global level by the United Nations International Drug Control 
Programme (UNDCP) (Hartnoll, 1991; Hartnoll et al., 1989; EMCDDA, 2000). There 
is not much choice in available data on drug use, and pragmatic reasons have played 
an important role in the choice of indicators. Currently five so-called 'key indicators' 
are being implemented in the European Union. These are 'general population and 
school surveys', 'estimates of problem drug use', 'data from drug-treatment services', 
'drug-related deaths' and 'drug-related infections' (HIV and hepatitis Β and C). Standards 
have been developed and current work is focused on collecting the data and overcoming 
practical problems in data quality and comparability. Other indicators are at an earlier 
stage of development, such as indicators of social problemsand crime, data from hospital 
and emergency rooms and data from the youth and dance scenes. 
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How to interpret drug-indicator data is not always straightforward. Sometimes it is 
simply assumed that the combined information from a set of indirect indicators reflects 
trends in the prevalence of problem drug use. However, indicator data may show 
fluctuations unrelated to prevalence, for example, due to changes in heroin supply or 
decreases in risk behaviour. Therefore indicators such as drug-treatment data, drug-
related mortality and drug-related infectious diseases are also very important for their 
own sake and for evaluating interventions directed at each of the specific sub-populations 
at risk, rather than simply for following trends in 'problem drug use'. 
Indicator data are often also of limited quality, due to their large coverage and routine 
nature, and it is dangerous to rely solely on indicators. Most routine data are not suitable 
for giving rapid insight into changing trends in problem use. For instance, the average 
latency time of five to eight years between first heroin use and first demand for treatment 
implies that treatment indicators are little suited to monitoring drug use in the non-
treated population (Rossi, 1999; Wiessing et al., submitted). To interpret trends such as 
an increase in drug-related deaths at national level, and to take appropriate measures, 
indicators should be complemented and validated by smaller in-depth studies. Regularly 
repeated, small-scale studies are also important for gaining insight into possible (changing) 
causes or risk factors and confounding factors of the observed trends, as in such studies 
much more background information can usually be gathered. Routine indicators and 
one-off studies might together give a more complete picture of a phenomenon such as 
problem drug use. Indicators provide lower-quality data but at low costs and with high 
geographical coverage, while local studies provide high-quality data from a more limited 
(often high-risk) area. 
Dynamic models 
Dynamic modelling originated from biology and infectious-diseases epidemiology 
(Anderson and May, 1992). Many of its more recent advances were also made in the 
infectious-diseases field, especially within AIDS research (Pasqualucci et al., 1998). 
Over the last 15 years, modelling developments have closely paralleled the increasing 
knowledge of the etiology and transmission of AIDS and other sexually transmitted 
diseases. During that period, modelling studies moved from very simple AIDS data 
extrapolations to highly complex transmission models with large sets of parameters. 
Modelling and empirical research on AIDS have also mutually informed each other on 
important concepts. While patient characteristics pointed to the existence of specific 
groups at increased risk, such as homosexual men and injecting drug users, dynamic 
modelling clarified the potential role of core groups (with high-risk behaviour and/or 
assortative - 'like-with-like' - mixing patterns and consequently high infection levels) 
in the overall transmission dynamics within a susceptible population (Kretzschmar et 
al., 1996). While the natural history of HIV infection was becoming clearer from cohort 
studies, modelling provided a means of clarification and simplification (e.g. by 
determining a number of discrete disease stages) and a basis for policy decisions (e.g. 
on treatment needs per stage) (Longini et al., 1989). The effect of possibly important 
biological parameters which could not easily be studied empirically were often postulated 
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from dynamic modelling work. For example, a simulation model could show that the 
very high level of infectiousness during the first weeks of HIV infection may determine 
most new infections in the population, putting the effectiveness of HIV screening as a 
prevention tool into question (Daar et al., 1991; Kretzschmar and Wiessing, 1998). 
For epidemiology at macro level, dynamic modelling can be a valuable complementary 
tool to following trends in indicators and other direct data analysis. Besides the more 
usual inductive or empirical methods of data collection and interpretation, where new 
insights follow from observation, dynamic modelling may often be nearer to a deductive 
approach, where new insights follow from theory. The use of the outcomes in real-life 
situations is sometimes quite limited and validation of the model assumptions to data 
can be very difficult. However, the importance of most types of dynamic modelling lies 
in the generation of theory that may provide a framework for practical decisions. 
It is not easy to define dynamic models, and to understand how they are used it may be 
helpful to compare them to the more familiar statistical models used for empirical data 
analysis, although even this difference is not clearcut. Most models consist of a set of 
mathematical equations, often in the form of a computer program, that describe a 
process (e.g. the spread of drug use) in a very simplified manner, and that can be used 
to understand the behaviour of that process. There may be a whole continuum of 
models between the extremes of pure empirical data analysis with statistical models 
and using mathematical or economic theory or dynamic models. Statistical modelling 
techniques, such as different types of regression analysis (generalised equations), factor, 
cluster and path analysis, often rely much more on data than, for example, many 
compartmental or system-dynamic models, which are often more theoretical. Dynamic 
models may rely more heavily on sometimes unproven assumptions, and may often be 
based on 'thin' data the quality of which is not certain, which makes it much more 
difficult to keep track of their validity. 
Figure 1: Some differences between statistical and dynamic modelling 
Statistical analysis/modelling Dynamic/mathematical modelling 
Inductive Deductive 
Data-driven, fewer assumptions Theory-driven, more assumptions 
<« ► 
Estimations, assessments 'Mind experiments', 'what if' 
Hypothesis testing Hypothesis generating 
Static analysis over time Dynamic, feedback loops 
Note: This scheme obviously does not fit all models. There are mathematical models that are very data-
driven and statistical models that are based on very little data. Also some statistical analysis is not 
static over time (e.g. time-series analysis, survival analysis) and deterministic mathematical models 
can be used for estimations. Many models, however, appear to fit this scheme. 
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Both extremes of the continuum are useful in, for example, drug epidemiology, but 
their use may be very different. Rigorous statistical data analysis, such as regression 
analysis based on individual data, is mostly not possible at macro level, but statistical 
models can often still suggest useful answers when there are gaps in data of a certain 
type. This can, for example, happen by imputing prevalence data (extra- or interpolation) 
from other moments in time or locations where more data are available, or by using 
other data sources and, if possible, adjusting for potential biases. This makes it possible 
to generate a result where no data were available, although again the interpretation 
must be undertaken with care. There is a clear need for this type of modelling at macro 
level, where good data often do not exist, at least in the drugs field. 
At the other end of the continuum, dynamic models can help in understanding a 
phenomenon, even if almost totally based on assumptions and with little or no data 
input. If the model is assumed to describe a process in real life sufficiently well, the 
behaviour of this process can be studied under different circumstances by varying 
parameter values and seeing the variation in outcomes. This semi-experimental situation 
is sometimes called 'what if' modelling, in other words, the question is what could 
happen under what circumstances if it is assumed that the process under study is well 
captured by the model. Modelling can thus provide a tool to simulate experiments that 
are not possible in real life for practical or ethical reasons. 
It is important to understand the differences between the various types of modelling 
and to interpret the results accordingly, either as 'scientific facts', 'theoretical hypotheses' 
or something in between, depending on the certainty of parameters and the validity of 
the basic model chosen. Modelling results may involve many unproven assumptions, 
may be based on data of unknown quality and the true scope for bias may be much 
larger than, for example, suggested by calculated confidence intervals. To understand 
the results and correctly interpret them it is indispensable to have at least some 
understanding of the assumptions behind the model. The limitations of the model 
should always be clearly stated and presented together with the results. However, even 
for specialists this is often difficult, and non-specialists may have no way of distinguishing 
valid results with important direct implications from academically interesting theory 
with little direct practical meaning. To prevent this type of problem it is important for 
modellers and other scientists to work together in multi-disciplinary teams. This is, 
however, only possible if the different disciplines have some understanding of each 
other's approaches and are prepared to acquire at least some knowledge of the other 
field. If such a collaboration exists, the modeller may generate 'meaning' from scarce 
data, and the topic expert (e.g. epidemiologist) can help interpret the validity of the 
results against his or her knowledge of real-life situations and data-quality issues. 
Within dynamic modelling different approaches are again possible. The starting point 
is often a relatively simple model that reflects the main elements and their relationships. 
However, the results are often criticised for not taking into account a possibly important 
variable. This may then subsequently be incorporated into the model and the model 
becomes more complex. This process may repeat itself resulting in highly complex 
models. Although these may resemble reality better than the simple models, it is often 
hard to keep track of what exactly happens and in practice they may not lead to better 
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or more valid results. As was the case in the AIDS field, the process of increasing 
complexity often directly reflects the state of the art of existing knowledge in the field. 
While some modellers attempt to incorporate as many parameters in their models as 
possible to increase the validity of their results, others prefer to work with simple models 
that can be easily understood. Simple models that succeed in giving new insights are 
often more influential (e.g. Kaplan and O'Keefe, 1989). Especially in the case of more 
complex models, sensitivity analysis is an important step. A sensitivity analysis looks at 
the influence of the different parameters on the modelling results by taking different, 
often extreme, values for these parameters. The model might then be found not to be 
sensitive to some of the parameters but very sensitive to others, which suggests how the 
model needs to be improved. The results of a complex modelling study can even be 
analysed applying statistical sampling techniques to the modelling results, as, for example, 
did Blower et al. (1991 ) in a study of HIV spread in New York. 
Figure 2: Two basic approaches to dynamic modelling 
'Simple' or Operational' models 
Less parameters/less data needs 
Less valid, more theoretical 
Complex transmission models 
Many parameters need estimation 
Nearer to reality, valid outcomes? 
Easier to use and understand 
Can be soived mathematically 
Cumbersome, hard to work with 
Often simulated 
An important question during the interpretation of modelling results is their intended 
use. Depending on the consequences, modelling results can be accepted either more 
or less conservatively. The same outcomes can be valid enough for publication in a 
high-level mathematical journal where the emphasis is on the methodological advances, 
while they may not be found sufficiently rigorous to be published in a high-level applied-
science (e.g. public-health) journal which focuses on the external validity of the results 
and their practical consequences. Even for applied use, however, the question is often 
whether it is better to have less valid results than no results at all, which often leads to 
accepting outcomes that may be less valid than would be desirable from a strictly 
scientific point of view. 
An example of the latter situation in drug epidemiology is prevalence estimation. 
Although sophisticated statistical models exist for local-level prevalence estimation of 
problem drug use, such as multi-sample capture-recapture with loglinear regression 
parameter estimation (Frischer et al., 1993), results are often not very clear due to data-
quality problems and the often wide confidence intervals, which may still severely 
underestimate uncertainty. At national level, geographic heterogeneity and low data 
availability make it often impossible to use these methods. Simple multipliers are being 
used with no possibility of calculating confidence intervals (EMCDDA, 1999) but at 
best of giving some qualitative indication of a plausibility range (Uhi and Seidler, 2000). 
24 
CHAPTER 1 
Still it is very important to have prevalence estimates at local and national level, which 
form a basis for a large variety of policy choices, and these low-quality estimates are in 
general accepted as the state of the art. Other examples can be found in forecasts of 
future developments and in scenario analyses, which by definition are unreliable and 
may prove wrong in time, but are still of such high value for policy-makers that they are 
widely used. 
Policy needs and problems using indicators and models 
Epidemiology is mostly an applied or problem-driven science, where much emphasis is 
placed on the policy relevance of new knowledge and studies. It may therefore be 
useful here to discuss briefly what are the possible needs of policy-makers. This is 
especially important for epidemiology at macro level, where the link with the needs of 
individual drug users may be much less obvious than, for instance, in specific treatment 
or outreach settings. 
The needs of a policy-maker may seem remarkably clear in general terms: to describe 
and understand a problem and follow trends over time; to design proper interventions; 
and to evaluate the results of interventions. In the case of drug use and its consequences, 
indicators and models may contribute to both a description and an understanding of 
the problem, while indicators are specifically suited to follow trends over time. Models 
may even help in designing and choosing proper interventions, for example, by assessing 
the cost-effectiveness of alternative options, although the basic knowledge of 'what 
works' (efficacy) needs to be assessed in carefully designed studies. Reality, however, 
seems harder than practice, and there is still little consensus among and between 
scientists, service providers and policy-makers about the most effective and relevant 
interventions, with opinions ranging from a total 'war on drugs' at one extreme to 
complete legalisation on the other. What is it that makes the drugs field seem so much 
more complex than would initially be assumed? The answer may partly be purely 
scientific/methodological, and partly lie in the interplay between science and policy. 
Some of the more methodological problems may also be a consequence of working at 
a high level of aggregation. Other problems relate to the lack of a clear case definition 
of a 'drug user', to lack of knowledge of the basic mechanisms of the spread of drug 
use, and lack of knowledge of progression into drug problems. 
First, using indicators at a macro scale, it is often not possible to use a clear case definition 
of addiction or dependence such as the Diagnostic and statistical manual (DSM) IV, or 
to use disease codes such as the international classification of diseases (ICD) due to the 
quality and limitations of routine data. Indicators such as survey data may give good-
quality information on lighter forms of drug use, but usually not on heavier patterns of 
drug use which cause most drug problems. Modelling techniques for prevalence 
estimation of problem drug use, such as capture-recapture, often rely on non-specialised 
data sources which have little information on drug use and thus do not permit using 
clear case definitions. A pragmatic solution may in that case be found by defining 
problem drug users as drug users that are in contact or in need of contact with health or 
social services, which, for example, in most European countries is mostly limited to 
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frequent heroin or amphetamine users. However, it is hard if not impossible to obtain 
more detail on the prevalence and patterns of problem drug use (e.g. breakdowns by 
type of drug) from these techniques and it is important that they are complemented by 
(expensive) local studies based on, for example, out-of-treatment recruitment of drug 
users. 
Second, much more knowledge is needed of the basic mechanisms of the spread of 
drug use and problem drug use or addiction. As long as no general consensus exists 
among scientists on what risk factors are the most influential, from the wide range of 
social, psychosocial and biological factors identified in different studies (Rhodes et al., 
1999), no good interventions can be expected. This lack of common understanding of 
a basic mechanism for the epidemiology of drug use also makes it difficult to reach 
consensus on results from modelling studies, contrary to more established fields as, for 
example, infectious-diseases epidemiology or the economy. Models of spread are often 
based on weak assumptions but can help to suggest the underlying processes. For 
instance, there is evidence that drug use often spreads as an infectious disease, in other 
words that the rate of new cases depends on the number of existing cases and the 
number of susceptible cases (Mackintosh and Stewart, 1979; De Alarcón, 1969). This 
may be understood in terms of each new drug user having a constant rate of initiating 
others. However, the role of supply factors (price of drugs, availability) and, unlike in 
the case of infectious diseases, the intentional marketing activities of drug dealers, are 
not well understood. Also, infectiousness (the probability of 'infecting' another person) 
may not be as constant as in a biological context and may depend on a range of unknown 
social factors. Unlike an infectious agent, the spread of drug use may be influenced by 
mass media, for example through developments in the music and fashion industries 
which may have contributed to the recent spread of ecstasy and other new synthetic 
drugs. 
Third, more work is still needed to clarify the natural history of progression to problem 
drug use. It may be less important to study what leads young people to experiment 
with illegal drugs, as this mechanism seems no different from experimenting with alcohol 
or tobacco at earlier ages (Kandel and Faust, 1975; Bauman and Phongsavan, 1999). It 
is, however, crucial to understand why some young people progress into frequent use 
of heroin while others never go beyond experimenting with cannabis. It may well be 
that this is mainly due to social factors, such as 'meeting the wrong friends'. It may also 
be that some people are genetically prone to addiction (Nestler, 2000) or continue 
using in order to 'self-medicate' negative moods and mental problems (Leshner, 1999). 
An infectious-disease type of modelling might again help in predicting the spread of 
heavy use and, for example, in estimating the cost-effectiveness of interventions. 
Concepts could then be used from infectious-diseases epidemiology, such as 'infecteds', 
'susceptibles', 'basic reproductive rate', 'herd immunity'. Key issues would be to 
distinguish 'susceptibles' from 'immunes' or to find a type of 'vaccination' that could 
turn 'susceptibles' into 'immunes', for example by detecting and treating depressive 
symptoms in young adults. If the epidemiology of illegal drug use would more resemble 
chronic-diseases epidemiology, models would focus on demographic or social 
developments that would lead to higher or lower prevalence/incidence of the 
predisposing genetic or mental-health factors in the general population. It would then 
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be important to identify those with a genetic or mental risk profile at an early stage and 
to find ways to protect these persons from addiction to any substance or behaviour 
(including, e.g., gambling) later on in life. 
Other problems in the study of drug use may be less purely scientific or methodological 
but rather illustrate the complex interface between science and policy. Possibly the 
clearest example is the illegal status of drug use. There are few epidemiological areas in 
which disease is viewed as illegal. This legal and often moral aspect complicates public-
health-oriented work on drug problems in different ways. 
First, methodologically sound studies on interventions are very difficult to set up, not 
only due to the difficult type and illegal habit of patients, but also because some of the 
potential interventions themselves are illegal. This complicates collecting hard evidence 
on policy options and the debate often continues in a vicious circle. This is obvious 
regarding a controversial intervention such as controlled heroin provision (Van den 
Brink et al., 1999; Uchtenhagen et al., 1999), but even substitution treatment, which 
has been well accepted in the scientific field (Des Jaríais and Hubbard, 1999), cannot 
always be provided easily everywhere. Patients are often treated within law-enforcement 
environments (prisons), which do not always allow a confidential doctor-patient 
relationship. Patients may also be in and out of treatment and prisons, continuously 
interrupting therapy, making positive effects difficult to sustain and thereby increasing 
the risk of adverse consequences such as HIV infection or overdose (Metzger et al., 
1998; Turnbull, 1997; Wiessing et al., 1996; van Ameijden et al., 1999). Moreover, the 
legal restrictions and stigma surrounding drug use in most countries lead to difficulties 
in obtaining reliable routine data or indicators (Hughes and Rieche, 1995). Drug users 
will try to keep away from any registries as much as possible, and even doctors might 
give a drug-related death a less stigmatised code on the death certificate in order to 
protect the relatives of the deceased. Legal restrictions might even affect scientific work 
in a more general manner, by influencing funding priorities or pressuring scientists to 
select 'politically correct' results. 
Second, the legal and moral perspectives often lead to much confusion about case 
definition in policy debates. Rather than talking about 'illegal drug use' in general, as is 
often done, it is important clearly to distinguish problem drug use from non-problem 
drug use. Even if in many countries (usually non-problem) cannabis use does not differ 
from (often problem) heroin use in legal terms, public-health consequences are vastly 
different. Many forms of drug use, even if illegal, do not lead to more problems for the 
individual or society than moderate smoking or alcohol use (Nicholson et al., 1999; 
Marwick, 1999). It is problem drug use, such as injecting or frequent use of heroin, 
crack and other hard drugs, that incurs most costs to society in the form of infections, 
deaths, addiction and crime (EMCDDA, 2000; Amaro, 1999). A policy-maker in general 
tries to minimise the social costs of drug use and these should therefore be directly 
targeted by interventions. Drug policies that do not distinguish between different modes 
of drug use may not be efficient and may even be counter-productive. Differentiating 
between lighter and heavier forms of drug use in policy objectives, using case definitions 
based on clear diagnostic rather than legal criteria, could greatly help progress in the 
drugs field. 
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Third, the lack of clarity in the definition of the problem and the lack of (possibilities to 
gather) scientific evidence have resulted in a lack of common objectives to reduce drug 
problems. While no one discusses whether HIV infection or cancer should be prevented 
or not, this consensus does not exist with regard to drug use. It is important to reach 
evidence-based agreement on general objectives and on an optimal balance of 
intervention priorities to reach these objectives (Hartnoll, 1990). Some scientists believe 
that reducing all drug use (if at all possible by law enforcement) will lead to less problem 
use as well, while others think that this is not possible and that law enforcement actually 
increases drug problems, having no or only small effects on the prevalence of non-
problem use (Uhi, 2000). Both approaches, however, imply totally different interventions, 
legal and preventive in one case and public-health-oriented in the other. It is interesting 
to note that usually little effect is found of changes in law enforcement on levels of 
problem drug use (MacCoun and Reuter, 1997; Lenke et al., 1996), and that countries 
with totally different policies may show very similar prevalence (EMCDDA, 2000). It 
may therefore be more useful to aim at preventing problem drug use and its secondary 
consequences, such as overdose and HIV transmission (Stimson, 1996; Wodak, 1995), 
as do most policies regarding alcohol abuse, rather than to attempt to eliminate all 
forms of drug use altogether. 
Where are we? 
As discussed above, five key indicators are currently being implemented in the European 
Union and others are still in development, but data quality and comparability issues 
have not yet been solved and data collection has only recently started. Many models of 
drug use exist but consensus on a basic mechanism to monitor the spread and progression 
of problem drug use is still lacking, while legal issues around drug use severely complicate 
the data collection and monitoring of problem drug use, and the development and 
evaluation of effective interventions. 
Improving the quality of problem drug-use monitoring is of great importance. While 
non-problem use can be followed through general population and school surveys, 
prevalence estimation of problem use with modelling approaches is still in its infancy. 
Prevalence and incidence are fundamental measures of the spread of problem drug 
use and the effects of policy interventions. While prevalence among sub-groups can 
provide information on exit rates from the drug-user population (e.g. through treatment), 
detailed information on incidence is important for assessing entry rates and evaluating 
preventive measures. 
At present, data quality does not permit the precise measurement of prevalence and 
incidence in most countries, even if important methodological advances are being 
made. It is necessary to obtain more commitment for quality data collection for such 
statistical estimation modelling as well as for developing dynamic models to investigate 
policy choices. Legal barriers (data-protection laws) have to be removed to facilitate 
scientific work on all potentially useful interventions, but also to improve data availability. 
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More multi-disciplinary work is necessary to clarify and describe the spread of problem 
drug use in space and time. Economic models need to be further developed to better 
estimate the costs to society of different consequences of drug use and to estimate the 
cost-effectiveness of policy options. The role of supply factors (drug-markets research) 
and how these interact with demand in general, but especially with progression to 
problem drug use, need to be clarified. Understanding of the spread of drug-related 
infectious diseases is more advanced than other areas of drug use. While practical 
work is needed on HIV prevention (such as increasing the coverage of interventions) 
prevention of hepatitis C infection still needs to be improved by better understanding 
the transmission among injecting drug users. As effectiveness of interventions cannot 
easily be assessed at macro level, the monitoring of disease should at least include 
monitoring coverage of the target population by those interventions (Habicht et al., 
1999). 
In conclusion, indicators and models form important and complementary tools for the 
epidemiology of drug use at macro level. Although quality of data and thus possible 
inferences are much weaker than in local studies, macro-level assessments are 
indispensable for guiding policy decisions. However, interpretation of results at macro 
level should be even more careful than in general, which conflicts with the fact that 
policy decisions have to be taken. There is still a range of problems specific to the field 
of drugs that needs to be solved before effective measures can be widely adopted. 
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WHAT ARE DYNAMIC MODELS AND HOW CAN 
THEY BE USED? 
Christine Godfrey, Steve Parrott, Matthew Sutton, Vanessa Waby, Philip Young with 
Catherine Comiskey, Martin Frischer, Gordon Hay, Matthew Hickman, Johannes Jager, 
James Kahan, Ludwig Kraus, Roberto Mollica, Maarten Postma, Gianpaolo Scalia 
Tomba, Roland Simon, Colin Taylor and Lucas Wiessing 
Drug use and problems vary across the countries of Europe, within each country and 
over time. Through the work of the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) and other European bodies, an increasing amount of data (both 
qualitative and quantitative) is being collated on drug use and problems. Knowledge of 
the current situation is important for policy-makers, but there is also a need to plan for 
the future. What sense can be made of the data available? Can trends in use or problems 
be predicted? Can simulations be made of different policy instruments to examine 
their potential consequences? 
Researchers use a number of tools to investigate these questions. A model is defined as 
a simplified description of a system or phenomena in order to assist in calculations and 
predictions. As may be expected, however, researchers from different areas of study 
have developed different models and used different statistical and mathematical 
techniques in order to attempt to put some of their models into practice. Which approach 
yields the most useful result? While some models may seem a gross simplification of a 
complex problem, others are so intricate and technical, denying the general reader's 
ability to understand the logic used, that the model becomes a 'black box'. 
During 1997, a group of experts drawn from across Europe met twice in York to consider 
the feasibility of developing dynamic models of drug use and related problems. Review 
papers were commissioned from this expert group and the extended and revised reviews 
form the main contents of this monograph (see full report, Godfrey et al., 1997). A 
further seminar, which included the original group of modelling experts, drug researchers 
and other drug specialists, was held in Lisbon in 1998. The aim of this seminar was to 
explore which policy questions could be addressed by which type of models and how 
the results of such modelling could be disseminated to policy-makers across Europe 
(Godfrey et al., 1998). 
This chapter contains a synthesis of the discussions and conclusions from these three 
different meetings. The potential policy questions are considered in the first section. 
The various types of models and a summary of their advantages and disadvantages is 
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given in the second section. How modelling techniques could be used to address policy 
questions and the potential for further research is explored in the third section. The 
chapter concludes with a discussion on the role of dynamic modelling. 
What are the policy questions? 
Drug issues span a vast array of policy areas at different levels and are of enormous 
international concern with some policies being addressed at this level. There are also 
national, local and community issues, which often cross cut traditional policy divisions. 
Policy-makers include not just politicians, but also bureaucrats. Developing relationships 
between researchers and the large number of different decision-makers may be 
problematic, but this does not necessarily imply that research cannot be fed into the 
policy-making process. 
Thè questions posed by policy-makers of all sorts tend to be easy to comprehend and 
beyond dispute. They centre on issues such as: how many people use drugs? How 
much do they consume? What are the consequences of this use? Which policies work? 
What are the costs of these policies? These questions can obviously be extended and 
one important role of modelling is to outline the dimensions of drug use and problems 
and their interactions. Part of the researcher's role is to demonstrate the impact of drug 
use and problems not just on physical consequences such as disease rates and health­
care systems, but also on social impacts. This extends to the effects on the community, 
the economy and the judicial system. 
Many policy concerns are of a comparable nature. Why is drug use in the policy­
maker's area higher or lower than in another? As more national and regional data 
become available policy-makers may be tempted to make invalid and inappropriate 
conclusions about the efficacy of their policies. Modelling data by formulating and 
testing hypotheses is one means of informing the policy debate. For example, research 
may be able to help explain why some countries have lower prevalence of cannabis 
use than others. Further collection of data, particularly over time, raises other policy-
driven questions, particularly why do use and patterns of drug use change? Why does 
some drug use become problematic? Can the results of policy changes be observed? 
While these questions are simple, the answers have proved difficult to find. Partly, research 
has been hampered by the lack of data. Modelling techniques have an important part to 
play in enabling researchers to make the best use of the limited available data. Bodies such 
as the EMCDDA, which are playing a major role in collating comparable data, are clearly 
important. Partly, there is a lack of research and researchers, with many modellers working 
in isolation and without major funding. However, these are not the only issues. 
One of the recurring themes of the discussions in this project was the link between 
researchers and policy-makers. In seeking funding researchers have been encouraged 
to stress the practical relevance of their work. However, the motivation and interests of 
researchers in a complex area may not be the same as those of the policy-maker. 
Researchers can become very frustrated if clear policy recommendations arising from 
research are not enacted. In contrast, policy-makers can become disillusioned if model 
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predictions prove false. Examples of the inaccuracy of the initial HIV/AIDS models in 
predicting the spread of HIV and consequent health-care resources from data were 
frequently quoted in discussions. Similarly, decision-makers can be discouraged from 
considering research if the model is not transparent and is masked in technicalities. 
There can be a long time lag between the policy-maker posing a question and researchers 
being able to provide an answer. Disputes between researchers can also alarm policy­
makers but be one of the main driving forces behind the development of research 
techniques and results. 
Continuing dialogue between researchers and policy-makers is clearly required. There 
is considerable variation across countries in how research is used in the policy-making 
process. In some countries there are bodies which act to synthesise research and bring 
researchers and decision-makers together. However, research also has to be timely and 
politically acceptable. The impact of research varies considerably, as was demonstrated 
by some of the case-study material used in the project. The first important aspect is the 
availability of data about policies. In the 1997 York seminar, Pierre Kopp presented 
analysis about the expenditure of the French government on different drug policies 
(Godfrey et al., 1998). These data are not readily available and as such they provide 
some background against which policy statements can be checked, for example, the 
balance between enforcement and treatment expenditures. Peter Reuter, at the same 
meeting, provided two examples of drug modelling work with different impacts on 
policy-making (Godfrey et al., 1998). In the first example, simple models were 
constructed to demonstrate the impact of various ways of restricting the supply of drugs. 
The policy background was a move to 'seal the borders' by using a military solution. 
This policy change was not fully supported by the military authorities and the model 
was able to demonstrate how the costs of smuggling varied by routes and the impact of 
alternative interdiction policies. The study, despite its limitations, did have an impact 
and this was also helped by general concern about the amount of expenditure on 
interdiction by the United States Congress. 
The second example, quoted by Reuter, involved the work of Rydell and Everingham 
(1994). This was a simulation model of the cost-effectiveness of treatment compared to 
enforcement policies to reduce cocaine consumption. This work has been favourably 
reviewed by other researchers and frequently quoted. It failed, however, to have any 
political impact, with no change in the proportions spent on enforcement compared to 
treatment despite the clear conclusions that treatment was more cost-effective. There 
can only be speculation about why this study failed to have a major policy impact. It 
could be simply that the budgets for interdiction are set centrally while those for treatment 
are set locally and that there was therefore no clear policy decision-making body to act 
on the results. It may be that the research was not timely because the US federal 
budget at that time was not the focus of a strong political debate. It may be that such 
research findings take a lot longer to be acted upon with the need for more fundamental 
shifts of opinion as the research results are disseminated more broadly. 
To summarise, researchers can contribute to the debate about drug use, problems and 
the effectiveness of alternative policy instruments. Modelling, with available data, is an 
important part of this research contribution. Policy questions and concerns are relatively 
35 
WHAT IS MODELLING AND HOW CAN IT BE USED? 
straightforward. However, drug problems themselves are complex and the lack of 
available data means that answers to these questions are not necessarily readily available. 
The next step is to explore the modelling techniques available and how they can be 
used to address policy questions. 
Types of model 
From the policy perspective, any model has to help illustrate the link between the 
prevalence of drug use, the problems created by drug use/the social impact of these 
problems and the policy response (see Figure 1). There are direct links between 
prevalence, problems and social impact which can influence policy responses. However, 
policies can be directed at the problems or at changing prevalence. Models of various 
sorts provide one approach to exploring the inter-relationships between different factors 
and explain some of the observed variations in drug use and problems over time and 
between countries. Further, the effects of policy measures can be explored using the 
results of such models within a 'what if' framework. In a dynamic framework the 
relationship between the prevalence and problems of drug use and policy impact may 
need to be traced through individuals' drug careers. At population level there is a need 
to examine the impact in specific time periods of the total of these individual effects. 
Different levels of geographical coverage of the models may be required to match the 
policy-making bodies across Europe. 
The major aim of the project which forms the basis of this monograph was to explore 
the feasibility of using dynamic models as a means of interpreting data on drug use and 
problems across Europe. It was recognised that the tasks would draw on research from 
many academic disciplines. This, coupled with the technical nature of the models, 
Figure 1 : Framework for models 
-► Prevalence 
I 
■>■ Problems I 
Social impact I 
Policy 
response 
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could lead to difficulties in finding common, agreed and accessible definitions and 
language. A subsidiary aim of the project was to uncover some of the potential confusions 
caused by the same terms being used in different techniques and to start to define 
some of the remaining disputed terms. 
The objectives of the project included an attempt to provide some inventory of the 
types of tools which may be used in models attempting to specify relationships between 
different factors impacting on the constructs set out in Figure 1. This inventory of models 
could not be restricted to those techniques already in use because of the current relative 
paucity of specific drug-related research. However, modeishave been increasingly used 
to address related areas, such as communicable diseases, and other substances, such as 
alcohol and tobacco. 
In discussion, it became clear that the term 'dynamic' could be interpreted in a wider 
sense than changes over time. Within Europe, the spread of drug use, drug supply and 
drug problems across geographical areas is of wide interest. To build models, a more 
fundamental understanding of the social processes which contribute to drug-using careers 
is also necessary. Many of the models have little behavioural foundation and it was felt 
that these aspects could not be neglected. 
Two further areas were considered: data requirements and data availability for models; 
and policy use and acceptability. In considering dynamic models, one interest at 
European level would be to refine the use of existing national data. A second objective 
would be to examine what data are collected and whether these data could be improved 
or augmented. All models are built on a series of assumptions. The mathematics and 
statistics needed to construct the models can be difficult for non-specialists to follow. 
For policy acceptability, it may be important for the process of model construction to 
be visible and understood by a wide audience. This may conflict with criteria developed 
by researchers. 
Considering the most feasible questions to be addressed, a model was proposed which 
extends and develops Figure 1. This schema, shown in Figure 2, has three main boxes: 
supply of drugs; policy interventions; and the main box describing drug use and 
problems. This main box illustrates the relationships which many models may seek to 
address. Obviously this schema does not explicitly cover different geographical areas, 
but it could be applied at different levels. An attempt was made to address different 
parts of this schema with a mixture of potential projects which are both feasible and of 
interest to policy-makers, as set out in the fourth section of this chapter. 
In the next section, a summary of what is known based on the reviews contributed by 
the participants at the seminars and the potential for different techniques to address 
these inter-relationships is discussed before the priorities to fill the gaps in knowledge, 
which may be of special interest to decision-makers, are explored. 
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Figure 2: Schema for research and policy questions 
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Findings from review papers and case studies 
In this section, a short summary of each review topic is presented based on the discussions 
at the second expert meeting. Where appropriate, references are made to the chapters 
below but the discussions at the expert meeting were based on earlier versions of these 
reviews. The discussion of each technique was framed around the following questions: 
• What are the outputs of the model? 
• To what extent are existing examples of these models applicable in Europe? 
• What geographic areas do the models consider? 
9 What are the data demands of the model? 
• Why have the models not been applied? 
• What would be the added value of further research? 
Geographic information systems 
Geographic information can be seen in two parts. These geographic information system 
(GIS) models have been mainly used as a means of displaying spatially referenced data 
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(see Chapter 3). This can be important in itself in identifying routes of the spread of 
diseases or socially related behaviour such as drug use. However, such systems can also 
be augmented by linking the spatial framework with relational databases and 
epidemiological functions. This could be applied to examining, for example, deprivation 
and town size in relation to the spread of drug use or to drug-supply routes. 
The technique was thought to have great potential at many levels and especially for the 
EMCDDA. The main advantage is the visibility of the output and its appeal to policy­
makers. However, the process may need considerable initial investments and more research 
is needed to develop some of the underlying functions of the spread of drug use. 
Dynamic models of data-production processes 
Chapter 4 contains a number of illustrations of the application of different techniques 
based on available data in various countries and addressing a range of research questions. 
This chapter illustrates how modelling techniques may be successfully applied. 
The advantage of the approach adopted in the original review paper was its pragmatism 
and the speed with which some results could be obtained. It had the advantage of 
making optimal use of available data to examine some important aspects of the impact 
of illicit drugs. However, one of the reasons the approach may not be widely adopted 
was that it was seen as over-simplistic. Collating data across Europe if comparability is 
required can also be very time-consuming. 
The discussion also highlighted the importance of not using one single methodology or 
set of data to model. Rather, there was a need to apply several approaches to reduce 
the uncertainties of modelling drug use and problems. 
Multiple-indicator models 
Multiple-indicator models use time series of indicators and statistical techniques to 
explore the links or correlations between the different indicators (see Chapter 5). These 
indicators are likely to be in three major groups: medical and treatment indicators; 
social indicators; and legal indicators. The relationships are also likely to be in the form 
of time lags. For example, the numbers in treatment in the current period may be 
linked to indicators of drug use several years earlier. 
The main advantage of this technique is that it uses available data. However, it would 
require time series of the 'same' indicator. These data may exist, but experience suggests 
that even collating data can be a time-consuming and resource-intensive process. 
However, the data-monitoring systems of different groups across Europe are addressing 
this problem. 
One disadvantage of the technique is that the correlations found do not imply causality. 
Changes in the social processes, which generate the indicators, are likely to invalidate 
the model predictions. Only by examining individual processes can some understanding 
be gained of the factors influencing the trends in different patterns of drug use and 
problems. 
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Back-calculation methodology 
This methodology has been applied and developed mainly to provide estimates of the 
total numbers of the population infected with HIV (see Chapter 6). The technique 
involves using the known or identified population of those with a disease with some 
'incubation rate' to back calculate the total number of infected persons. The purpose 
of this technique is to generate estimates of the 'hidden' population, which is clearly of 
policy interest as well as providing potential input into other modelling techniques. 
The back-calculation method has been applied extensively throughout Europe to the 
problem of estimating the numbers infected with HIV. It may have applications in other 
diseases linked to drug use. The expert group also discussed ways of applying the 
technique to measuring the hidden population of drug users. The proposal was that it 
may be possible to use data on the numbers presenting for treatment for drug problems 
with data on the time delay between drug initiation and treatment to estimate the 
hidden pool of users. This may be appropriate for some type of drug use, for example 
opiate use, but not for others. However, not all opiate users will present for treatment 
and hence using the back-calculation method could be seen as providing a minimum 
estimate. This proportion attending for treatment may also vary with the supply of 
treatment over time. It was not clear whether different behavioural aspects could be 
incorporated easily within an essentially mechanistic model, although different statistical 
techniques could be used to simulate the importance of different assumptions. Despite 
these issues, this technique appeared promising for addressing some questions. 
The mathematical and statistical techniques used to perform the back calculation vary. 
While such technicalities may be difficult to describe in full, the concept of the model 
can be described in relatively simple terms. There is a pool of expertise across Europe 
in applying this model, although it may need refining on a country-by-country basis. 
One disadvantage of the model is its sensitivity to small changes in the input data. 
Compartmental modelling and stochastic dynamic systems 
The basis of these types of models is the division of the population into two or more 
groups (see Chapter 7). The models then explore how individuals move from one 
compartment to another. In some circumstances, the rate at which individuals transfer 
through the compartments is known and in other models different probability rates can 
be tested. The technique provides a means of combining data from different sources in 
a systematic way to offer insights into drug use and related problems. An example was 
given of how such models may be used to explore how individuals move through a 
drug-using career. It also provides a framework in which different scenarios can be 
explored. 
These types of models have been used across Europe in the study of the spread of HIV. 
They have also been used to estimate the spread of HIV among injecting drug users. 
One possible disadvantage is that estimates depend heavily on the parameters employed 
and the realism of the structure of the underlying compartmental model. The models 
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(depending on the complexity) are demanding of data, but building conceptual 
frameworks may help refine existing data-collection methods. 
Discussion of the models highlighted the basic need to understand the social process 
affecting an individual's drug-using career or the process of initiating drug use. This 
points to the need for multidisciplinar/ approaches to the development of models. 
System-dynamic models 
This term caused some confusion as it referred to a group of models that contained 
some of the techniques used elsewhere. The distinguishing feature of a system-dynamic 
model is the attempt to examine the flows between different parts of a system (see 
Chapter 8). Generally, some sort of feedback mechanism is generated between the 
different parts of the system, rather than being a form of progression as in some of the 
compartmental models. However, parallels were noted between system-dynamic models 
and the compartmental and scenario models described in other chapters. 
System-dynamic models have also been applied to more aggregated data than 
compartmental models. Examples are provided in the research generated by RAND 
(Rydell and Everingham, 1994), where such models have been used to simulate policy 
changes such as switches of expenditure between enforcement and treatment. More 
aggregated models frequently use a combination of methods and techniques to generate 
data for their simulations. More individually based models may have applications in 
examining problem drug use, treatment take-up and consequences through time. 
Discussion suggests that these types of model have the potential to address very important 
policy questions. However, some models are very complex and may not be sustainable 
given current data availability. The more complex the model, the more useful it could 
be. The critical question remains, however, how to pre-judge the benefits associated 
with extending the complexity of the model of each stage. 
Structural equations and path analysis 
The aim of these techniques is to examine the relationships between known variables 
to examine the underlying (latent) concepts (see Chapter 9). These are generally 
exploratory tools rather than ones leading to predictions, although they have been 
applied to explore aspects such as the concepts that may lead individuals through 
different pathways of drug use. The models generally use individually based data. 
One advantage of the techniques discussed by the group was the ability to explore data 
to find previously unknown relationships. This may be a useful technique to apply to 
survey data. Unobservable constructs are used widely in some disciplines such as 
psychology, but may not be so acceptable to a broader audience. It is perhaps the 
'black box' nature of the models which limits their acceptability to policy-makers. Such 
models may be of much wider use to the research community. 
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Modelling infectious diseases and other health consequences of drug use 
This is clearly an important area of application of different modelling techniques (see 
Chapter 10). These models have the primary aim of examining the factors that influence 
the spread of different health consequences and predicting that spread. There is a 
body of work on the spread of HIV and the issue is how the models can be extended to 
other diseases. The expert group expressed particular concern about the spread of the 
hepatitis C virus (HCV) among the drug-using population. 
The objective of the different models is to understand the quantitative relationships 
between the characteristics of a specific disease, the contact patterns in the population 
within which it is transmitted and the resulting incidence and prevalence. The models 
can also be used to simulate the effects of prevention programmes and provide data for 
modelling cost consequences. 
In some of the examples presented, behavioural aspects, such as the dynamics of social 
networks, were combined with some of the more mechanistic models of disease spread. 
These behavioural models are more difficult to develop and require additional data, 
especially on drug-using careers and behaviours. Because of the differences between 
areas these models are generally applied at local level. 
There may be advantages in starting exploratory work with simple models. This may be 
seen as a priority given the consequences to individuals of the spread of these diseases. 
Scenario analysis 
This was another term which caused some confusion. Chapter 11 focuses on one specific 
type of analysis and aims to set out a conceptual model for exploring the health impact 
of drug use at multinational level. As the main model is conceptual rather than 
mathematical, it is necessary to build conceptual boxes and draw out the main 
relationships between the boxes. In the model for the European Commission Concerted 
action on multinational AIDS scenarios, for example, the main 'boxes' were: policy; 
demography; determinants of behaviour; health status; health-care system and 
associated costs; and autonomous developments such as medical technology, macro-
economic factors and socio-cultural factors. Some links can be seen between this area 
and compartmental models and system-dynamic models. The next step is collecting 
data and examining all the impact factors. Once the data have been collated this usually 
forces some simplification of the conceptual model. Different techniques are then 
combined to 'solve' the model and its consequences. The next step is then to set a 
reference scenario given certain conditions and simulate changes from the reference 
scenario by altering some of the model's policy parameters. 
The advantage of this type of scenario analysis is that it explores the links between 
different policy developments and consequences. Many other techniques are used in 
constructing the models. It does, however, demand considerable resources. It could be 
seen as a useful framework within which to develop more detailed research work. As 
such it may provide a link between the models exploring the factors influencing drug 
use and those tracing consequences. 
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There are other more qualitative approaches to scenario analysis and these involve a 
different combination of approaches. Policy-makers may, for example, be asked about 
which states they would most desire in the future and what they would most wish to 
avoid. The modellers then attempt to trace back from these outcomes the processes 
which affect them. This allows insights into what steps have to be taken in the present 
to get to some desired outcome in future. This type of approach may well have 
applications in the drugs field and could provide useful insights into the policy-making 
process not covered by other more mathematical and statistically based models. 
Modelling cost consequences 
This is a form of economic modelling which takes the results of many other models to 
consider the resource impact of different patterns of drug use and their consequences 
(see Chapter 12). Its advantage is the policy interest. However, to apply this approach 
across Europe, some standardisation of data-collection methods is required and this 
may be very resource intensive. The benefits of standardisation are that comparisons 
can be made across countries on a like-for-like basis. 
The basis of most health-care-cost consequences models is the use of an appropriate 
epidemiological sub-model, a model for the health-care needs and then one for 
estimating the costs. The details of the model required vary with the disease and the 
treatment needs at different stages of development of the disease. The reliability of the 
results of the model depends on the quality and representativeness of the data used for 
estimation. Health-care-cost data across Europe are of varied quality. Several possible 
developments were considered by the expert group, including examining the cost 
consequences of the hepatitis Β virus (HBV) and HCV 
While health consequences were seen as a starting point and would link with other 
modelling work, there are a number of additional consequences of particular policy 
concern. The expert group considered some of the other consequences that may need 
modelling, especially crime costs. 
Economic-market models 
Economic-market models examine the interaction between the behaviour of those 
supplying drugs and those consuming drugs (see Chapter 13). The purpose is to generate 
estimates of the determinants of dynamic patterns of drug prevalence or incidence. 
They can be applied both at the population (macro) level and at the individual (micro) 
level. 
Population-level models can be applied using some of the data currently available 
across Europe. Such models are generally applied to time series of data across the same 
geographic area. However, developments using individual-level data illustrate some 
uses of this technique to demonstrate the potential importance of economic factors in 
influencing drug-using behaviour and its associated consequences. 
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Some studies have been undertaken across Europe to examine the economic 
determinants of drug use, but few have been conducted on the factors influencing the 
supply of drugs. Because aggregate-level data are already collected, it was thought by 
the experts that well-founded economic models had the potential directly to inform 
policies, for example by identifying where to concentrate enforcement activities. At 
individual level, the disadvantages of these models were the demands on data and 
expertise. As within other areas, progress may be made if a multi-disciplinary approach 
were to be adopted. 
Chaos models 
An additional paper was presented at the second expert meeting. This was not an 
identified area for review, but rather an innovative area of research which was reported 
by a Spanish team of researchers. The potential for chaos models is to explore the 
spread of drug use and simulate within the model how different factors may alter the 
spread of drug use and its consequences. One disadvantage of the technique is the 
sensitivity to initial starting conditions. Another potential problem is explaining the 
model to policy-makers. However, the proof of the model will come with its application, 
as is being pursued within the Spanish group. There is scope for testing the basic model 
in other areas of Europe, although this is likely to be seen as a specific research task 
needing national research funding rather than being suitable for more general application 
at European level. 
Where next? Research priorities 
The reviews conducted for this project yielded a long list of potential research projects 
which are detailed in the following chapters of this monograph. Some areas are more 
developed than others and new work could be undertaken relatively quickly. Rather 
than prioritising research needs from the review papers, however, the expert group 
considered the potential questions that could be addressed and matched techniques 
to these questions. Six questions were identified by the group. These questions were 
seen as being of interest in themselves, and as fitting into different areas of the schema 
set out in Figure 2, above: 
What are the levels of drug use and problems? This could be considered over time, 
area and drug type. Geographic information systems maybe useful for filling in gaps 
in information across Europe. Applications of back calculations, compartmental 
models and system-dynamic models could also be appropriate. 
• How can the spread of new drugs be predicted? This was a potential area for 
conceptual scenario analysis using a variety of methods to understand social 
phenomena. 
• What is the current drug-using career? Changes in drug-using behaviour and the 
interaction with treatment were seen as areas to which compartmental modelling 
could be applied. With data it may be possible to model gateways into drug use. 
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How can social processes be modelled? These processes were seen as vital 
components of various modelling techniques. This is an area where there were gaps 
in techniques within the expert group. There was potential for considering different 
quantitative and qualitative data on risk factors, social networks and processes. As 
well as epidemiological, sociological and economic models, chaos theory may have 
some potential here. 
What are the current costs of drug use and the cost-effectiveness of policies designed 
to reduce these costs? The need to model the cost consequences of HCV and HBV 
was seen as a high priority. 
How can the impact of interventions be modelled? Again a variety of approaches 
could be used including compartmental modelling, system-dynamic models, cost 
and cost-effectiveness models and scenario analysis. 
These questions fit different boxes or combinations of boxes set out in Figure 2, above. 
A multi-disciplinary team is required to develop many of the models and to begin to 
answer these questions. There may also be added value in developing similar approaches 
across a number of European countries. Pursuing modelling in each of these areas 
would provide inputs into more comprehensive models of the whole supply, demand 
and policy system. 
The questions were considered further with additional experts in the seminar held in 
1998 in Lisbon. A summary of the group discussion is given below. The aim of each 
workshop was to identify practical and feasible ideas for new research projects. In 
some areas projects were already under way and more work is being developed. 
Modelling the health consequences of drug use - HBV/HCV/HIV 
Of immediate concern was understanding the spread of these diseases. It was also seen 
as important to compare interventions in order to predict the future consequences and 
estimate the costs. There was a role for using infection rates as an indicator. A further 
area of work was to improve the quality of the treatment data on HIV/hepatitis. 
Breaking this down into its component parts, the first issue is to estimate or model the size 
of the problem in terms of prevalence, consequences and risk in the general population. 
On interventions it was necessary to consider the effect of reporting delay, the potential to 
reach new injecting drug users and the issue of whether such interventions should be 
targeted towards risky behaviours. There is also a considerable dynamic component and a 
need to model the incubation period and the effects on different birth cohorts. 
The data needed include the incubation time, the risk of infection, and the interaction 
of hepatitis with HIV. There are also requirements for data on treatment options, the 
proportion offered treatment, rates of success, the interaction of interferon and opiate 
use, and the different stages of the symptomatic phase of the disease. There are data 
from HIV cohorts and from behaviour surveys. Comparisons could be made between 
countries, but there are doubts about the reliability of some data, for example, on the 
proportion sharing needles. 
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Some modelling work has been undertaken on, and there is potential for considerable 
areas of new research into, preventing the spread of HIV from drug users to the general 
population. Further data could be input into models of transmission to the general 
population, partner studies and vertical transmission from mother to child. It was also 
necessary to build in interventions which acted on behaviour both before and after 
transmission. One option was to work with local prevalence projects and look at mortality, 
treatment, the import and export from the locality, and the hidden population that 
could be reached through outreach work. Costs could be considered but only after 
clarifying the dynamics of the disease. More specifically there were studies that could 
be undertaken on hepatitis Β and the impact of vaccination and better treatment as 
well as the potential effects for the general population. Finally, there is a need to consider 
the routine data collected at European level and there may be some support for this 
type of research from former Directorate-General V, now the Health and Consumer 
Protection Directorate-General. 
The priorities identified by the seminar were: 
• modelling the spread of HIV; 
• modelling interventions. 
Geographically based models 
Geographically based models like CIS are capable of capturing, analysing and displaying 
spatially referenced data. These models have been facilitated by the availability of 
digital map data which provide a spatial framework in which to attach the attributable 
data. They can be used to study the associations between location, environment and 
disease. Drug use is a dynamic process and spreads through a population both through 
micro diffusion (the spread of drug use among individuals within groups) and macro 
diffusion (where drug use spreads across geographic boundaries). The major current 
impediment is the lack of empirical data although both GIS maps and relational databases 
are becoming more readily available. The other data need is for the epidemiological 
functions, which would be part of wider GIS models. 
The main outputs from GIS models are spatial-temporal maps. The models can, with 
dynamic models of forecasting, provide a means of visualising trends in drug diffusion 
and provide information for identifying populations at risk. For example, the Community 
epidemiology working group in the United States has provided simple maps for 25 
cities displaying data, but has not in this case linked the maps and data to epidemiological 
functions which could be used for prediction. 
To proceed there is a need to decide at which geographic level to start the analysis: 
city; region; or country. It was considered best to start at city level and then to extend 
the work. The requirements are for as much information about the city and the socio­
economic and demographic data as possible. Finding epidemiological functions for 
these systems needs to be developed. 
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The group discussed the work already being undertaken in Spain, Italy, the Netherlands 
and the UK. In most cases these were mapping exercises and therefore the priority 
questions were the feasibility of incorporating models into GIS systems. The attraction 
of the maps for policy-makers and their important role especially in studying the spread 
of drug use and problems was recognised. 
There was discussion about the best way to proceed with the EMCDDA on the work. 
Should researchers in individual countries work separately and then link up? Or should 
a common format be followed? It was considered important, at least, for a common 
decision to be made on the choice of appropriate software. 
The first need was to conduct surveys of what data were available and it was considered 
sensible to send questionnaires to national focal points. It was also important to check 
the availability of suitable maps, data on drugs, and socio-economic information. The 
feasibility of the modelling work was the hardest component. The group's priorities 
were to ensure that some projects took place, possibly in pilot areas such as Amsterdam, 
Glasgow and Slovakia. 
The two priorities for this group were identified as: 
• undertaking some pilot mapping exercises; 
• developing the analytic framework. 
Economic modelling of markets 
The group brought a number of different perspectives on the analysis of drug markets. 
Available data were discussed, as was whether these data could explain effects such as 
large changes in prices. A number of complex hypotheses relating market factors to 
drug use and drug-related consequences, such as deaths, were discussed by the group. 
The relationship between individual behaviour and how that translates into market 
aggregates, as displayed in some of the data presented by Leif Lenke on the impact of 
price changes on drug-use patterns, was also considered. The conclusion from this 
discussion was that there was a need for data and analysis in the following areas: 
« the framework of markets across Europe; 
• how individuals behave - micro-economics; 
• using the first two areas to inform macro models. 
There was further discussion about understanding the markets in Europe and how they 
may differ from those in the US. There were also some differences within Europe. 
Variations across drugs and types of users and the interactions between markets may 
well be more fluid in Europe than in the US. There was a need to gather information 
and to model the supplying organisations and the role of users/dealers. 
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From this discussion three areas of research were identified: 
a qualitative study of the individuals involved in the organisation of drug markets 
across Europe; 
a review and analysis of studies of the micro-economic behaviour to set out potential 
models which could be developed and tested within the European market; 
• an examination of the potential for building macro-level models. This would consider 
the implications of control and other policies on markets and be capable of examining 
the role of other factors such as demographics. 
Costs and cost-benefit studies 
It is clear that the social costs of drug use and the cost-effectiveness of different policy 
options are of great public and policy interest, although the results of cost-benefit 
studies will not always directly influence the policy process. There was considerable 
discussion on what areas would form the priority of any research. Data and research 
methods were well tried within the health area. It was agreed that evaluating criminal-
justice interventions was more difficult but of vital policy interest, especially given the 
proportion of public expenditure in that area. 
Three broad areas of work were identified and discussed further: 
' social-cost studies; 
* cost-benefit or cost-effectiveness studies; 
public-expenditure analysis. 
Social-cost studies have considerable public impact and the results of a study of the 
costs of illicit drugs In Canada (Single et al., 1996) were discussed. There was considerable 
debate about the methodology adopted. The international guidelines developed under 
the aegis of the Canadian Centre on Substance Abuse provide a review and a starting 
point for cross-European studies (Single et al., 1995). There is still some development 
required in a number of areas, especially the estimates of lost productivity. 
Any research in this area would be best undertaken within a common framework and 
it is clear that a multi-disciplinary approach is required. There is also a case for a number 
of sub-studies, for example on specific health-care issues. In addition, other studies, for 
example looking at public-expenditure implications, are important. 
In terms of economic evaluation there is a need for a similar set of linked activities. 
Work is required to develop the application of economic techniques to illicit drug 
interventions, for example in identifying, measuring and valuing many of the multiple 
outcomes from drug programmes. The most obvious place to start is to conduct 
evaluations within each sector, for example comparing different treatment approaches; 
enforcement; prevention; public nuisance; and harm-reduction interventions. The next 
step is to consider between-programme evaluation, for example the balance of public 
spending on enforcement and treatment. 
48 
CHAPTER 2 
The group considered the priorities from this long list to be: 
developing guidelines for social cost for Europe and undertaking a number of 
applications; 
developing a framework for the cost-benefit analysis of drug interventions. 
Social processes and initiation of drug use 
This is a key area but is still relatively under-researched. The group discussed data on 
the onset of drug use and came to the following conclusions. While there can be models, 
they have to be interpreted with care, as drug use is not the same as addiction. It is 
therefore important to develop measures which reflect health and social processes. 
This suggests a need to analyse drug careers, not the onset of drug use. However, this 
requires richer data sets. 
Even if models are developed, care needs to be taken that results are not over-
generalised. The same model would not apply to all drugs, cultures or time periods. 
There was also a need to recognise the role of social, environmental and policy variables. 
The group prioritised the following areas: 
modelling risk factors across countries; 
■ measuring risk behaviours and developing methods to analyse these data. 
Time trends and incidence 
The participants in the Lisbon seminar came from very varied backgrounds including 
treatment centres, epidemiology, criminology, geography and mathematics and statistical 
modelling. There was a brief discussion of the review papers from the 1997 York meetings 
and then the group concentrated on the potential use of the back-calculation method. 
There was debate about the feasibility of using the method and the parallel use of 
survey data. There were some questions about the reliability of information and the 
impact of changes over time, for example in services available. It was thought, however, 
that there was potential for application to the analysis of first treatment and first police 
arrest. 
The group also considered the link with policy. Why is it necessary to know incidence 
and time trends of heroin use? Clearly there is a need to consider the future demand 
for treatment services and to predict consequences such as those of hepatitis C. There 
is also a need to know how to chart the evaluation of overall drug strategies and policies. 
The group went on to consider the study of other drugs, perhaps through the use of 
survey data. However, it was thought important not to dilute effort and concentrating 
initially on one drug may be more practical. A further extension was to consider the 
model with cessation rates, which again is of prime policy concern. 
The first step was to consider the time lags involved and the appropriate distribution to 
employ. There was potential to learn from other countries outside Europe. The group 
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concluded that there were sufficient data and expertise, but some resources were needed 
to bring these together. 
The main priorities were: 
* developing and testing the model for heroin; 
* considering the application to other drugs. 
Conclusions 
A number of important policy questions could be addressed by the different modelling 
techniques described in this monograph. Some techniques are based on complex 
mathematics or theories, while others can be presented in simpler terms for wider 
audiences. The debates at the two expert meetings in York and the later seminar in 
Lisbon were lively and generated many ideas for future work. It was clear that a wide 
agenda for research has been set out and while there was some purpose to maintaining 
the mechanisms to keep the wider group in contact, there was also a need for sub­
groups to take some areas forward to test the practicalities of model building. 
Cooperation is required both across academic disciplines and between researchers 
and policy-makers throughout Europe. Several projects are currently under way to test 
some of the ideas set out in the following chapters. 
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WITH AVAILABLE DATA 

INTRODUCTION 
T he models discussed in Part II attempt to integrate different indicators to provide meaningful interpretations of trends in problem drug use. The models vary in their assumptions and uses and are relatively data-demanding, but also may 
provide information that remains fairly close to direct observations, thereby increasing 
reliability. 
In Chapter 3, Frischer and Heatlie explore the potential of linking geographic information 
systems to a drug-forecasting model. They envisage integrating different sources of data 
to produce predictions of geographic spread that can be mapped. They argue that 
increased mobility and increased availability of data in Europe would make such a system 
useful at European level. Their model is based on a limited number of parameters, but it 
is able to describe adequately the spread of drug use over larger geographic areas (micro-
diffusion), similar to infectious-disease models. 
Carla Rossi concentrates on the different sources of available data that might give 
information about the 'hidden' drug phenomenon in Chapter 4. She stresses the 
importance of a systematic approach to understanding and describing the data-production 
processes that result in observable records in agencies. Rossi argues that models describing 
observable macro-data in a simple manner are more useful for policy purposes than 
complex models that attempt to mimic the micro-phenomenon of the spread of drug 
use among individuals. Rossi discusses indicators available in different countries and 
suggests that appropriate mathematical and statistical functions should be used to describe 
the indicators taking account of their interdependences. 
In Chapter 5, Mollica and Mariani follow a similar line of thinking as Rossi by proposing 
the use of a multiple-indicator model for monitoring prevalence and risk of drug addiction. 
By combining time series of drug-related data from different sources the authors suggest 
that the relationships between the observed phenomena can be studied. In the proposed 
model, different indicators can in turn be seen as dependent or independent variables, 
depending on the aim of the analysis, while interactions and inter-correlations can be 
taken into account. 
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CHAPTER 3 
MODELLING DRUG MISUSE IN EUROPE USING 
GEOGRAPHIC INFORMATION SYSTEMS 
Martin Frischer and Heath Heatlie 
Current methods for estimating incidence and prevalence of drug misuse tend to be 
retrospective and are not capable of forecasting spatio-temporal trends. Mapping of 
drug misuse is restricted to displays of incidence and prevalence rates. In contrast, 
various disciplines (e.g. ecology and environmental health) are increasingly using 
geographic information systems (GIS) to study associations between location, 
environment and behaviour. Advances in computing and graphical technology enable 
spatially referenced data to be linked to relational databases and epidemiological 
functions. GIS thus provide a powerful tool for analysing the spread of phenomena 
over time and space and GIS models have been used to predict disease spread from 
infected to susceptible populations. The development of a European drug-misuse GIS 
would be a logical progression in view of improvements in drug-misuse surveillance in 
Europe. It would provide: spatio-temporal maps of drug incidence and prevalence; 
dynamic methods of forecasting and visualising trends in drug diffusion; and information 
for identifying populations at risk and prioritising resource allocation. 
Increasing personal freedom and scope for travel within Europe have led to speculation 
that opportunities will arise for new forms of drug trafficking and drug use (Dorn and 
White, 1994). This has already occurred in the European part of the former Soviet 
Union (Lee, 1992) as a consequence of the social and economic changes which have 
taken place since the mid-1980s. However, there are few data from this region with 
which to paint a reliable picture of current prevalence of drug misuse. In Europe there 
is increasing recognition that reliable epidemiological information is important for 
prevention and treatment activities. In recent years there have been renewed efforts to 
ascertain the level of drug misuse in several countries using a range of methodologies 
(e.g. IFT, 1994; Sandwijk et al., 1995; ISDD, 1997). In general, methods such as 
population surveys and capture-recapture analyses provide period prevalence figures 
and sometimes incidence, but lack any intrinsic mechanism for forecasting trends. 
In order to predict drug-use trends it is necessary to understand the factors that influence 
an individual's decision to use drugs. Concepts like personal freedom are not easily 
quantified, but, on the other hand, drug use has been linked to a range of intrapersonal, 
interpersonal and environmental factors (Ramsey and Percy, 1996). To the extent that 
these factors vary, consequent changes in drug use can be predicted. 
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Drug use is also dynamic, spreading throughout populations and across regions. 
Pioneering work by Hunt and Chambers (1976) in the United States focused on two 
processes (see Figure 1 ). The first process, called micro-diffusion, refers to the spread of 
drug use among individuals within groups. It depends on known drug users' propensity 
to 'transmit' drug use to new users in a similar manner to infectious diseases. The 
second process, macro-diffusion, refers to the transmission of drug use across 
geographical boundaries. This process is thought to occur in the same manner as other 
new phenomena (e.g. the geographical diffusion of television stations in the US in the 
1960s). Hunt and Chambers were able to create a map showing the spread of heroin 
epidemics in the US during the 1970s by analysing data from drug-treatment 
programmes. Heroin use appears to have begun on the north-east coast along the 
chain of cities from Boston to Washington, and in southern California. Large inland and 
Gulf-coast cities were also early centres of epidemic use. Heroin moved to the interior, 
from these continental margins, spreading sequentially from cities in regions of high-
population density to those of lower density. 
Although Hunt and Chambers' analysis was an attempt to demonstrate that drug misuse 
spreads in a lawful way, their model was based on only two parameters: a simple 
infectious-diseases function (micro-diffusion); and empirical observations of geographical 
spread (macro-diffusion). The model did not link the geographical framework to other 
information, such as the population's socio-economic status or geographical features 
Figure 1: Isochrony of peak heroin use in the United States, 1968-73 
1969 1970 
1969 
•..1971 
1968 
Source: adapted from Hunt and Chambers (1976) 
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such as transport routes. In the interval since the publication of their work, a new 
multidisciplinary methodology has emerged which could now incorporate such 
information by exploiting relational databases and spatio-temporal GIS. 
What is a geographic information system? 
Although there are many types of geographic information system, they are all capable 
of capturing, analysing and displaying spatially referenced data. GIS development has 
been facilitated by the availability of digital map data which provide a spatial framework 
on which to attach the attribute data (see Figure 2). The main characteristic of a GIS is 
the ability to link spatially referenced data to a relational database that contains relevant 
information (e.g. population data, transport routes or other socio-economic data). These 
features, together with more powerful spatial-analysis tools, distinguish GIS from early 
mapping programmes that simply displayed information. 
GIS capabilities 
Data capture and storage 
Increasingly, maps and associated attribute data (e.g. census statistics) are commercially 
available, but where no data exist for a project, they can be entered into a GIS from 
external sources by either scanning maps or tracing over a map's features using a digitising 
tablet. Attribute data can be entered from either existing studies or public-domain data 
sets. 
Figure 2: Schematic representation of a typical geographic information system 
Map and data layers Composite map showing countries, cities, principal transport 
routes and socio-economic data 
Transport routes 
Socio-economic data 
Countries 
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A GIS stores both spatial map data and associated attribute data. Attribute data are 
stored in a relational database­management system contained within the GIS and 
accessed by a spreadsheet or query­driven user interface. The GIS can accomplish 
everything that a traditional database system can by querying, selecting and manipulating 
data. 
Map data are encoded into a set of numbers so that the geometry of the map is available 
to enable spatial queries, but also so that the maps can be stored digitally in one or 
more files. Maps are encoded by using both the coordinate information and encoded 
topology, so that the relationships between points, lines and areas, such as the adjacency 
of regions or the connectivity of lines, are known in advance. 
Data selection 
Data records in a GIS can be retrieved in one of two ways. First, the relational database 
can be searched and selections made on the basis of a feature's attributes and their 
values (see Figure 3). For example, European cities with household surveys within the 
last two years could be selected and then displayed. Second, a GIS also allows spatial 
retrieval, for example, the map could be searched for all European towns with 
populations of 50­100,000 and within 100 km of a major city. Each query could be 
linked to several data layers, for example, socio­economic status and transport links. 
Figure 3: Geographic information systems can be queried via database or map 
(spatial representation) 
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Spatial analysis and GIS 
There are generally three phases in applying GIS: visualisation; exploratory data analysis; 
and model building (Gatrell and Bailey, 1995). 
Visualisation 
Visualisation is an important tool for showing the change in disease patterns over time. 
Animation, embedded within a GIS, is highly effective in depicting the spread or retreat 
of disease over space and time. The spread of the AIDS epidemic in the United States 
as it moved from and within major cities was illustrated using animated maps (Openshaw 
et al., 1987). Figure 1, above, shows a similar process for drug misuse. Visualisation can 
also be used in novel ways to explore the results of traditional statistical analysis. 
Displaying the locations of outlier and influential values on maps and showing variation 
in values over space can add a great deal to epidemiologic research. Although such 
tools are still being developed, they would benefit greatly from a closer and more 
seamless link between statistical packages and GIS (Gatrell and Bailey, 1995). 
Exploratory data analysis 
The quantity and diversity of spatial data in a GIS can be overwhelming and exploratory 
methods can help the analyst make sense of data to address 'what if' questions. Advances 
in computing and graphics technology have made this one of the most active areas in 
GIS/spatial-analysis research. Among the most important exploratory methods for 
epidemiology and public health are methods for identifying space-time clusters or 'hot 
spots'of disease. For example, Marshall (1991) produced maps displaying the proximity 
of significant disease clusters to environmental hazards such as nuclear facilities. 
Spatial-diffusion models analyse and predict the spread of phenomena over space and 
time and have been widely used in understanding the spatial diffusion of disease spread 
(Thomas, 1990). Such models are quite similar to spatial-interaction models except 
that they have an explicit temporal dimension. The models can predict how diseases 
spread, spatially and temporally, from infected to susceptible people in an area by 
incorporating time and space, along with basic epidemiological concepts (Haggett, 
1994) and aid in understanding the emergence of infectious disease. 
Spatial auto-correlation methods and space-time correlograms can be used to explore 
spatial and temporal patterns. These methods provide a general sense of the speed and 
geographic pattern of diffusion. Although the methods have not typically been 
incorporated into GIS, there is great potential for doing so, especially with recent 
advances in computer animation. 
Model building 
Modelling includes procedures for testing hypotheses about the causes of disease and 
the nature of disease transmission. In general, modelling involves the integration of GIS 
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with statistical and epidemiological methods. GIS can generate data for epidemiological 
models, display the results of statistical analysis, and model processes that occur over 
space. The first two points are evident in recent, regression-based analyses of disease 
risk, such as the study of Lyme disease (Glass et al., 1995). In this study, a GIS was used 
not only to integrate diverse data sets and calculate new variables, such as slope and 
distance from forest, but also to map geographic variation in disease risk, as predicted 
from a logistic-regression model. 
Other GIS models are more explicitly spatial, expressing relationships or flows between 
people and places. Spatial-interaction and spatial-diffusion models are of particular 
relevance to the study of emerging diseases. Spatial-interaction models analyse and 
predict the movement of people, information and goods from place to place (Ding and 
Fotheringham, 1992). The flows of people between rural areas, villages, cities and 
countries are all forms of spatial interaction that are central to disease transmission. It is 
possible to identify areas most at risk for disease transmission by accurately modelling 
these flows and thus target intervention efforts. Spatial-interaction models reflect two 
principles: that interaction decreases with distance; and that it increases with population 
size or 'attractiveness'. Given actual flow data, values can be estimated that show the 
effects of distance and population size (or other 'attractiveness' factors) on interaction. 
The models can then be used to predict spatial-interaction patterns elsewhere. Although 
spatial-interaction models and GIS developed separately, some GIS now have spatial-
interaction-modelling capabilities. 
Applications of GIS in epidemiology 
GIS have already been used to study associations between location, environment and 
disease. Recent applications include the surveillance and monitoring of vector-borne diseases 
(Glass et al., 1995; Beck et al., 1995; Richards, 1993); water-borne diseases (Clarke et al., 
1991 ); environmental health hazards (Braddock, 1994); exposure to electromagnetic fields 
(Wartenberg et al., 1993); predicting child pedestrian injuries (Barnes and Peck, 1994); 
and prescribing patterns in primary and secondary care (Pryce et al., 1996). 
In a recent study in Baltimore County, Maryland, GIS and epidemiologic methods were 
combined to identify and locate environmental risk factors associated with Lyme disease 
(Glass et al., 1995). Ecological data such as watershed, land use, soil type, geology and 
forest distribution were collected at the residences of Lyme disease patients and 
compared with data collected at a randomly selected set of addresses. A risk model 
was generated combining both GIS and logistic-regression analysis to locate areas where 
Lyme disease is most likely to occur. 
GIS are being used to identify locations of high prevalence and monitor intervention 
and control programmes in areas of Guatemala for onchocerciasis (Richards, 1993) 
and in Africa for trypanosomiasis (WHO, 1989). Spatial and ecological data are combined 
with epidemiological data to enable analysis of variables that play important roles in 
disease transmission. This integration of data is essential for health-policy planning, 
decision-making and ongoing surveillance efforts. For example, as part of the Guinea 
worm eradication effort, the United Nation's Children's Emergency Fund placed pumps 
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in villages most infected with the disease to ensure access to a safe water supply (Kitron 
et al., 1994). GIS enabled researchers to locate high-prevalence areas and populations 
at risk, identify areas in need of resources and make decisions on resource allocation 
(Roger et al., 1993). Epidemiological data showed a marked reduction in prevalence in 
villages where pumps were introduced. 
GIS and drug misuse 
GIS have already been shown to be useful in epidemiological research and for facilitating 
interventions. While mapping of drug prevalence is currently rudimentary, the pioneering 
work of Hunt and Chambers provides a basic framework for developing GIS in relation 
to drug misuse. However, developing a practical GIS system will require careful 
consideration of several issues. 
Scope 
The main aim of a GIS drug-misuse system is to create a dynamic model for forecasting 
and displaying spatio-temporal trends. As mentioned at the start of this chapter, drug 
misuse is dependent on a wide range of factors, only some of which are likely to be 
successfully modelled. Previous research indicates that standard variables such as socio­
economic status are generally not very good predictors. This is probably because diffusion 
of drug use is a dynamic process. Such processes have not been modelled, although 
there has been some interesting qualitative work on peer groups and social networks 
(Neagius et al., 1994). Available data on diffusion indicate that drug epidemics tend 
not to be indigenous, but are dependent on a variety of economic, social and political 
factors. The extent of diffusion also depends on individuals' predisposition to experiment 
with psychoactive substances. In Western Europe, increasing levels of post-war drug 
use have been attributed to greater individualism and consumerism. Psychological factors 
may also play an important role with the weakening of family relationships and 
lengthening periods of adolescence (Rutter and Smith, 1995). 
One of the main impediments to applying GIS to drug misuse has been the lack of 
empirical data to include in a GIS database. However, during the 1990s there have 
been numerous studies and considerable improvement in European surveillance data 
(see EMCDDA, 1997). Furthermore, as mentioned above, GIS maps and relational 
databases can now be created or purchased. These developments have created a climate 
whereby a GIS for drug misuse can now be realistically considered. Figure 4 highlights 
the conceptual framework underpinning the proposed GIS for drug misuse. 
Steps in creating a drug-misuse GIS 
Although drug use can diffuse at various levels (micro, macro, international), the common 
link is a function that specifies how drug use spreads among individuals in a population. 
Two pilot computer programs have been developed based on deprivation status and 
town size. Both programs were developed for the Strathclyde region of Scotland. 
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Figure 4: Components of a geographic information system 
Geographic information system 
Maps Database 
Spatial selection Database selection 
\ 7 
Epidemiological functions Active analysis 
feedback 
Graphic and report generation 
Analysis output 
The first program models drug diffusion in relation to deprivation within the city of 
Glasgow. It assumes that drug use starts in the 'worst' areas within Glasgow and spreads 
to 'better' areas. The program forecasts incidence and prevalence, in relation to six 
parameters: 
* population size of the various areas (graded 1 to 8 in terms of affluence); 
• estimated peak prevalence (can be variable over affluence); 
• speed of spread across types of area; 
• duration of addicts' drug-using career; 
* length of epidemic cycle; 
* year epidemic trends were first observed. 
The second program assumes that drug use spreads from denser to less dense areas 
(i.e. urban to rural) within the Strathclyde conurbation (of which Glasgow is the major 
city). All other parameters are the same. Using the observation that epidemic trends in 
drug use were first noticed in Glasgow in 1980, it has been possible - with hindsight-
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to generate Incidence and prevalence estimates which correspond to capture-recapture 
estimates of injecting drug use in Glasgow in 1990. 
These programs represent a preliminary attempt to model drug diffusion. Although 
they do not constitute a GIS, they do include rudimentary relational and geographical 
components. In order to create a GIS for drug-misuse forecasting, the following would 
have to take place to develop relational, epidemiological and mapping capabilities: 
obtaining digital data to construct the spatial framework for the study area (digital 
maps); 
selecting appropriate attribute data to help explain the diffusion of drug misuse 
(census data, national surveys, transport flows, major import routes); 
developing new models to predict the rate of diffusion (e.g. allow modelling for the 
effect of policy/intervention (analogy with vaccination campaign for infectious 
disease); 
creating an output interface to allow dynamic user interaction and temporal displays 
of predicted diffusion rates given a 'what if' scenario. 
Conclusions 
In many areas of Europe, patterns of drug use are changing. The mechanisms of diffusion 
are diverse: introduction of new practices by new users; tourism and migration; cross-
border contact; drug transportation; and increasing opportunities for economic and 
international contact. GIS offer a dynamic and flexible approach to visualising the 
diffusion of drug use in Europe. 
What are the model outputs? 
The creation of a drug-misuse GIS would produce: 
* spatio-temporal maps of drug incidence and prevalence; 
dynamic methods of forecasting and visualising trends in drug diffusion; 
information for identifying populations at risk and areas requiring resources for 
prevention and treatment. 
To what extent are existing applications of these models applicable in Europe? 
GIS have been used to address diverse topics in the fields of ecology, infectious diseases 
and environmental health. 
What are the data demands of the model? 
The GIS requires: 
digital maps of Europe which can be focused at city, region, country and international 
level; 
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relational databases of socio-demographic data, population statistics, known drug-
use statistics (e.g. surveys, prevalence-estimation studies); 
epidemiological functions for estimating drug incidence and prevalence. 
Why have the models not been applied more extensively in Europe? 
Although drug-use trends are increasingly being mapped, GIS development has been 
slow for a number of reasons including lack of knowledge regarding GIS capabilities, 
inadequate relational data and rudimentary epidemiological knowledge of drug diffusion. 
GIS development will require a multi-disciplinary team. 
Should there be a research project to develop and apply these models in Europe? 
The development of a drug-misuse GIS would create a powerful visualisation and 
forecasting tool with easily understandable outcomes. A drug-misuse GIS could also be 
a focal point for integrating and developing epidemiological understanding of trends in 
drug use within and across Europe. 
What geographic areas do the models consider? 
A flexible GIS system would be capable of modelling drug use at city, regional, country 
and international levels. 
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USING AVAILABLE DATA WITH DYNAMIC MODELS 
TO ESTIMATE THE EXTENT OF PROBLEM DRUG USE 
Carla Rossi 
Problem drug use is a hidden phenomenon that can only be studied by indirect indicators 
linked to its observable consequences, such as crime, health problems, infectious diseases 
and death. This chapter begins with a description of possible indicators available in 
different countries. One of the major problems in monitoring problem drug use and in 
evaluating control strategies is determining the extent of the problem, that is, the size of 
the drug-using population. To this end, various mathematical models have been used. 
Specifically, these models are based on the production processes of the observable 
data, which produce the observable indicators. Such models allow the data collected 
by social agencies to be used for estimating the size of the hidden population of interest 
and for making inferences. Several examples are reported to show how to implement 
the various methods, and potentialities and problems are discussed. The models taken 
into account are essentially dynamic models, such as Poisson models, multiple capture-
recapture models and infectious-disease models. The sources of available data are also 
discussed and various existing data from different sources and countries are used in the 
examples of application. 
Models, data and indicators for hidden processes 
In developing policies and evaluating interventions for controlling the use and abuse of 
illicit drugs, it is necessary clearly to define the objectives to be reached, the means of 
achieving those objectives and, most importantly, the measurements (i.e. data) to be 
used for monitoring interventions. To analyse a complex phenomenon like drug abuse, 
a systematic approach must be adopted, including the use of statistical methodologies 
for both describing and interpreting the current situation and proper mathematical and 
statistical models for making inferences and predicting trends. However, to perform 
these types of analyses on the collective phenomenon of the illicit drug market, it is 
necessary to have reliable data on the various critical events that constitute the visible 
part of the phenomenon and to use suitable mathematical models of the production 
processes of such observational data (Rossi, 1999a). 
In fact, observational data, which are already available in various countries, should play 
an important role in developing and monitoring national and international drug policies 
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and in developing suitable mathematical and statistical models to support decision­
making. Mathematical models describing currently available macro-data are much more 
useful than complex mathematical models for mirroring micro-phenomena, which 
require different kinds of experimental processes of data collection and would be difficult 
to implement. These complex models would also be very costly and time consuming, 
as shown for ad hoc population surveys for measuring the extent of illegal substance 
use and abuse among the general population or particular subgroups. 
In any case, one of the primary concerns is to determine the nature and the extent of 
the problem so that appropriate objectives and strategies can be developed; thus the 
first step is to estimate the size of the population of drug users and, more specifically, of 
'problem' drug users. However, since the use of psychoactive drugs is restricted or 
considered illicit in most countries, drug consumers and dealers are forced to conceal 
their habits. As a consequence, the extent of illicit drug use and abuse and the size of 
the drug market can only be measured by indirect methods based on mathematical 
models that mirror the behaviours of various measures or indicators, such as those 
developed to estimate 'hidden' phenomena (NIDA, 1990). Table 1 lists a set of indirect 
indicators developed within the World drug report project of the United Nations 
International Drug Control Programme (UNDCP). These indicators refer to some 
observable aspects of drug abuse, known as 'drug-related phenomena'. Indeed, it is 
quite difficult to identify epidemiological aspects related solely to the use of illegal 
drugs, particularly if such substances are not considered to represent serious health 
hazards (e.g. cannabis, whose use does not seem to cause any major detectable 
problems). 
All of the indicators listed in Table 1 are relative measures obtained by dividing the 
absolute frequencies by the sizes of the corresponding reference populations. Statistics 
on drug seizures can be simply expressed in per capita units with respect to the general 
population. Although these statistics are of little use in analyses of a single country 
where absolute figures can also be used, they are extremely useful for cross-sectional 
analyses. 
Some of the indicators consist of directly observed data recorded by social agencies, 
for instance data on drug seizures, which are recorded by the police, or data on persons 
detained, which are recorded by justice departments. Other indicators are based on 
different records kept by social agencies or on survey data. Since a variety of data 
sources are used, the quality and accuracy of the indicators are not comparable. In 
particular, data from surveys conducted in different countries with the aim of estimating 
the prevalence of drug use cannot generally be compared because of major differences 
in the basic methodology. 
Many indicators are indirect measures of several phenomena simultaneously, in 
particular, most indicators of drug-related phenomena are linked to both health 
consequences and law enforcement and are indirect measures of the extent of the 
illicit drug market and, consequently, of illicit drug use as well. Thus these indicators 
cannot be used independently, and appropriate mathematical and statistical models 
are required. For instance, the absolute frequency of persons detained for drug-related 
offences, denoted by 'nd', can be supposed to be a function of law-enforcement policies, 
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Table 1 : Possible indicators of 
Indicator 
drug-related phenomena 
Measuring 
Drug-related deaths 
Hospital admissions 
Clients of drug-treatment services 
AIDS and other infections due to drug use 
Injecting drug use 
Frequency or daily abuse 
Life-time prevalence of use 
Number of seizures/quantities seized 
Warnings and similar actions 
Persons detained for drug-related offences 
Drug abusers detained for other crimes 
Expenditure on education, community 
activities, etc. 
Risky use of drugs/extent of drug market 
Drug-related morbidity/extent of drug 
market 
Rehabilitation policy/extent of drug market 
Risky use of drugs/extent of drug market 
Risky use of drugs 
Risky use of drugs/extent of drug market 
Extent of use 
Law-enforcement policy/extent of drug 
market 
Repression policy/extent of drug market 
Law-enforcement policy/extent of drug 
market 
Drug-related criminality/extent of drug 
market 
Prevention policy 
denoted by 'le', and of the extent of the illicit drug market, denoted by 'dm', as in the 
following equation: 
nd=f(le,dm) 
In particular, the equation below can be considered as quite reasonable 
nd=f{(le)(dm)}=k(le)(dm) 
assuming that nd is equal to zero if either the extent of the market or the law-enforcement 
is zero and that nd is reasonably proportional to both quantities. Other indicators can 
be estimated with similar equations. Since most of these indicators depend on dm, 
there is a strong mutual correlation among them. 
To obtain adequate results in the processes of modelling and of making inferences, it is 
thus particularly important to analyse the different means used for collecting the necessary 
data, that is, to discuss the different sources of data and to set up suitable dynamic 
models of the data-production processes. In fact, the quality of data may strongly depend 
on how they are collected and on the specific objectives of the data collection: these 
aspects should be taken into account when proposing a mathematical model. 
The following section, 'Data sources', describes the main sources of experimental and 
observational data on drug-related phenomena. This is followed by a brief description 
of the various drug-related phenomena and by a critical analysis of several studies 
conducted in different countries with the aim of investigating the peculiarities of the 
69 
MODELLING DRUG USE WITH AVAILABLE DATA 
various approaches and the different assumptions that are needed to develop sound 
inferential procedures. The final section of this chapter describes certain mathematical 
models, both classical and original, and evaluates their application to existing data sets 
from different countries, thus allowing for a better understanding of the advantages 
and limitations of these models. 
Data sources 
There are two main sources of data on drug-related phenomena: records from social 
agencies such as the police, hospitals or prisons, which produce observational data; 
and anonymous surveys for studying the different phenomena (e.g. prevalence among 
high-school seniors), which produce experimental data. Both sources have their 
advantages and limitations. Data from social agencies are usually recorded for 
administrative purposes rather than for monitoring the phenomena. As a result, the 
format of the records is not ideal for making quantitative socio-economic analyses or 
for easily choosing mathematical models and making inferences. Furthermore, such 
data can only be released in an aggregated form via statistical tables, and the aggregation 
often only serves some bureaucratic purpose (e.g. reporting data to the national 
parliament or to the United Nations). Consequently, the most useful information (i.e. 
correlations among different phenomena) is usually lost. Surveys can be used to gather 
more complete and complex information on the phenomena via an appropriate 
questionnaire. However, if the questionnaire is too complex and/or the questions on 
illicit drug use are too direct, some respondents may have difficulties in understanding 
the questions or they may try to conceal their illegal habits, even when anonymity is 
guaranteed. Other respondents may simply decide not to answer certain questions, 
thus creating the problem of missing data, which cannot be addressed using 
straightforward statistical methods. Moreover, surveys are costly and time-consuming. 
Examples of both sources of data (i.e. social agencies and surveys) are provided below 
in order to explain how these sources can best be used and to suggest how the data-
gathering process can be improved and modelled to make inferences on the various 
hidden processes of interest. 
Surveys (experimental data) 
Surveys constitute a means of systematically gathering information on a given population. 
Those conducted on all members of the population are referred to as 'census surveys', 
whereas those targeting specific sub-populations or groups are known as 'sample surveys'. 
Determining which of these two types of surveys is most appropriate is generally based 
on the specific objectives to be reached and the resources that are available: for studying 
the phenomenon of drug use and abuse, sample surveys are in most cases the only 
reasonable choice. 
When designing a sample survey, particular care must be taken in choosing the sampling 
technique. Only random sampling allows results to be generalised to the entire 
population, keeping the estimation error under control. Unfortunately, random sampling 
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is not feasible for the hidden populations considered here. Thus, to minimise errors, 
the only alternative is to make suitable prior assumptions and to properly model, 
mathematically, the data-generating process. 
Records from social agencies (observational data) 
Many different agencies collect data related to illegal drug use and abuse. Data collected 
in connection with the process of law enforcement can be distinguished from those collected 
in connection with the process of health care. Unfortunately, the collection of data by 
social agencies is strictly related to the given country's regulations, laws and policies on 
drug-related phenomena, and available information only refers to the visible part of the 
hidden processes. In particular, for drug use and abuse, some inference can be made 
based on data collected on the health consequences of drug abuse, whereas for aspects 
linked to the illegal market or crime, data on different aspects of law enforcement can be 
used. In any case, for this source of data, as for data from surveys, it is crucial to make 
suitable assumptions and to set up proper models for the data-production processes. 
Furthermore, more reliable results can be obtained by pooling data from different sources 
(e.g. different social agencies and sample surveys) in order to overcome problems related 
to the existing correlations of the indicators. Finally, to gain an understanding of the 
overall issue, both observable and hidden drug-related phenomena must be analysed. 
Drug-related phenomena 
The drug problem involves not only those phenomena linked to addiction in the strict 
sense - such as morbidity due to infectious and chronic diseases, drug-related deaths 
(caused by overdose, infectious diseases, endocarditis and cirrhosis), and the medical 
assistance offered to drug abusers (assistance from the national health service and periods 
spent in live-in rehabilitation centres) - but also many other aspects that have a 
considerable impact on individuals who have no connection whatsoever with drug 
addiction (e.g. victims of petty crimes linked to drug addiction). The potential effects of 
these specific aspects are considered below. 
Health consequences of illegal drug abuse 
The health consequences of drug abuse include all aspects of the phenomenon that 
have an impact on health services: illnesses linked to drug addiction (e.g. hepatitis, 
endocarditis, septicaemia and AIDS); hospital admissions due to intoxication or other 
causes strictly related to drug use; initiatives undertaken by health services to rehabilitate 
drug abusers (e.g. out-patient and inpatient facilities and mobile units); and juvenile 
mortality linked to drug addiction (overdose, AIDS, violent deaths and deaths caused 
by infections and other drug-related syndromes). It must be stressed that these processes, 
which can be modelled to make inferences about the hidden phenomenon of drug use 
and abuse that cause them, greatly depend on the specific drug used and on existing 
policies. In fact, the type of drug most commonly injected varies by country: heroin 
and opiates in the European Union; cocaine in the United States; and central nervous 
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system stimulants in Sweden. This must be taken into account when proposing models. 
The different drug laws, policies and therapeutic treatments for drug addicts should 
also be taken into account. For example, in countries where hepatitis Β prevention 
programmes targeting intravenous drug users (IDUs) were implemented in the early 
1980s, the spread of HIV and AIDS seems to be limited among IDUs. 
Law enforcement 
Addressing the issue of law enforcement entails analysing the following aspects: police 
operations for controlling money laundering or the consumption of and trafficking in 
substances defined by legislation as narcotic drugs or psychoactive substances; people 
detained for drug-related crimes (i.e. for breaking drug laws or for being drug users 
who have committed serious or petty crimes connected with the drug market); and 
relative administrative or penal proceedings. 
The illegal drug market 
The illegal drug market can be quantified by determining or estimating the number of 
people working in this economic sector. Data for making inferences about this 
phenomenon using appropriate models can be obtained from records of drug seizures, 
incarcerations and proceedings for drug-related offences. 
Organised and petty crime 
'Petty crime' includes those crimes linked to the drug-using lifestyle of abusers (e.g. 
petty larceny, bag-snatching and pick-pocketing); 'organised crime' refers to the illegal 
drug market (e.g. production of and trafficking in drugs, and crimes committed by 
criminal organisations against persons belonging to rival 'cartels'). Based on the data 
concerning these drug-related phenomena and on the corresponding mathematical 
models, it is possible to perform the following types of analyses: 
• analysis of an individual country for monitoring national drug policies and conducting 
cost-effectiveness analyses; 
• panel studies for analysing and forecasting trends; and 
• cross-sectional analyses for comparing regional or national policies or monitoring 
international policies. 
Again, it must be stressed that the statistics available from social agencies and, at times, 
those from surveys, are strictly related to the given country's specific drug-control 
regulations, which greatly determine the specific categories used to disaggregate data. 
Study examples 
The examples provided below include descriptions of various methodologies and of 
the problems encountered when modelling processes of data production and collection 
to estimate the size of hidden populations and monitor drug-related phenomena. These 
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examples highlight the fact that, in order for a model to be useful, it must include 
empirical data on specific laws and policies. The data used for the examples were 
taken from the Core Countries database (see UNDCF; 1977). 
A panel study: the military conscript survey in Sweden 
This study is a census survey conducted among military conscripts using a specific 
questionnaire. One of the questions included in the questionnaire is whether or not 
the individual has used illegal substances. Given that this is a direct question that requires 
a direct answer, it is necessary to consider the degree of reliability of the information 
collected (i.e. the observed frequency of use based on the number of self-reported 
affirmative responses) and the potential to generalise this information (i.e. to estimate 
the prevalence among the population based on this observed frequency). 
It is clear that simple reporting of use would be misleading, as there were many missing 
answers and the proportion of missing data increased sharply fol lowing the 
implementation of stricter drug regulations in Sweden in 1980: in 1980 there was a 
4 % rate of missing data, increasing to 17 % in 1994. Specifically, this increase may 
reflect the passing of a law in 1992 on coercive care of adult drug abusers, as well as 
the criminalisation of drug use in 1988 and the introduction in 1993 of a maximum 
sentence of six months' imprisonment for drug use. Despite the fact that the conscripts 
were guaranteed anonymity, these laws may have influenced their decision of whether 
or not to answer the question. 
To increase the reliability of this kind of survey, randomised response models (RRM) 
can be used, even when questionnaires include questions on the use of illegal substances. 
Though RRM entails additional costs and time, the results obtained (observed 
prevalences) are more reliable and can generally be used as unbiased estimates of the 
population prevalences. When using RRM, an appropriate (i.e. simple) stochastic model 
is needed to mirror the data-production mechanism. Selected results from an experiment 
based both on direct answers and on answers using RRM are reported in the country 
profile for Italy in the UNDCP World drug report (1997) and in Stovali (1993). 
The RRM method is aimed at reassuring the respondent that affirmative answers to 
questions on illicit behaviour cannot be imputed to him or her. Specifically, the question 
is answered indirectly by the respondent, using the following procedure: 
* When designing the questionnaire, the 'problematic' question is paired with a 
'neutral' question, for instance: 
1. 'Have you used illicit drugs in the past month?' 
1 '. 'Were you born in the first quarter of the year?' 
* The respondent is requested to use a random mechanism with two outputs to choose 
which question to answer. The probabilities of the outputs of the random mechanism 
are known by the interviewer. For instance, the respondent is asked to toss dice, 
without the interviewer seeing the outcome, and to answer the first question if the 
result is 1 or 2 and the second question otherwise. 
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The respondent simply answers 'yes' or 'no' and the specific question answered is 
known only to him or her. 
If the unknown prevalence of the illicit behaviour is denoted by p, the probability of 
the first output in the random mechanism (in this case 1/3) denoted by q, the probability 
of an affirmative answer to the second question (in this case 1/4) by m, and the relative 
frequency of the affirmative answers by f, then ρ can be estimated using the following 
equation: 
p = {f-m(l-q)}/q if the result is greater than zero 
p=0 otherwise 
The resulting estimate has been shown to be correct and consistent. In a study performed 
in Perugia, Italy, a large number of university students were interviewed to study the 
performance of the procedure using 'problematic' questions on drug use and racist 
behaviour. The results (Stovali, 1993) were quite satisfactory and show that the estimated 
prevalences obtained using direct questions were consistently lower than those obtained 
when using RRM. 
• One question was: 'Has anyone offered you illicit drugs in the past year?' The 
observed prevalence based on the direct method was 1 0 % , whereas it was 15.8 % 
using RRM. 
• Another question was: 'Have you used cannabis or derivatives in the past year?' 
The observed prevalence was 5.3 % with the direct method and 24.6 % with RRM. 
• A further interesting question was: 'Have you used amphetamines or similar drugs 
in the past year?' The observed prevalences were 1.6 % and 5.9 %, respectively. 
The procedure was also applied by the city of Verona, Italy, in 1981 and again at the 
end of the 1980s to estimate the prevalence of illicit drug use, of drug-offering near 
schools, and of other types of behaviour linked to the illicit drug market and to drug use 
among high-school students. 
The three questions on drug use were as follows: 
• 'Have you used any kind of drug in the past year?' (one-year prevalence); 
• 'Have you used any hard drug (i.e. injected) in the past year?'; 
• 'Has anyone offered you illicit drugs in the past year?' 
Panel analyses based on records from social agencies 
Two similar panel analyses performed in Italy and Sweden are described and compared 
below. 
As an example of an analysis based on panel data from social agencies, time trends of 
incarceration in Italy are examined, including an assessment of the impact on the Italian 
population and the possible influence of different laws on the frequency of detention 
of IDUs (Table 2). In brief, a 1990 law on drug abuse seems to have resulted in an 
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Table 2: Mean number of inmates, detention rate of IDUs and percentage 
of inmates represented by IDUs (IDU %) by year, Italy, 1986-95 
Mean no. Detention rate 
Year of inmates (x 100 000) IDU % 
1986 33 609 59 18 
1987 31 773 55 16 
1988 31 382 55 24 
1989 30 680 53 25 
1990 25 931 45 28 
1991 32 971 58 32 
1992 45 538 80 32 
1993 50 748 90 30 
1994 52 410 92 29 
1995 49 027 86 29 
Source: Italian Ministry of Justice (1997) 
increased detention rate of IDUs and an increased percentage of prisoners represented 
by IDUs (IDU %). A 1993 referendum that depenalised the personal possession of 
drugs also seems to have influenced the IDU %, apparently resulting in a decreasing 
trend. To test the hypothesis that the IDU % has significantly changed since 1993, a 
comparison can be made, using a standard hypothesis test for the means of non-paired 
data, between the average IDU % for 1991-92 and that for 1994-95. The comparison 
produces a u statistic (u = 10) that is highly significant for both unilateral and bilateral 
tests compared to the standard normal variate. The same result can be obtained 
comparing the means before and after 1990. This, of course, does not mean that the 
1990 law or the 1993 referendum had a causal effect on the trends of the phenomena 
analysed, but only that there is a significant statistical association. The study of the 
possible causality does not just involve statistical methods, which can only provide 
some clues and indications for investigating other means and information and a proper 
dynamic model of the entire process. 
The second example of a panel analysis refers to incarceration in Sweden (Table 3). 
The IDU % shows an initial increase followed by a trend of stabilisation. Thus it does 
not seem to be influenced by the enactment of a new law on the coercive care of adult 
drug abusers in 1982, the criminalisation of drug use in 1988 or the introduction of a 
maximum sentence of six months' imprisonment for drug use in 1993. Only the 
difference between the percentages before and after 1982 is statistically significant. 
A cross-sectional analysis: the impact of drug-related deaths in different countries 
Deaths caused by drugs are often mistakenly considered to be one of the main indicators 
of the impact, whether positive or negative, of initiatives for controlling drug abuse. 
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Table 3: Mean number of inmates and IDUs and percentage 
of inmates represented by IDUs (IDU %) by year, Sweden, 1980-95 
Year 
1980 
1981 
1982 
1983 
1984 
1985 
1986 
1987 
1988 
1989 
1990 
1991 
1992 
1993 
1994 
1995 
Mean no. 
of inmates 
3 795 
4116 
4112 
4 280 
3 708 
3 617 
3 414 
3 792 
3 933 
3 944 
4 036 
3 803 
4 005 
4 290 
4 581 
4 408 
Mean no. 
of IDU inmates 
962 
1 168 
1 291 
1 487 
1 158 
1 336 
1 381 
1 509 
1 654 
1 653 
1 597 
1 586 
11 672 
1 742 
1 813 
1 773 
IDU % 
25 
28 
31 
35 
31 
37 
40 
40 
42 
42 
40 
42 
42 
41 
40 
40 
Source: Swedish Council for Information on Alcohol and other Drugs (1996) 
Since the data provided in Table 4 are not uniform, at least with regard to the year 
under study, comparisons can only be used to show how the methodology works and 
to provide examples of potential problems. It should also be noted that the definition 
of 'drug-related death', also referred to as 'substance-abuse-related mortality', differs 
by country and that it depends on the type of drug most commonly correlated with 
death. Some countries only consider overdoses as drug-related deaths, whereas others 
include drug-related accidents and deaths due to long-term abuse. Data-collection 
techniques may also vary and thus provide different results. When data were available 
from different national sources, mainly social agencies, even in the same country, 
discrepancies were detected in the reported numbers of drug-related deaths, as 
demonstrated, for example, in Italy (Conti et al., 1999). 
The main problem with cross-sectional analyses is thus related to the non-comparability of 
country statistics, due to the use of different definitions and data-collection systems. These 
considerations should be taken into account when developing a model of health 
consequences of drug use and abuse or a model of drug-related mortality, especially when 
death statistics are used for the purposes of estimation, evaluation and monitoring. 
To overcome this problem and to obtain an overall picture of the situation in various 
countries, it is possible to use ordinal indicators (grading) instead of numerical measures. 
This entails arranging the different countries according to indicators and using, for 
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Table 4: Number of drug-related deaths and per capita equivalent in 
various countries, 1991 and 1992 
Country Year 
Australia 
Austria 
France 
Germany 
Italy 
Spain 
Sweden 
Switzerland 
UK 
USA 
1992 
1991 
1991 
1992 
1992 
1991 
1994 
1991 
1992 
1992 
No. of 
drug-related 
deaths 
820 
116 
411 
2 099 
1 217 
579 
203 
405 
1 421 
5 601 
Per capita 
equivalent 
(residents in 
thousands) 
0.046 
0.015 
0.007 
0.026 
0.021 
0.015 
0.023 
0.060 
0.024 
0.022 
Note: EU Member States are given in bold type 
Sources: UNDCP(1994, 1997) 
comparative purposes, a grading system, which is less affected by shifts and errors in 
the basic data (this procedure is commonly adopted for analysing the quality of life in 
various countries or cities). 
A cross-sectional analysis: the impact of the HIV/AIDS epidemic among IDUs 
The European Centre for the Epidemiological Monitoring of AIDS, Paris, collects quarterly 
individual data on AIDS cases notified in European countries. Table 5 shows the 1995 
incidences per million IDUs. 
The rankings can be used to perform cross-sectional analyses of the major health 
consequences of drug abuse, namely drug-related deaths and AIDS, by totalling the 
ranking figures in each country (Table 6). 
In Switzerland, the ranking for drug-related deaths is equal to that of AIDS, and if 
considering the total of the two rankings, there are similarities between Austria and the 
United Kingdom and between France and Sweden. However, when considering the 
individual rankings in each country, there are considerable differences among the 
countries listed. These variations are due to the fact that the deaths related to injecting 
drug use, either directly or indirectly (i.e. those related to AIDS among IDUs and those 
strictly related to drugs), have different distributions in the different countries. It must 
be noted that since the two death processes involve the same population of IDUs 
engaging in risk behaviour, they represent competing risks. Thus the two figures are 
negatively correlated within each country and require a suitable mathematical model 
to be interpreted and used for making inferences. In any case, as explained below, 
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Table 5: AIDS incidence among IDUs and ranking in selected European countries, 1995 
AIDS incidence 
Country (x 1 000 000 IDUs) Ranking 
Austria 5 4.5 
Denmark 6 6.0 
France 22 7.0 
Germany 3 2.5 
Netherlands 5 4.5 
Italy 61 10.0 
Portugal 41 9.0 
Spain 115 11.0 
Sweden 3 2.5 
Switzerland 32 8.0 
UK 2 1.0 
Source: European Centre for the Epidemiological Monitoring of AIDS (1996) 
Table 6: Overall rankings of two major health consequences of 
drug abuse for selected European countries 
Country 
Austria 
Denmark 
France 
Germany 
Netherlands 
Italy 
Portugal 
Spain 
Sweden 
Switzerland 
UK 
Ranking of 
drug-related deaths 
2.5 
-
1.0 
7.0 
-
4.0 
-
2.5 
5.0 
8.0 
6.0 
Ranking of 
AIDS 
4.5 
6.0 
7.0 
2.5 
4.5 
10.0 
9.0 
11.0 
2.5 
8.0 
1.0 
Total 
7.0 
-
8.0 
9.5 
-
14.0 
-
13.5 
7.r> 
16.0 
7.0 
Note: - indicates data not available 
particular care must be taken when using AIDS and death processesto make inferences 
about the hidden population of IDUs. In the presence of the AIDS epidemic among 
IDUs, some of the popular estimates obtained by simple multiplication methods on the 
basis of death statistics can be quite inconsistent. Thus, the two processes must be 
carefully modelled (proper point processes) in order to obtain useful and comparable 
estimates. 
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Multiple sources: improving inferences on drug-related phenomena 
As mentioned above, one of the crucial aspects of monitoring drug-related phenomena 
is estimating the extent of drug use and abuse, which can only be done using indirect 
methods. Provided below is a description of how to use some of these methods, which 
depend on the type of data available from social-agency records and, in some cases, 
from surveys. 
Estimates obtained by stratified calibration samples 
This methodology can be used when a calibration population is available and the 
prevalence of the hidden attribute of interest (e.g. illicit drug use) can be observed or 
estimated among this population. For example, for a calibration sample stratified by 
variables such as gender, age and employment status, among others, with single strata 
denoted byS1, S2,... Sk, the corresponding observed prevalences of the hidden attribute 
denoted by p1, p2, . . . pk, and the sub-populations corresponding to the strata denoted 
by N1, N2, . . . Nk individuals, the size of the hidden population can be estimated using 
the following equation: 
Nh = Nlpl+N2p2 + ...+Nkpk 
This method provides good estimates only if the strata and the sub-populations are 
homogeneous; in other words, the hypothesis that the data observed in the various 
sub-samples are randomly chosen (simple random-sampling model) must be assumed 
to be true. This is the crucial hypothesis of this method and it should always be verified 
before the method is applied. 
Estimates obtained by probabilistic modelling 
As pointed out, it is crucial to develop suitable basic hypotheses on the data-production 
process and on the structure and properties of the available sample data. It is also 
important properly to integrate data and information from different sources in order to 
obtain better estimates of the size of the hidden populations. 
In the following examples, data from different sources are used to make inferences 
about the prevalence of 'heavy' (HU) and 'non-heavy' (NHU) drug use in different 
countries. 'Heavy use' is defined as daily or injecting use. 
Estimating prevalence using data modelled by truncated Poisson processes 
Table 7 presents data on the total number of drug users notified to the different social 
agencies in Sweden during 1992, disaggregated with respect to the number of 
notifications per person during the period and with respect to the type of drug use 
(i.e. heavy use and non-heavy use). 
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Table 7: Number of drug users notified to different social agencies in Sweden, 1992 
Number of 
notifications 
1 
2 
3 
4 
5 
6 
>6 
TOTAL 
HU 
Number 
3 675 
2 207 
1 390 
788 
492 
250 
301 
9 103 
% 
40 
24 
15 
9 
5 
3 
3 
100 
Number 
8 088 
1 709 
414 
135 
34 
4 
4 
10 388 
NHU 
% 
77.86 
16.45 
3.99 
1.31 
0.33 
0.04 
0.04 
100.00 
Total 
11 763 
3 916 
1 804 
923 
526 
254 
315 
19 491 
Note: data disaggregated with respect to the number of times a single person was notified during the 
period and with respect to type of use (HU or NHU) 
Source: Olsson et al. (1992) 
A simple mathematical model that could be used for heavy and non-heavy users is the 
truncated Poisson model, approximating the binomial model, which allows for the 
calculation of the probabilities related to the number of notifications per person per 
year (see Figure 1 below), in other words, the probability that a single drug user, whether 
engaging in heavy use or not, is notified k times during a specific year (k = 1,2, ...). On 
the basis of these probabilities, it is possible to predict the expected number of persons 
notified k times in a specific year and, by comparing these data with the actual observed 
data, it is possible to estimate the proportion of the population that is hidden (i.e. the 
size of the population which corresponds to zero notifications during that year). 
The different estimates obtained for the parameters of the Poisson model using different 
pairs of k values and data from Table 7 indicate that once a person has been notified, 
he or she is more likely to be identified again than those who have never been notified. 
In other words, the intensity of the notification processes is lower for the first notifications, 
compared to successive ones, for several reasons: 
Once a person is known to be a drug user, it is easier to identify him or her again as 
a drug user. 
* Certain drug users tend to engage in riskier behaviour with respect to the rest of the 
drug-using population and are easier targets for the notification process. 
* Once individuals have been identified at least once, they may become less cautious 
and engage in riskier behaviour because they are aware of already being known as 
drug users. 
These considerations are confirmed by the observation that the notification processes 
for non-heavy use have lower intensities than those for heavy use, since individuals 
practising NHU engage in less risky behaviour (i.e. they are not daily users or injectors). 
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Figure 1: Truncated Poisson model 
The general formulae of the models are: 
nke~n 
P(HU = k) = N 
k! 
mke~r" 
P(NHU = k) = M —— 
k! 
where k refers to the number of notifications, as reported in the first column of Table 7, and 
n and m are the intensities of the notification processes per person, related respectively to 
HU and NHU. Both are unknown and must be estimated using the available data. 
If the expected number of persons notified for a given value of k are considered, the following 
equation can be used: 
E(HU = k) = N — 
k! 
mke~l" 
P(NHU = k) = M —— 
k! 
where N and M are the overall sizes of the hidden populations of drug users to be estimated 
(HU and NHU, respectively). 
If the observed data are used as estimates of the expectations, suitable values can be found 
for the unknown quantities, and the fitting of the Poisson model to the observed data can be 
checked. 
Thus the processes of notification are not homogeneous Poisson processes. Using some 
mathematics, appropriate generalisations of the Poisson process (Cox processes) can 
be applied to better model the notification processes for heavy and non-heavy use and 
to obtain estimates for the different intensities and population sizes. However, in the 
present case, it is possible to estimate at least the order of magnitude of the populations 
simply by using the mean values of the intensities, specifically, calculating the mean of 
the intensities obtained by different pairs of equations. This is done (excluding the first 
notification) using k<7 given that individuals notified a greater number of times (k>6) 
account for a small percentage of the cases, providing data that may be less reliable. 
Using this simplified procedure, the following results are obtained: 
n=2.6, N=19 000; m = 0.7 M=24 000 
where n and m are the intensities (rate per person per year) of the notification processes 
per person for heavy and non-heavy use, respectively, and N and M are the overall 
sizes of the hidden populations of drug users (heavy and non-heavy use, respectively). 
The estimated order of magnitude for N is totally consistent with the estimate obtained 
by Olsson et al. (1992) by using multiple capture-recapture methods. 
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Estimation methods based on multiple capture-recapture 
The same individuals may appear on records from several social agencies. For instance, 
heavy heroin users may appear in the database of health-care services (HCS), in the 
database of the Prison Administrative Authority (PAA) and in the National Register of 
AIDS Cases (RAIDS). 
If some of the registers refer to the same period of time (e.g. a specified quarter or 
semester), a simple multiple-classification model can be used to estimate the average 
size of the hidden population during the period, under the basic hypothesis that the 
registration processes are independent. For example, if there are simultaneous 
registrations in the databases of the PAA and RAIDS, it can be supposed that the basic 
hypothesis holds and the data can be reported using a summary table, such as that 
illustrated below (Figure 2). 
Figure 2: Cross-tabulation of data from the PAA and RAIDS in the same period 
RAIDS 
PAA 
+ 
N4-+ N + - N + * 
N -+ 
N*+ N * - N 
Notes: N = the size 'of the hidden population (to be estimated) 
N + + = the observed absolute frequency of the persons registered in both databases 
N- = the size of the population not observed in either of the databases (unknown) 
NH— = the observed absolute frequency of the persons registered only in RAIDS 
N-+ = the observed absolute frequency of the persons registered only in the PAA 
N-* = the size of the population not registered in RAIDS (unknown) 
N + * = the observed absolute frequency of the persons registered in RAIDS 
N*+ = the observed absolute frequency of the persons registered in the PAA 
N*- = the size of the population not registered in the PAA (unknown) 
If the hypothesis of independence between the registrations is satisfied, then the estimate 
of N simply results in 
N=(N+*)(N*+)/(N++) 
If the two sources are correlated, then estimates are obtained from above (negative 
correlation between the two sources) or from below (positive correlation). 
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The method can be easily generalised to more than two data sources and to dynamic 
situations and can be applied to data gathered by different social agencies in different 
countries. Provided below are two examples of how the method can be used. 
Estimating the number of heavy heroin users in Italy 
Figure 3 refers to data from the PAA and RAIDS in Italy. 
Based on these data 
N=218000 
which is the estimated size of the population of heavy heroin users (i.e. the population 
exposed to the risk of being registered (captured) by both the PAA and RAIDS). However, 
this figure probably represents a low estimate, due to positive correlation between the 
two recording systems. 
Figure 3: Cross-tabulation of observed data from the PAA and RAIDS, Italy, first half of 
1996 
PAA 
+ 
106 1 594 1 700 
RAIDS 
13 494 
13 600 
Note: * indicates missing data 
Sources: Italian Ministry of Justice (1997) and COA (1997) 
Estimating the number of heavy drug users in the United Kingdom 
The UK Home Office Statistical bulletin includes tables on different drug-related 
phenomena, in particular, data on notifications of heavy drug users and of drug-related 
deaths among heavy users. The two processes can reasonably be considered as 
independent and as affecting the same hidden population. Thus data can be classified 
according to Figure 2 above, resulting in Figure 4 below. 
Straightforward calculations produce the following estimate: 
N=136 000 
This estimate is quite consistent with those provided by official UK agencies and reported 
bytheUNDCP(1997). 
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Figure 4: Cross-tabulation of observed data incidences, 1992 
Drug-related deaths 
+ 
+ 259 24 444 24 703 
Notifications 
1 162 * 
1 421 
Note: * indicates missing data 
Source: Home Office (1994) 
Estimating the prevalence of heavy heroin users involved in acquisitive crimes 
Most heavy heroin users in Italy are involved in criminal activities to make money to 
buy drugs and, as in other countries, they mainly commit acquisitive crime (e.g. theft 
and robbery) or deal in drugs. Some of these individuals are identified, reported and 
prosecuted for such crimes and are thus included in crime statistics and in the database 
of the PAA. 
According to PAA statistics for the second half of 1995, the absolute frequency (Na) of 
imprisonment of IDUs for acquisitive crimes was 5 788 (the same order of magnitude 
for 1996). Crime statistics and data from a multipurpose investigation (Indagine 
multiscopo), reported by the Italian National Institute of Statistics (ISTAT, 1993), provide 
the following additional information, which allows for calibration: 
the proportion of persons involved in acquisitive crimes that are known to the police 
and for whom the criminal proceedings have begun isf=5 % (this figure has remained 
fairly constant in recent years); 
the proportion of acquisitive crimes that are reported to the police is about q=45%. 
If all of the data and information from the two sources are pooled, the order of magnitude 
N of the hidden population of heavy drug users (mainly heroin users) involved in 
acquisitive crimes in the second half of 1995 can be estimated using the simple formula 
(homogeneous model): 
N = Na/(fq) 
The result obtained by straightforward calculation is: 
N=257 244 
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However, this is presumably a high estimate because of the positive correlation of the 
events A={an IDU committing an acquisitive crime} and B = {being reported to the 
police and prosecuted}, due to possible previous notifications. 
The order of magnitude obtained is extremely consistent with the estimated size of the 
hidden population of heavy users, obtained previously on the basis of AIDS and PAA 
data. It must also be pointed out that the present estimation does not include IDUs 
who do not commit acquisitive crimes but who nonetheless deal in drugs. It also excludes 
those not involved in any criminal activity. Indeed, the number of drug users imprisoned 
for dealing in drugs in the same period is quite high: 6 353. Unfortunately, the same 
information cannot be used on the proportion of dealers who are reported and 
prosecuted. Thus data on imprisonment of drug dealers cannot be used as above to 
improve the estimates. It must also be taken into account that an unknown, and possibly 
high, proportion of IDUs are involved in both criminal activities. 
All of the estimation methods reported above can also be used to estimate the time 
trends of problem drug use when applied in different time periods. For this purpose, 
more suitable dynamic models can be used, as shown below. 
Estimating the prevalence of heavy heroin users using a Markov mode! 
Markov and semi-Markov models can be used to make projections for various 
phenomena related to drug use. In particular, they can be used to model the spread of 
the HIV/AIDS epidemic among IDUs and to make inferences about the prevalence of 
heavy injecting drug users. In the following example, one of the 'simple' dynamic models 
for the HIV/AIDS epidemic, developed within the EU Concerted action (PL 931723) 
multinational scenario analysis concerning epidemiological, social and economic aspects 
of HIV-AIDS on society, is used to estimate the trend of this prevalence in Italy in the 
period 1990-96, using data from the Italian Ministry of Justice and the PAA. The 
relationship between the two competitive processes of death (i.e. deaths directly related 
to drugs and deaths from AIDS) is also addressed (for details on the model and the 
estimation methods, see Rossi and Schinaia, 1998, and Pasqualucci et al., 1998). 
The rationale behind this kind of simple dynamic model is: 
* to use only macro parameters that can be mostly estimated using epidemiological 
data and studies reported in the literature in order to obtain robust forecasting and 
estimation results; 
* to generate projections for available data (in the present case, AIDS-incidence data 
and mortality data, reported quarterly) also taking into account the processes of 
under-reporting and reporting delay that affect actual observed data; 
* to base the model on only a few internal parameters that mirror different kinds of 
behaviour affecting the infectivity process, to be estimated by comparing projections 
and observed data, using suitable statistical methods (e.g. maximum likelihood and 
minimum χ2). 
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The rationale for using such models to make inferences on the dynamics of the IDU is: 
to use external information to model the relations between injecting drug use and 
HIV infection, in order to estimate the prevalence of injecting use on the basis of 
the evaluated HIV/AIDS prevalence; 
• to compare the results with those obtained by other sources or methods, in order to 
validate the estimates and to increase accuracy and robustness. 
Some similar ideas can be found in Kaplan and Soloshatz (1993). 
As an example, the case of an epidemic mode! which provides the overall prevalence 
of HIV and AIDS cases separately can be used. By using external information on the 
proportion of IDUs among HIV-infected individuals, denoted by P(IDU/HIV) = p(HIV) 
and provided by the HIV surveillance system, and the proportion of HIV-infected 
individuals among IDUs, denoted by P(HIV/IDU) = q(HIV) and provided by various 
sources (sample surveys among incarcerated IDUs or IDUs in treatment), the model 
can provide an estimate of the total number of IDUs, denoted by N(IDU), using the 
following simple calibration formula based on the total number of HIV-infected 
individuals, denoted by N(HIV), projected by whichever epidemic model is used: 
N(IDU)= N(HIV)P(HIV) 
q(HIV) 
Similarly, AIDS prevalence can be used in place of HIV prevalence: 
N(IDU)= N(AIDS)p(A,DS) 
q(AIDS) 
Unfortunately, the denominators q(HIV) (i.e. the estimated proportion of HIV-infected 
individuals among IDUs) and q(AIDS) are not always available from routine statistics. 
For example, neither of the sources available in Italy (i.e. sample surveys of IDUs in the 
health-care services and surveys of those in prison) distinguish between cases of HIV 
and AIDS in their official published reports. Thus, only the denominator q(HIV or AIDS) 
can be used, modifying the above formula as follows: 
= N(HIV)p(HIV) + N(AIDS)p(AIDS) 
q(HIV or AIDS) 
In simple terms, the formula divides the current numbers of HIV-infected life-time 
IDUs, obtained by an epidemic model of the HIV/AIDS epidemic from AIDS cases, by 
the estimated current rate of infection in IDUs. It must be noted that the results of the 
estimation method are based only on the projections of the absolute prevalence (number 
of cases) of HIV and AIDS, obtained by whichever epidemic model is used (numerator 
of the calibration formula), and on the estimate of the proportion of individuals with 
HIV or AIDS among IDUs (denominator of the calibration formula), coming from official 
statistics, which are easily obtainable. It must be noted that the results are sensitive to 
uncertainties both in the numerator and the denominator, and these uncertainties 
become particularly important when present in the denominator. For example, if the 
estimated denominator is 2 % and the country's actual denominator is 4 %, the error of 
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the estimate of N(IDU) is 100 %. Thus the accuracy of the estimated denominator is 
important for obtaining good results, especially for those countries where the HIV/ 
AIDS epidemic is small. 
The calibration formula can be applied either at national level, when national estimates 
of the denominator are available, or at local level, when only local estimates are available 
(the numerator can always be estimated at local or national level). The local estimates 
of N(IDU) can be used as anchor points for other methods for obtaining national 
estimates. This possibility is particularly interesting for those countries where local 
prevalence estimates of problem drug use are not available or where obtaining these 
estimates is problematic or costly. The results obtained by the use of the Mover-Stayer 
model on Italian data are reported in Table 8 together with the analogous estimates 
obtained by the multiple capture-recapture method (Rossi, 1999b). These estimates 
are quite consistent with other previously reported estimates. 
The population of IDUs was estimated to have increased from the beginning of the 
1990s until 1995, followed by a decreasing or stabilising trend which coincided with 
an increase in reported drug-related deaths. This effect may be mostly due to the fact 
that the competing risk of death related to the AIDS epidemic has been decreasing in 
recent years among IDUs, with a consequent increase in the risk of dying from drug-
related causes. However, it must also be considered that there is a delay in the process 
that generates drug-related deaths from drug addiction. In fact, data from harm-reduction 
programmes and hospital admissions for non-fatal overdoses indicate that for each 
death from overdose there are approximately ten non-fatal overdoses. Thus, to model 
the mortality process, non fatal-overdoses should also be considered and such events, 
which have an intensity ten times that of drug mortality. These cause a time lag between 
the onset of injecting drug use and the death process (UNDCF) 1997). Therefore, the 
recent increase in the number of drug-related deaths observed in Italy has probably 
been generated by the increase in injecting drug use in previous years. To further study 
Table 8: Number of IDUs in Italy estimated using the Mover -Stayer model for the 
HIV/AIDS epidemic and multiple capture-recapture model, 
and the number of drug-related deaths by year, 1990-96 
Year 
1990 
1991 
1992 
1993 
1994 
1995 
1996 
Notes: MS = 
CC = 
DRD = 
= Mover-
= capture 
= drug-re 
IDUs (MS) 
180 000 
211 000 
224 000 
244 000 
279 000 
310 000 
297 000 
Stayer model 
:-recapture 
lated deaths 
IDUs (CC) 
140 000 
190 000 
230 000 
190 000 
225 000 
235 000 
220 000 
DRD 
1 161 
1 383 
1 217 
888 
867 
1 195 
1 564 
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this phenomenon, the incidence curve of injecting drug use should be estimated, since 
the prevalence curve is not a sensitive enough indicator. 
These considerations confirm that the number of deaths caused by drugs cannot be 
used as one of the main indicators of the impact of policies developed over the years or 
across different countries. They also demonstrate the hazards of estimating the prevalence 
of injecting use by calibration or multiplication methods based solely on death statistics. 
Other health consequences, such as hepatitis Β and C, can also be used as indicators. 
However, the problem with these indicators, at least for Italy, is that notifications of 
these infections is not compulsory. 
It is possible to compare the trends of the estimated prevalences of IDUs with other kinds 
of indicators related to the hidden population, such as the incidence and prevalence of 
IDUs in public or private health-care services, the incidence and prevalence of IDUs in 
jail, and statistics on heroin seizures. First, it is possible to calculate the mutual correlation 
coefficients between couples of indicators. These coefficients can be used to determine 
whether the two indicators considered tend to show similar behaviours (both of them 
increasing or both decreasing) or different ones (one increasing and the other decreasing). 
In particular, when the correlation coefficient is close to 1, there is a strong tendency for 
the two indicators to display similar behaviour, whereas when the coefficient is close to -
1, different behaviour is likely. To facilitate the examination of such mutual coefficients, 
they can be arranged in a table known as a 'correlation matrix'. Table 9 is a correlation 
Table 9: Correlation matrix related to selected variables (PRCOM) , 1 9 9 0 - 9 6 
PRPHC 
PRPHC 1.00 
1NPHC 
INCOM 
PRPRI 
INPRI 
SEIZK 
IDU(MS) 
IDU(CC) 
PRCOM 
INPHC 
0.97 
1.00 
INCOM 
0.59 
0.72 
1.00 
PRPRI 
0.86 
0.88 
0.83 
1.00 
INPRI 
0.50 
0.55 
0.88 
0.83 
1.00 
SEIZK 
0.22 
0.22 
0.21 
0.08 
0.19 
1.00 
IDU 
(MS) 
0.94 
0.95 
0.50 
0.75 
0.29 
0.11 
1.00 
IDU 
(CC) 
0.87 
0.91 
0.79 
0.84 
0.65 
0.49 
0.79 
1.00 
PRCOM 
0.32 
0.59 
0.90 
0.74 
0.91 
0.33 
0.30 
0.72 
1.00 
Notes: PRPHC = prevalence of IDUs in public health-care services 
INPHC = incidence of IDUs in public health-care services 
INCOM = incidence of IDUs in private health-care services 
PRPI = prevalence of IDUs in prison 
INPRI = incidence of IDUs in prison 
SEIZK = seizures (in kg) 
IDU (MS) = injecting drug users using the Mover-Stayer model 
IDU (CC) = injecting drug users using the multiple capture-recapture model 
PRCOM = prevalence of IDUs in private health-care services 
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matrix that allows a straightforward comparison to be made among the estimated 
prevalences of injecting drug use and the other indicators of interest. 
All of the values of the correlation coefficients between the statistics directly related to 
the extent of injecting heroin use and the prevalence estimates are significantly high, 
except those related to seizure statistics, which strongly depend on repression policies 
and the type of police interventions. These high values of the correlation constitute an 
indirect validation of the estimation procedures used. This confirms the agreement 
between some important indicators of drug-related phenomena and the prevalence 
estimates reported above. 
Conclusions 
The main purpose of this chapter was to demonstrate the use of available routine data 
and of dynamic models for estimating the number of problem drug users. With respect 
to other methods which can be applied to estimate the same hidden population, the 
models presented here allow for the use of data that are generally available in most 
Western countries. 
In any case, due to the various uncertainties, related both to data and models, several 
models and methods should be applied whenever possible in order to obtain the best 
description of the hidden population of interest. In the previous sections, this joint use 
of different methods allowed some conclusions to be drawn, at least regarding trends 
and the order of magnitude of the population. 
The observed agreement in the prevalence trends estimated by different methods allows 
some indicators to be used for monitoring different control interventions, at least from 
a qualitative point of view. It must again be stressed that better analysis could be 
performed to monitor interventions on the basis of the incidence curve of injecting 
drug use. 
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MULTIPLE-INDICATOR MODELS 
Roberto Mollica and Fabio Mariani 
Dynamic multiple-indicator models start from the choice of indicators and data available. 
However, drug-related problems are related to the context in which they occur. Dynamic 
evolution of drug use, markets and consumption may vary among countries, and in 
each country among different local and geographic areas, such as rural, suburban or 
urban sites. For the rest of this chapter, the geographic area understudy is referred toas 
the'location'. The target and risk-exposed population is only a part of the total population 
of the considered geographic area. Law enforcement and penalties, addiction treatment 
and care availability, diseases related to illicit drug use and consequent social costs also 
vary across and within countries. 
These general considerations show that working on a multiple-indicator model involves 
being aware of the overlapping aspects which contribute to defining the model and its 
outputs. In this chapter, a monitoring model is proposed which could predict changes 
in the main aspects of drug use and related diseases over time. To pursue this aim the 
use of cause-effect relationships among some indicators is hypothesised. Because of 
the delay between the effect to be observed and the factors which cause that effect, a 
dynamic model capable of providing predictions can be created. Starting from these 
concepts, the model building and its difficulties are discussed in turn. 
As known, every 'location' will have its own approach to drug use and related problems. 
A common model which could be applied to different locations would not necessarily 
emerge from individual studies. Specific sets of indicators relevant to the study location 
may be developed. This would, however, complicate the data-collection requirements 
of such models. If comparisons are being made across large geographic areas, then 
there may be considerable differences between the models. 
The other main characteristic of dynamic models is the collection of data over time. 
The chosen indicators have also to be real and timely to give up-to-date information. 
How the model works 
In this chapter, a simple but effective definition of indicators is proposed to allow the 
same collection for different populations and/or different 'locations' at different times. 
To make model applicability easier, the following indicators are suggested as shared 
characteristics which can be collected in every context. They are classified into three 
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main groups: social (S); legal (L); and medical (M). It is then demonstrated how the 
defined indicators could be combined in a dynamic model. 
Social indicators 
This group involves the most meaningful parameters for social data and situations 
commonly observed in an addict's life. They are considered as risk factors and can also 
be used as predictor factors. The data for these indicators can be acquired from national 
data sources on the general population and can be considered as indicators of social 
disruption. 
51 disaggregate familiar nuclei: separation and divorce can be linked to this item as 
indirect demonstrations of life stress. 
52 total unemployed people: this reflects social general entity of welfare. Lack of 
welfare generally leads to crime and illicit activities. 
53 interruption after primary school: this is akin to a condition that reflects an early 
predisposition to anti-social behaviour. 
Legal indicators 
This second group of indicators includes detected offences related to drug problems. 
Such indicators may be very sensitive to context changes like the spread of new drugs 
and new kinds of addiction. It may be possible to use such indicators as early-warning 
measures of emerging trends. 
LI drug-related law offences: easy and simple evidence about the size and 
characteristics of the black market and major crimes concerning drug use and 
problems. In the case of seizures, the type of drug seized may be indicative of 
market/consumer orientation. 
L2 minor offences: generally these indicate how great is the use of illicit drugs as 
street addicts are involved in this kind of offence to maintain their drug needs. 
L3 under-age arrests: this item could address the 'at risk' population which will still 
be present in the future. 
Medical indicators 
While the social and legal indicators are probably easy to acquire from national and/or 
local reports, not all locations may currently have the proposed health and treatment 
data. However, it is hypothesised that these would match the aims of developing dynamic 
models. 
M7 treated drug users: in particular, this item is valid in the locations where treatments 
are offered to addicts. Some kinds of treatment define the population, as methadone 
treatment does for heroin addicts. For these reasons, the variable could not be 
considered for the analysis of some drug issues. 
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M2 drug-related deaths: this includes not only overdoses, but also crime-related or 
violent deaths that can be linked to drug involvement (car crashes). Such data may 
be available from coroners' reports or autopsy evidence. 
* M3 emergency room: all emergency-room admittances for suspected drug use could 
be detected and recorded. It may be useful to separate patient's demands for 
treatment (if available) or police involvement (if compulsory). 
M4 AIDS cases related to intravenous drug use (IDU): This indicator could involve 
only the numbers at a late stage of HIV infection. While HIV prevalence and incidence 
estimates now have greater accuracy, the numbers are not easily routinely recorded. 
Moreover, new therapies for HIV could delay progression to AIDS. The number of 
new subjects who have undergone anti-HIV treatment could be a good series for 
this indicator, but these data may not be easy to collect. 
The variables listed above represent the main and minimal list that allow the development 
of a proposal for a dynamic model. Most of these data were reported in EMCDDA 
(1995). This suggests that such data are of great importance in drug-addiction monitoring 
and they are studied and surveyed as being discriminate entities and indicators for risk 
conditions. Because in some cases the same variable is investigated and collected using 
different tools or times, the difficulties of matching information among European 
countries could be relevant to the discussion about developing these models. 
Each item can be observed at different times and they can all be clustered at the same 
time (Figure 1). These clusters represent single-point-in-time observation about real 
situations and risk conditions at that time. Consecutive observations indicate the course 
of variables, and in this way some correlation can be found among them. It is interesting 
looking for correlations between risk factors (for example all S and L3 variables) and 
point effects (for example M and other L items) to create the model. In fact, if risk 
factors show a correlation with the next-point-in-time evidence with a certain delay, 
the first data points of risk factors could be used to predict indicators of problems for 
the following period (Figure 2). It is obvious that variables interact with each other at 
different strengths and that a coefficient that allows adjustments between indicators 
using a mathematical model is therefore required. Moreover, by developing the model 
In subsequent periods it would be possible to obtain greater and greater accuracy as 
Figure 1: Example of clustered observations 
Timed 
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T1 1.3 
T2 7.3 
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1 200 
1 nsn 
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M3 
5 940 
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M4 
4 896 
5 691 
Note: data are indicative but not real 
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the historical list of observations grows. For this reason, such a model can be used and 
developed with limited data sets and then amended over time. 
Theoretically, such a model could be used to investigate a specific event, or drug-
related problem, as the outcome of the modelling process. The application of such a 
model may vary on the basis of specific need. If, for example, someone wants to forecast 
the number of emergency-room admittances in order to reinforce staff with a toxicologist, 
the dependent variable will be emergency-room admittance. All other variables 
contribute to the model, as independent factors, in generating the outcome needed. 
However, the variables or indicators would have a different impact in other examples. 
Starting from the risk indicators, the at-risk population and the number potentially 
involved in drug use could be predicted, but some other events (the availability of new 
out-patient treatment resources, for example) could interact with this prediction. This 
is because the presence of any kind of treatment protects addicts from fatal accidents. 
A similar interaction of indicators in a model is constructed to estimate the number of 
Figure 2: Example of trends in variables 
50 OOO-i 
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drug-related deaths. The introduction of methadone treatment protects from street 
opiate overdoses but not deaths from car crashes or those due to the abuse of other 
substances. On the basis of their involvement in the model, variables can be independent 
factors or co-factors and, moreover, both multiple correlation and multiple collinearity 
may apply in the model. Another example concerns predicting minor offences. The 
number of minor offences recorded is related to the number of people involved in 
illicit drug use, especially the number of street users, to the rate of unemployment and 
to the presence/absence of treatment units. Moreover, the model could address the 
effectiveness and efficiency of new laws regarding addicts or new therapeutic 
approaches. 
Two Italian experiences illustrate the potential. The first example is from a study in 
Sardinia into methadone take-home prohibited by a new law at the beginning of the 
1990s. It was seen from a time series of indicators that the application of the new law 
resulted in a dramatic reduction in the treated population. In fact, many addicts preferred 
to quit treatment hoping to abstain from any drug use rather than lose the job they 
were able to preserve or had found during treatment. The second example is from 
Milan and was a study performed by one of the authors of this paper. It was seen that 
low-threshold methadone intervention at a public out-patient unit located in city suburbs 
resulted in a growth in the treated population (ten-fold in three years), a reduction in 
unemployment rates, low HIV incidence and improvements in welfare through 
monitoring indicators. 
The model suggested shows flexibility and can be personalised to suit specific needs. 
For example (how many people will attend treatment units...) in 'locations' (...in Italy...) 
over time (...in next two years?). 
Some weak points to these data-driven models must, however, be underlined. For 
example, people presenting risk factors could be already involved in drug problems 
which cannot be recorded at that time. They can only be recorded when there is the 
evidence of involvement and when variables (estimates at a point in time) demonstrate 
what is the known situation of the drug use. The sense of the model, however, is not to 
fit a drug-addict population estimate, even if a capture-recapture model could 
implement these data, but rather to investigate dynamic relationships. 
Other issues emerge if a specific population, such as those aged 15 to 44, is considered, 
and if how great is the phenomenon to be observed is defined. A selected population 
will have limited variations over a long time and small average changes from one time 
period to the next. Absolute observation could be recorded and used in the model, but 
this would not reflect the prevalence rate. 
Another bias is delay between causes and effects. Time intervals may vary in these 
models from months to years. In a study of a population of addicts, it took an average 
of ten years (with low standard deviation) between the onset of addiction and enrolment 
in a therapeutic programme. This means that the course of addiction follows some 
general rules: onset during adolescence and youth; continuous use until young adult 
age; and treatment attempts. The first period corresponds to the S1, S3 and L3 variables, 
the second to S2, L1, L2, M2 and M3, and the last one to M1 and M4. It could not be 
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the same for other countries where prevention strategies allow early admittance to 
treatment or where law-enforcement agencies impose increasingly severe penalties or, 
again, where HIV/AIDS has a low impact on social health (for example the north to 
south gradient of prevalence and incidence in Italy). As generally a small 'location' will 
keep the same characteristics over several years, it is possible to predict the future 
situation of a requested target outcome. If the number of minor offences or 
unemployment are found to follow primary-school interruption over a one-year period 
it will then be possible to hypothesise the importance of next year's minor offences or 
unemployment predicted by other co-factors or collinearities if the number of last 
year's school interruptions is known. As has been reported, the ten years' gap between 
illicit drug-use onset and admittance to treatment could give an accurate idea of how 
many people will be treated within the coming years. This would allow for planning the 
development of new units or, conversely, the closure of opened ones. 
The dynamic model controls itself every time data are updated. Unexpected results 
can be used to allow the model to verify its accuracy and correct contingent trends. As 
observations can be scheduled differently (every month, every year or every week), it is 
also possible to develop a short-, medium- or long-period forecast when cause-effect 
relationships are linked by different time periods. The figures below explain model 
construction and development with hypothetical data. Each cell represents a value, 
each column a variable and each row a cluster. In Figure 3, a 15-period observation is 
simulated and each cell is labelled by variable name and registration time to make it 
recognisable at the next step. 
In Figure 4, the delay periods which link the cause-effect relationships among the 
variables are hypothesised. 
At this point there are both tabled data and delay times. Moving columns (variables) by 
the time of their delay gives a new figure (Figure 5); each row shows the situation 
arranged by variable time links, and new clusters are now generated. Linked clusters 
would match the real temporal relationships between variables. 
Blue labels are data which could be estimated if variables show correlations with each 
other. In other words, these are the target indicators the dynamic multiple-indicator 
model is intended to predict. Simple bivariate correlations allow a first indication about 
how variables are coupled and related, and it could be the first meaningful target to 
reach. To understand how much a variable is influenced by others, regression models 
have to be applied. The evidence gained in such analysis gives the strength of the 
relationship between the independent factors and the dependent one. If any relationship 
is observed, blue-labelled cells can be estimated as there is a forecast for each of them. 
In this hypothetical example, most of the variables have long delay periods in reference 
to M1 and M4 factors making possible a long-term forecast about these two variables 
which are 'well controlled' by real data; M1/T25 cell hypothesis will be less precise 
because they depend on other derived values (all blue ones). 
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Figure 3: Data table 
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Conclusions 
The applicability of dynamic multiple-indicator models depends on the relationships 
between the indicators. During practical experience of such models, unexpected and 
unsuspected effects were found, and sometimes it is not so easy to justify these results. 
They could be caused by a false response or a new phenomenon. Using the same 
process it is possible to perform retrospective studies on selected populations when 
explanation of an event is needed or is not completely understood. The study of low-
threshold treatment with the aim of harm reduction was an interesting example. It is 
generally believed that such interventions are targeted at compromised and marginalised 
people, but the results showed that an unsuspected population of employed, highly 
educated and HIV-negative individuals were contacted and recruited. The results from 
the indicator model showed that a still-not compromised population susceptible to 
harm-reduction programmes had been captured by this programme. 
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Figure 4: Delay periods 
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As described, the main features of the model outlined in this chapter can address 
multiple uses. First, it has potential as a predictor tool to estimate the future development 
of specific problems in different fields of addiction. Alternatively, it could be used to 
adjust hospital resources if surveillance methods suggest that these interventions are 
needed. The second use is to verify, retrospectively, any expected or unexpected 
consequence, its relationship with the original target and to check model adequacy for 
future forecasting. This last use suggests an updating system calibrating the model for 
the next estimation and adjusting the model itself. A third use is to study the evidence 
of cause-effect relationships between legal or government or local logistic interventions 
and drug demand or social-health consequences. 
Both European countries and the European Monitoring Centre for Drugs and Drug 
Addiction would be interested to know in advance what will be the impact of drug and 
drug-related problems and this type of model could give some important information 
in this regard. Model development and shared data-collection methods would permit 
comparison among countries. The variables suggested in this chapter are present in all 
countries. The complexity of the task could generate difficulties in model use because 
relationships between variables vary across 'locations', and so an analysis of historical 
data is needed to generate equations which consider mult iple correlation, 
multicollinearity, regression and correction coefficients. Even if the model will correct 
itself over time, some minimal previous observations are needed to address the starting 
point of the model estimation. This means that, in spite of the easy accessibility and 
recovery of data, model development must be preceded by a data-collection system. 
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Figure 5: Data arranged by delay periods 
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Finally, developing these types of models involves a shared and simple monitoring activity 
with predictor characteristics. Many institutions involved in drug problems would like 
to know in advance how many people will use illicit drugs or will be HIV positive in the 
AIDS phase or will be exposed to risk of death or, again, will have legal problems as a 
drug consumer. Moreover, the model has built in the possibility of verifying its own 
forecasts and developments in model effectiveness and efficiency. The opportunity of 
retrospective clinical and social studies will allow the acquisition of experiences which 
lead to increasingly helpful suggestions to reduce drug demand. 
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INTRODUCTION 
/
n Chapter 6, Comiskey and Hay present the back-calculation (BC) method as a tool 
to estimate unobserved incidence of a disease from observed data and to account 
for a latency time to onset of disease. This method has been extensively used and 
further developed to estimate HIV incidence from observed AIDS data. The authors 
discuss the application of BC models to drugs data, for example, for estimating onset 
incidence of problem use from observed treatment data and the need for research into 
the 'incubation time' or latency time from first drug use to first treatment. 
Hay and Comiskey discuss in Chapter 7 the application of compartmental models in 
different fields, notably infectious-diseases epidemiology, and their usefulness for 
estimating drug use. They introduce the concept of deterministic and stochastic models 
with their different implications for results (existence or not of random variation) and 
method of analysis (mathematical versus computational). The authors raise relevant 
questions about the applicability of models to describe the spread of drug use, given the 
basic uncertainty and lack of consensus about underlying mechanisms and definitions 
and lack of adequate data. 
In Chapter 8, Taylor and Young distinguish static and dynamic models, defining the latter 
as those in which a population is traced over time. A series of basic issues concerning 
dynamic modelling are discussed, including time frame and geographic boundaries of a 
prevalence-estimation exercise, types and levels of drugs used and the relationship 
between definitions of drug use and the use of data sources. The authors also describe 
and evaluate a number of modelling techniques adopted in this class of model. Finally, 
system-dynamic modelling is discussed, which describes an interconnected set of 
endogenous feedback mechanisms (time movements and accumulations of people, 
materials and information), most of which are not observable but which generate 
observable output over time. 
In their following chapter, Taylor and Young describe the use of factor analysis to either 
confirm or explore underlying latent variables from observed variables. The authors argue 
that working with composite latent variables is often nearer to reality than interpreting 
use of each drug separately, as most drug users are polydrug users and there are different 
and combined ways of using (e.g. moderate or heavy alcohol use in combination with 
other drugs). Taylor and Young then discuss structural-equation modelling and conclude 
that these highly complex models are difficult to manage and are of less practical value, 
but are a potentially very useful explorative tool to understand how underlying theoretical 
concepts can be fitted into models of drug prevalence. 
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CHAPTER 6 
THE METHOD OF BACK CALCULATION AS A MEANS 
OF ESTIMATING INCIDENCE 
Catherine Comiskey and Gordon Hay 
The method of back calculation uses knowledge of the numbers of AIDS cases (after 
adjustment for reporting delays) and information on the incubation period distribution 
to derive estimates of those previously infected with the HIV virus. This method has 
been widely adopted by statisticians and mathematicians working in the United States 
and in Europe as a means of providing essential estimates of the unknown numbers 
who are HIV infectious and short-term predictions of future numbers with AIDS. This 
chapter provides a detailed, non-technical description of the method. Working with 
the first estimates based on Irish AIDS cases, the anomalies in the method with respect 
to the Irish data are illustrated. They are then confirmed by comparing the results with 
those derived in the UK and US and highlighting the limitations inherent in the approach. 
It is discussed where the method has been applied in the past and suggestions are 
made for future model developments and applications within drug research. A critical 
assessment of the model type is given for future use as well as recommendations on its 
use and feasibility. 
Model description 
Knowledge of the numbers infected with the HIV virus and of the incubation period 
distribution allows the number of AIDS cases which can be expected in the future from 
these HIV patients to be predicted. Conversely, if the number of AIDS cases (after 
adjustment for reporting delays) is known and information on the incubation period 
distribution is available, estimates for those previously infected with the HIV virus may 
be derived. The numbers previously infected can then be projected forward to obtain 
short-term predictions for the number of AIDS cases. This method is known as back 
calculation. It must be stressed, however, that since the proportion of those infected 
who eventually go on to develop AIDS is unknown, and as the number of diagnosed 
AIDS cases is being used, this method provides estimates only for those infected who 
will eventually go on to develop the disease. It is these disease numbers, however, that 
health authorities and policy-makers have to finance and plan for. 
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This relationship between the incidence of AIDS cases, the incidence of HIV infections 
and the distribution of the incubation period ¡swell documented and may be expressed 
in the form 
a(t) = j h(t - u) f(u) du 
where a(t) is the rate of new diagnoses of AIDS cases, h(t) is the rate of acquiring HIV 
infection and fifí.) is the distribution of the incubation period. The method of back 
calculation is based on the premise that if any two of these three quantities are known 
then the third can be derived. With the current AIDS epidemic both a(t), the rate of 
new diagnoses of AIDS cases, and f(t), the distribution of the incubation period, can be 
observed and measured, hence h(t), the unknown number of HIV cases, at time t can 
also be derived. The choice of distribution for both a(t) and f(t) is, however, very varied 
and depends upon the stage of the epidemic and the availability of data. Estimates of 
HIV incidence derived from the back-calculation method will vary depending on the 
distributions used. This is discussed further in later sections. 
It is important to remember that the number of diagnosed AIDS cases are adjusted for 
reporting delays. Reporting delays in countries vary and arise when a department of 
health acts as the centre for the collation of national data on AIDS, with diagnosed 
cases being reported directly to an AIDS coordinator. A considerable time lag may 
occur between the time that a case is diagnosed and the time at which it is recorded in 
the national AIDS figures (the difference between these times being known as the 
reporting delay). It is at the time of diagnosis and not the time of reporting that the 
patient will need treatment and it is therefore necessary to plan for and work with the 
number of diagnosed cases. 
Where has the model been applied? 
This approach to estimating the incidence of HIV infection and projections for the 
number of AIDS cases was first proposed in the United States (Brookmeyer and Gail, 
1986) and in the United Kingdom (Isham, 1988; Day and Core, 1988). Further 
discussions on the method applied to the US epidemic appeared in the late 1980s 
(Brookmeyer and Damiano, 1989). Back calculation as a means of predicting the 
incidence of HIV infection in the UK was discussed again in a review of mathematical 
and statistical studies of HIV (Anderson, 1989). More recently, this method was adapted 
to provide further predictions of the AIDS epidemic in the UK (Day et al., 1989). For 
application to the sparse Irish data the method was adapted further (Comiskey and 
Ruskin, 1992). 
Similarly, the method has been applied across Europe, for example to reported AIDS 
cases in Amsterdam (Hendricks et al., 1992). The authors, like Comiskey and Ruskin, 
found that the choice of the exact model greatly influenced the predictions. In Italy, the 
method is also implemented to estimate the incidence and prevalence of HIV (Mariotto 
and Cascioli, 1996). Authors found that the choice of one particular back-calculation 
model over another among three different models considered seemed to be a minor 
component of the uncertainty when compared to the uncertainty due to all other 
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sources. Variations in model choice are also addressed in the literature (Cooley et al., 
1996). These authors combine information from 12 different studies in an effort to 
estimate the AIDS incubation distribution with greater precision than is possible from a 
single study. In their conclusions they stress that back-calculation approaches should 
allow the incubation distribution to take several forms to adequately represent HIV 
estimation uncertainty. 
The method has also been applied to the prediction of the HIV/AIDS epidemic in the 
low-prevalence countries of Central and Eastern Europe (Downs et al., 1997). This 
study included the Asian republics of the former Soviet Union. The authors found that 
recent reports of rapidly increasing HIV infection rates suggest that back calculation 
may seriously underestimate the size of the epidemic in low-prevalence countries. The 
application of the method has not been confined to Europe and the United States, but 
has also been used in Australia (Becker and Chao, 1994) and in the city of Perth in 
Western Australia (Comiskey, 1996). Becker and Chao (1994) improve the results from 
the method by assuming that quarterly HIV incidences are not independent. 
To summarise, the back-calculation method has been applied globally and under diverse 
conditions. The core idea of the method remains unchanged in that the back-calculation 
is from known AIDS incidence, through the incubation-period distribution in order to 
estimate the unknown or hidden pool of HIV carriers. The implementation of the 
method, however, varies considerably between authors and its technical details are 
continually being refined. A key factor in the implementation of the method is the 
choice of the incubation-period distribution. Estimates of HIV incidence and prevalence 
derived from the method will vary considerably depending on the mathematical or 
statistical nature of the distribution used by the researcher. In spite of these reservations, 
the method continues to be employed and receives considerable attention in the 
academic press. 
The method used for the example illustrated here is based upon the knowledge of the 
distribution of AIDS cases and the distribution of the incubation period (Brookmeyer 
and Gail, 1986; Brookmeyer and Damiano, 1989; Anderson, 1989). The sensitivity of 
this method to parameter estimates has been discussed in the literature (Wilson et al., 
1992) and many authors have sLudied ways of improving the method by using either 
age-specific incidence rates or more accurate estimates of the incubation-period 
distribution by using dates of first positive HIV test (Rosenburg, 1994; Dietz et al., 
1994; Marschner, 1994). In the United Kingdom, work has been carried out on the 
study of the incubation-period distribution (Anderson and Medley, 1988). The authors 
fit a gamma distribution with a mean of 14.3 years with approximately 4 0 % of all those 
infected progressing to AIDS within ten years. In this example, this choice of incubation 
distribution is implemented. The method is illustrated with data on Irish AIDS cases 
from 1982 to 1992. In the light of comments on the necessity for validation of HIV 
predictions (Bailey, 1994) the results from the improved back-projection method 
compare favourably with HIV predictions arising from transmission models of HIV and 
AIDS in Ireland. 
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Adjusting the number of diagnosed AIDS cases for reporting delays 
For every AIDS case reported in Ireland, data are supplied on the risk group (and other 
demographic features) of the patient and the date that he or she was diagnosed as 
falling within the Centres for Disease Control (CDC) definition of an AIDS case. At the 
time the model was applied, the CDC classified those with the HIV virus into four 
groups: Croup I, seroconversion; Group II, asymptomatic; Group III, progressive 
generalised lymphadenopathy; and Group IV, patients with clinical manifestations of 
HIV infection designated by assignment to one or more sub-groups (A-Ε). Within Group 
IV, sub-group classification is independent of the presence or absence of 
lymphadenopath. Sub-group IV C1 defined an AIDS case. It consisted of patients with 
secondary infectious diseases defined as the diagnosis of an infectious disease associated 
with HIV infection and/or at least moderately indicative of a defect in cell-mediated 
immunity. Included are patients with symptomatic or invasive disease due to one of a 
number of specified secondary infectious diseases. 
The problem of reporting delays in the number of AIDS cases is discussed (Brookmeyer 
and Damiano, 1989). These authors base their method on a conditional likelihood for 
estimating the reporting delay distribution. Their method has been adapted to adjust 
the reported numbers of Irish AIDS cases (Comiskey and Ruskin, 1992). 
Methods 
The integral equation model arising in back projection is a linear Volterra equation of 
the first kind with a difference kernel 
a(l)=\h(t-u)f(u)du (1) 
where aft) is the rate of new diagnoses of AIDS cases (adjusted for reporting delays), h(t) 
is the rate of acquiring HIV infection and /"CO is the distribution of the incubation period. 
Although equation 1 may be viewed as the convolution of h(t) and f(t), it is difficult to 
find a solution by means of inverse Laplace transforms when f(t) is given by a gamma 
distribution with parameter α eR. However equation 1 can be changed into a generalised 
Abel integral equation by differentiation. The solution is then given in terms of an 
integral in the two known functions a(t) and f(t). The resulting integral can then be 
solved in terms of incomplete and complete gamma functions and error bounds for all 
solutions can be provided (Comiskey, 1992). 
Three different mathematical forms for the growth in the annual incidence of AIDS 
cases, a(t), are considered here. It has been shown that in Europe the numbers of new 
AIDS cases grew rapidly in the early years of the epidemic (Downs et al., 1987). This 
has since been followed by a period of slower growth with doubling times increasing. 
Three forms for a(t) are considered to describe the rate of new diagnosis of AIDS cases: 
a(t) = a0exp(a1t-a2t2) (2) 
a(t) = (b0 + b fi I exp(l-t) + b2 (3) 
aft) = c0 + c¿ + c2t2 <4' 
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These three forms reflect empirical results up to 1990 which suggest an initial period of 
exponential growth in AIDS cases. The first growth rate for aft), the quadratic exponential, 
describes rapidly increasing AIDS incidence from 1990. The second, the linear logistic, 
describes decreasing incidence from 1990 and the third, the quadratic, describes steadily 
increasing incidence from 1990. These are chosen not to model the future incidence 
of AIDS cases, but rather to model the range of values for which to estimate h(t). 
The solution of 1 is considered when 
f(0=%^t«->exp(-X) 
with 2 < α < 3. The detailed analytical and numerical solution of the back­calculation 
model in 1 given the incubation­period distribution 5 above and the various choices 
for AIDS growth in 2, 3 and 4 are provided (Comiskey, 1991). 
Results 
In the above equation, t = 1 corresponds to the first year (1982) that AIDS cases were 
reported in Ireland. The functions 2 to 4, which describe the rate of appearance of new 
AIDS cases given different growth patterns, were fitted to the AIDS incidence data for 
1982 to 1991. The parameter estimates for the three choices of a(t) along with r', the 
coefficient of determination, are given in Table 1. The expected annual AIDS incidence 
these parameters give rise to is given in Table 2. 
Solving equation (1 ) for h(t) (Comiskey, 1991 ) gives rise to the estimates in Table 3 for 
the incidence of HIV infection in Ireland from 1982 to 1991. 
Discussion 
The exact solution of the back­projection equation 1 together with the three different 
growth rates in annual AIDS incidence and the gamma incubation­period distribution 
5 provides predictions of 1 351 to 3 054 HIV positive cases in Ireland from 1 January 
1982 to 1 January 1990. This is between 1.5 and 3.4 times the number known to the 
health authorities at that time. 
Table 1 : Parameter estimates obtained for a(t) given three different growth rates in 
AIDS cases 
1. Quadratic exponential ¿0 = 0.6065 a. = 0.5838 a2 = 0.0078 r2 = 93.5·% 
2. Linear logistic b0= 0.1514 b,= 0.0144 b2 = 5.0640 r2 = 94.3% 
3. Quadratic c0= 1.9500 c,= 2.8140 c2= 1.0189 r2 = 97.3% 
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Table 2: Expected and observed annual AIDS incidence 
Year 
1982 
1983 
1984 
1985 
1986 
1987 
1988 
1989 
1990 
1991 
Growth 1 
1.08 
1.89 
3.26 
5.53 
9.25 
15.23 
24.69 
39.40 
61.91 
95.77 
Growth 2 
5.20 
5.40 
5.86 
6.95 
9.41 
14.74 
25.58 
45.07 
70.97 
67.82 
Growth 3 
0.15 
0.40 
2.68 
6.70 
13.35 
21.75 
32.18 
44.65 
59.15 
75.70 
Observed 
2 
1 
3 
5 
6 
20 
38 
51 
61 
70 
Table 3: Estimated incidence of HIV, given different growth rates in AIDS cases 
Year 
1982 
1983 
1984 
1985 
1986 
1987 
1988 
1989 
1990 
1991 
Total to 
1 Jan 1990 
1 Jan 1992 
Growth 1 
46 
71 
115 
182 
287 
441 
669 
989 
1 470 
2113 
2 800 
6 383 
Growth 2 
26 
43 
86 
181 
369 
692 
1 049 
608 
-4 427 
-28 544 
3 054 
-
Growth 3 
125 
128 
138 
153 
170 
190 
211 
236 
262 
291 
1 351 
1 904 
Known 
-
-
-
306 
229 
143 
116 
116 
110 
136 
910 
1 156 
Note: - indicates data not available 
If the predictions are extended to 1 January 1992, the model predicts between 1 904 
and 6 383 HIV positives in Ireland up to that time. This estimate is between 1.6 and 5.5 
times the number known at that time to the Department of Health arising from tests 
carried out at the National Virus Reference Laboratory at University College Dublin. 
Looking at the individual predictions more closely, growth rate 1 estimates a total of 
2 800 HIV positives up to 1 January 1990. This would appear to be a reasonable 
prediction given that there were 910 known HIV positives up to that time. However, 
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after 1990 the model estimates a rapid increase in the numbers testing HIV positive. 
This is due to the fact that growth rate 1 describes a rapid increase in annual AIDS 
incidence from that time. This is then reflected in the estimates for HIV incidence. 
Growth rate 2 describes increasing incidence in annual AIDS cases up to 1990 followed 
by decreasing incidence from this time. Estimates of the numbers of HIV positive cases 
reflect this, with a total of 3 054 positives predicted between 1 January 1982 and 1 
January 1990. This model then predicts negative incidence from 1990 and cannot be 
used to provide estimates for later years. 
Growth rate 3 describes increasing annual AIDS incidence up to 1 January 1990 then 
continues with a steady increase from that time to 1992. Estimates based on this choice 
of growth rate reflect this increase, with 1 351 cases being estimated for 1982 to 1989 
inclusive and 1 904 cases estimated for 1982 to 1991 inclusive. 
Overall estimates for the cumulative HIV incidence from 1 January 1982 to 1 January 
1992 vary by a factor of 3.35 (1 904 cases to 6 383 cases). This is a considerable 
improvement on previous estimates. Similar results have arisen in the analysis of the 
UK data, where estimates varied by a factor of 3 (20 000 to 60 000 cases) (Isham, 
1988). In his analysis of these estimates Cox believed the lower end of the range to be 
more plausible as it corresponded closely to that derived from direct estimation (Cox, 
1988). 
Bailey discusses the importance of validating results when modelling public-health, 
and in particular HIV and AIDS, data (Bailey, 1994). One approach he advocates is the 
cross-checking of findings with independent research results. Some very encouraging 
results can be obtained if the results discussed above are compared with those arising 
from transmission models of HIV infections and AIDS in Ireland. These alternative models 
predict a total of 4 034 infectious people in Ireland in 1991. This number derived from 
the transmission-model predictions is in the middle of the range predicted by the back-
projection method (Comiskey, 1991). 
For planning purposes it would seem prudent then to work with an Irish estimate of 
approximately 2 000 to 4 000 HIV positives in Ireland between 1982 and 1991 inclusive. 
However, it must be stressed that as yet the exact incubation period is unknown as is 
how the growth in annual AIDS incidence is changing. All estimates must be viewed 
with caution until further research into these areas is undertaken. As knowledge of 
these unknowns increases, the methods discussed in this chapter for estimating the 
incidence of HIV infection can be applied with increasing confidence. 
Model development and applications 
To date, the back-calculation model has been developed primarily for estimating the 
hidden HIV incidence and future short-term predictions of AIDS incidence within a 
community or within a section of a community as illustrated in the example. As growth 
in the numbers acquiring disease in one country may follow a different pattern to that 
of another country, detailed methods developed for one application may need 
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considerable technical refinement and alteration when applied in a different setting. 
Research has shown that estimates derived by the back-calculation method are highly 
sensitive to the choice of AIDS incubation-period distribution used and, as such, much 
work has been and is still being carried out on improving and refining knowledge of 
this incubation period. 
It is the opinion of the authors that advantage should be taken of the extensive European 
and global research that has been conducted on the back-calculation method. 
These models have not to the authors' knowledge been used in other drug-related 
areas, in particular to the problem of estimating incidence of drug use within a 
community. To provide a range of estimates of the prevalence of intravenous drug use 
in Los Angeles, CA, a combination of methods including multiple capture-recapture, 
synthetic estimation and back-calculation of AIDS incidence has been used (Hser, 1993). 
Hser, who is based at the Drug Abuse Research Centre at the University of California, 
Los Angeles, advocates the employment of complementary methods and data sources. 
The back-calculation model has been widely used by the applied statistical and 
mathematical profession. It has not, however, been widely embraced by the general 
medical, epidemiological and health professions. This is not due to a lack of data, but 
more perhaps to the technical nature of the method. Research publications tend to 
stress developments in the technicalities of the method rather than the relevance of the 
method to policy-makers. The application of the method to disease prediction was also 
relatively novel prior to the rapid growth in the number of AIDS cases in the mid-to-
late 1980s. There are some interesting exceptions to this: Cox (1988) and Day (1996) 
both provide predictions of the number of new AIDS cases for the Department of 
Health in England and Wales based on the back-calculation method. Whether the 
predictions provided in their reports directly affected and influenced government health 
policy and resource allocation is a question beyond the scope of this chapter. 
Critical assessment of the method for future research 
The back-calculation model for estimating the hidden HIV population and AIDS 
prediction has been applied throughout Europe. The technicalities of the method have 
been extensively researched and published. It has not to date been used as a means for 
estimating the hidden drug-using population. Advantage should be taken of 
developments in the method which uses the known number of AIDS cases (adjusted 
for reporting delays) to estimate the unknown number of HIV cases. This is accomplished 
by back calculating from the AIDS cases through the use of the incubation-period 
distribution to estimate the pool of HIV cases these AIDS cases must have come from. 
The same approach may be used to back calculate from the known number of drug 
users to estimate the larger pool of unknown drug users these known users came from. 
Consider the case where information is known about opiate users first attending for 
treatment. (These are analogous to AIDS cases who attend for treatment.) Information 
is sought from the opiate user on when they first started taking opiate drugs. From this 
information, the distribution of times from first opiate use to first attending treatment 
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may be estimated. (This idea is analogous to the distribution of incubation times from 
first acquiring HIV to developing AIDS.) It is now possible to back calculate from the 
known numbers of opiate users through the use of the so-called incubation period to 
estimate the pool of hidden opiate users the known users came from. (This is directly 
analogous to back calculating from AIDS cases to HIV cases.) The data demands for 
such research to be conducted are not extensive and in many cases the data exist and 
are already in place. Many cities have been collecting survey questions on the nature of 
primary and secondary drug use, age of first use and dates of first treatment for this 
drug use. The data derived from the answers to all of these epidemiological questions 
are perhaps under-used at present. Further use of these and other epidemiological 
studies across Europe would benefit all. 
The added value of using the back-calculation method is that within many of the 
European cities with which the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) has existing links for either capture-recapture or dynamic-
modelling studies there already exists the back-calculation technical expertise. In 
addition, the EMCDDA has access to the relevant drug-treatment data. 
Conclusions 
In order to apply this method to the problem of estimating drug incidence it is first 
essential that research into the nature of distribution of times from first misusing drugs 
to first seeking treatment is carried out. This is analogous to a disease-incubation-period 
distribution, that is, times from first acquiring infection to first presenting for disease 
treatment. The data for this study may be drawn from existing local surveys on drug use 
and first treatment. Very little is known about this so-called incubation-period distribution, 
yet the back-calculation literature demonstrates that it is precisely the choice of this 
distribution that will affect future predicted estimates. Depending on the priorities of 
the research, this study could concentrate on one type or one mode of drug misuse, for 
example opiate misuse or injecting drug use. One such study is currently being piloted 
in several European countries under the direction of the EMCDDA (private 
communication). In addition, a study of the distribution of incubation times or times to 
first treatment and a subsequent application of the back-calculation method to estimating 
incidence of opiate use in Dublin, Ireland, has been conducted (Hand, 1999). 
Second, a pilot study to assess the feasibility of applying the back-calculation method 
to estimating the hidden prevalence of drug misuse is being undertaken. This second 
objective will follow on from and implement the findings on distribution of times to first 
treatment. To determine the usefulness and reliability of the back-calculation estimates 
the results should be compared with estimates derived from other methods previously 
applied. The authors and many other researchers collaborating with the EMCDDA are 
currently working on prevalence estimates from the multiple capture-recapture method. 
Given time and economic resource constraints it would seem obvious therefore to 
compare estimates derived from back calculation with estimates from these soon-to-
be-completed studies. 
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Over a longer time frame, if the results of a back-calculation feasibility study proved 
worthwhile, the method may be developed further for use with a range of drug-related 
problems other than HIV and AIDS. If the EMCDDA's back-calculation feasibility study 
did not produce worthwhile estimates when compared with other methods, then the 
reports to the EMCDDA will highlight why this was the case, be it deficiencies in the 
primary data collection or in the variability of the method, and improvements can be 
recommended. Future surveys and data collection can then take note of these 
recommendations. 
With regard to the resource needs of such a feasibility study, many of the data structures 
are already in place. The technicalities of the method are also well documented. There 
would be requirements for access to the necessary epidemiological data and their 
appropriate collation. Finally, for such a study to be of benefit to the wider community, 
it is essential that the implications of the research and estimates derived be placed 
within the context of relevance and implication for health professionals, policy-makers 
and those with the responsibility of scarce and valuable resource allocation. 
In conclusion, to quote the pioneering biomathematician Ν. Τ J. Bailey (1975): 
In the face of misery and suffering on a monumental scale, epidemic theory 
is a luxury mankind can ill afford. The world must not only be interpreted: 
it must be changed. 
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CHAPTER 7 
C O M P A R T M E N T A L M O D E L L I N G A N D S T O C H A S T I C 
DYNAMIC SYSTEMS 
Gordon Hay and Catherine Comiskey 
Many quantities are of interest to drug-misuse researchers, such as the number of people 
that inject heroin or the number of children that begin using drugs at a particular age. 
These two quantifiable 'groups' are examples of compartments. The number of people 
in each of these groups, or compartments, may be dependent on the number in others, 
for example the number of people that inject heroin may be related to the number that 
smoke the drug, whereas the number of children who begin using drugs may be related 
to the number that smoke or drink alcohol. 
Compartmental models provide a framework in which numbers of people in different 
compartments, and the relationships between different compartments, can be described 
analytically. Two different types of compartmental models are described in this chapter: 
deterministic models in which the numbers in each category are completely determined 
by the model; and stochastic models in which random effects can result in different 
outcomes. 
Compartmental models are well established in modelling the spread of diseases, including 
HIV/AIDS. Recent models which examine the spread of HIV in drug-using populations 
split those populations into different compartments. Although these compartments are 
created to make disease-spread models more realistic, for example by assigning drug 
injectors into groups that share needles daily, weekly or monthly, drug-using populations 
can be described in other ways, by examining drug-using careers or levels of drug use. 
Drug-related consequences can be added into compartmental models, such as social 
problems or health-care-related costs. 
Some other examples of compartmental models, in particular some of the few 
applications to drug-related problems, are considered in this chapter. The use of these 
modelling techniques is then assessed and recommendations are made on the feasibility 
of the future use of these models by the European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA). 
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Figure 1 : Deterministic and stochastic models 
Two main types of mathematical models have commonly been used to describe the spread 
of diseases. 
Deterministic models are easy to formulate and easy to solve, however such models do not 
include random fluctuations and therefore may not be suitable for modelling some 
epidemiological processes, particularly when the numbers of people infected are small. 
Stochastic models include random fluctuations in the numbers of people infected, although 
these models are often harder to work with. Computer programs can, however, assist in 
working with stochastic models. 
Both types of model assume that the population can be split into compartments, and the 
result from the models is often the number of people infected over time. 
Model description 
This section addresses how mathematical models can be developed to describe the 
spread of a disease such as HIV/AIDS. Although there are two schools of thought in 
epidemiological mathematical modelling (see Figure 1 ), both assume that the population 
in which the disease spreads can be grouped into compartments, such as those that are 
infected and those that are not. One type of mathematical model, the deterministic 
model, assumes that the numbers infected increases or decreases at a specific rate. This 
rate is usually related to the numbers in different compartments and the rate can change 
over time. In a stochastic model, the rates at which the number infected changes is 
replaced by probabilities, thus the random nature of disease spread can be included. 
Once the population has been split into relevant compartments, it is a comparatively 
easy exercise to describe mathematically how the size of these compartments will change 
over time. For example, in the deterministic model this is done by formulating a set of 
differential equations. These equations can easily be solved to give the number of 
people infected over time. The stochastic equivalents are harder to solve, and 
computational methods are often needed to provide results. 
As a necessary precursor to using either modelling technique, a way of describing the 
transmission dynamics of the particular disease using numbers has to be created. This is 
initially done in the context of a deterministic model which ¡soften easier to work with. 
Compartments can be constructed, and when describing the spread of a disease such 
as measles three compartments can be constructed to describe the different stages in 
the disease process: susceptible; infected; and recovered (see Figure 2). 
The terms 'susceptible' and 'infected' are self-explanatory; however, it should be noted 
that as infection with measles results in immunity, the people in that group cannot be 
reinfected. This basic description is often called the SIR model, and each individual in 
a population will be in one of these three compartments. At each point in time, there 
will be a fixed number of people in each of these compartments, and using mathematical 
notation, the numbers of people in the three compartments can be called X(t), Y(t) and 
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Figure 2: The SIR model 
Susceptible 
X(0 
ßXY Infected 
Y(t) 
ΤΎ Recovered 
Z(t) 
Z(i). The presence of t in the notation is a reminder that the number of people in each 
compartment changes over time. 
This change can be described in a system of differential equations. In this system, the 
rate of change of each variable, denoted by dX(t)/dt, dY(t)/dt and dZ{t)/dt, depends on 
the values X(t), Y(t) and Z(t), as shown in equation 1. 
^L=­ßxv (1) 
dt 
dY 
dt 
dZ 
dt 
= ßXY-yy 
γΥ 
Here, by convention, X(t) In the differential equation is replaced by X for convenience, 
although the value is still dependent on the time t. There are several things of note in 
this system of differential equations, which is a deterministic model for the spread of 
measles. First there are two parameters in this model, β and y. The first is the infection 
rate and the second the recovery rate. These are the only parameters in the model and 
as such the model is very simple as it does not include other processes such as birth of 
susceptibles or removal from any compartment for reasons such as death. If total 
population size is denoted as N(t), then N(t) = X(t) + Y(t) + Z{t), or more interestingly 
dN dX dY_ dX_ 
dt ~ dt dt dt 
(2) 
ßXY + ßXY­ yY + ΎΥ 
0 
which shows that the population size is fixed. What should also be noted from equation 
1 is that the rate at which the number of susceptibles decreases is proportional to the 
product of X and Y. In other words, the number of new infections depends on the 
contact rate between susceptibles and infectives and this is known as the mass-action 
law. 
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As previously stated, this is a very basic model and there have been refinements to it in 
the context of measles modelling, and also in modelling the spread of other diseases. 
One further example is a model that examines the spread of a sexually transmitted 
disease. Here the population of males and females must be described separately. If the 
number of susceptible, infected and recovered males is given as X(t), Y(t) and Z(t), and 
the number of susceptible, infected and recovered females asx(t), y(t) and z(t), then a 
basic model, which is just an extension of the previous model to two interacting 
populations, will be 
^=~ßxy (3) 
dt H y 
dY 
=βΧΥ- γΥ dt 
dZ 
dt 
dx 
Jt~~ 
=γΥ 
-β'χΥ 
dy ■j=ß'*Y- Y y 
dz , 
d-rYy 
Here there will be two infection rates, β for males becoming infected by infectious 
females and β' for females becoming infected by males. Similarly there will be two 
recovery rates yand γ' for males and females respectively. Again the mass­action law is 
relevant as the number of new infections in males is proportional to the product of X 
and y and in females is proportional to the product of χ and Y. 
In the context of deterministic modelling, these basic models can be simply extended 
by including either the number of interacting populations or the number of compartments 
that describe a single population. A good example of this type of modelling is that 
which describes the heterosexual spread of HIV. While there are still two interacting 
populations, males and females, the number of compartments which describe the spread 
of the disease can be increased to include an AIDS compartment, as well as a 
compartment which contains those who are infected but not yet infectious. Another 
way of extending these simple deterministic models would be to include more interacting 
populations. For example, the homosexual spread and the needle­sharing spread of 
HIV can all be modelled simultaneously by constructing compartments for each 
population and modelling the rate at which the numbers in these compartments change 
between populations. A good example of this would be female drug injectors who are 
also prostitutes and thus come into contact with male heterosexual clients. 
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These deterministic models are quite simple to construct and computational methods 
have been developed to solve the differential equations to show how the number of 
infected people changes over time. However, as the name suggests, the spread of the 
disease is determined at the start of the epidemic in that there is no randomness in the 
disease process. Thus deterministic models can be seen as an approximation to more 
realistic stochastic models in which randomness is included. Unless the populations 
that are being examined are small, or the numbers in some of the compartments as 
described above become small, then deterministic models are often adequate. 
To include randomness, stochastic models examine the probability that a person changes 
from one compartment to another, instead of assuming that the numbers change at a 
determined rate. Equation 1 can be converted into a corresponding stochastic model 
as in equation 3 where, only looking at the numbers of susceptibles and infectives, in a 
small time period At 
Pr{(X,V0->(X-1,Y+1)}=j3XYAt (4) 
Pr{(X,Y)-^(X,Y-1)} = yYAt 
In other words, the probability that one susceptible becomes infected within the small 
time period Δί \s ßXYAt and, if this happens, the number of susceptibles decreases from 
X to X­1 and correspondingly the number of infectives increases from Y to Y+1. In 
constructing these probabilities it is assumed that only one event can happen in the 
small time interval Δί. As in the deterministic model, the probability is proportional to 
the product of the number of susceptibles and infectives. 
Stochastic models can also be extended by including more compartments and interacting 
populations, but the theory behind stochastic models is far more complicated than that 
behind deterministic models and thus stochastic models in which solutions to these 
types of equations are examined are rare. 
A more common form of stochastic modelling which employs compartments is the use 
of Monte Carlo simulation models. In these the probability of an event, such as a 
susceptible becoming infected, is evaluated within a computer program and a random 
number generator is used to decide whether or not this event should be simulated. 
Thus approximations to stochastic models can be readily evaluated and stochastic 
simulation languages are becoming more and more popular to simulate processes within 
science and engineering. 
While the examples above, like most compartmental models, describe a time-dependent 
process, this does not always have to be the case. In some diseases, the age of a person 
is important, therefore the number of susceptibles, infectives and recovereds may be 
better described as X{a,t), Y(a,t) and Z(a,t) where age is denoted by a. The numbers in 
these compartments can vary over time and over age groups and differential equations 
can be constructed to describe the process. The parameters in these models are often 
age-dependent. These differential equations are more complex than equations 1 and 2 
as they involve the rate of change over time and over age and are more correctly 
known as partial differential equations. They can be solved easily using numerical 
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methods and the numbers of people infected at different times and at different ages 
can be calculated. 
Just as the models which only examine the rate of change over time can be extended to 
model the rate of change between ages, deterministic models can also be extended to 
include spatial effects. As previously described, there can be two interacting populations 
such as males and females in which compartments can be created to describe the 
sexual spread of a disease. This is similar to a situation in which there are two or more 
towns with the disease spreading between them. Here, a compartmental structure 
with differential equations can be created including both disease spread within towns 
and between towns. 
Where have the models been applied? 
Compartmental models, and the deterministic or stochastic methods used in conjunction 
with them, have many uses, in particular biological population dynamics and 
epidemiology. The use of mathematics in describing social processes such as the spread 
of disease has been well established since the start of the twentieth century when 
Hamer (1906) examined the spread of measles and Ross (1911) examined the spread 
of malaria. Although the fields of epidemiology and mathematical modelling have 
advanced rapidly since then, some assumptions and principles are basic to subsequent 
research. Advances in modelling sexually transmitted diseases have been made, for 
example Hethcote and Yorke (1984). Anderson and May (1991) provide an excellent 
review of mathematical modelling of infectious diseases. The growth of animal 
populations and the interaction between different populations have been studied 
extensively, including predator-prey models in which the population dynamics of one 
animal depend on the numbers of another animal on which they prey. Renshaw (1991 ) 
provides a review of these fields, in which he also examines spatial population dynamics. 
Kaplan (1989) used a deterministic model to describe the spread of HIV among drug 
injectors. In this basic model he assumed a constant population size and that the disease 
spread through drug injectors sharing needles in shooting galleries. As such, this model 
was not very realistic in predicting the future course of the disease; however, the use of 
control strategies, such as needle exchanges, was evaluated. Indeed, it was a condition 
of the legalisation of needle exchanges in the US state of Connecticut that some kind of 
evaluation of a needle exchange was undertaken. Caulkins and Kaplan (1991 ) extended 
this model to allow for a varying population size of drug injectors. In this model they 
showed the population dynamics of the intravenous (IV) drug-using population as 
^=€Ν(ϋ>-μΝ(ϋ (5) 
dt 
Here they assume that the rate at which people join the population of IV drug users is 
proportional to the number of current users raised to some power v, where ν is non-
negative and strictly less than one. They present two arguments about the potential 
value of v. If the new users begin injecting because of other people injecting then the 
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number of new injectors increases with the number of current injectors and hence ν 
would be close to one. If, however, injectable drugs are freely available such that any 
person who is predisposed to inject drugs will and the recruitment rate is determined 
by social factors then ν could be quite small. At the extreme, if ν is zero then people 
would begin injecting drugs at a constant rate c. Caulkins and Kaplan also assume that 
current injectors cease injecting at a constant rate μ. They go on to estimate some of 
the parameters used in the model, both before and after the introduction of AIDS, and 
show that due to AIDS, the number of drug injectors will decrease. 
This population­size model is combined with a disease­spread model in which a 
population of drug injectors shares possibly infected needles. Thus three compartments 
are modelled, ß(t), the fraction of needles that are infected, l(t) the number of infected 
injectors and U(t) the number of uninfected injectors at time t. Differential equations 
which describe the transmission dynamics are constructed and employ the parameters 
related to population size and to the infection process. 
Billard and Dayananda (1993) look closer at the rate at which people begin using drugs 
in their eloquently titled paper 'Drug addiction ­ pushers generated from the addicts'. 
They combine a population­size deterministic model with a previous model of 
Hoppensteadt and Murray (1981) who considered the concentration of a drug in the 
blood of drug users. Billard and Dayananda use the mass­action law in that the rate of 
change of the number of addicts is proportional to the product of the number of addicts 
and non­addicts. They also assume that pushers are normally hard­core drug users 
such that the number of pushers will be proportional to the number of addicts. This 
highly mathematical paper is not at all realistic in the context of predicting how many 
people will begin using drugs, but demonstrates some of the theory behind deterministic 
and stochastic modelling. 
Some models that examine the spread of HIV among drug injectors provide basic 
attempts at describing the population dynamics of drug use. Peterson et al. (1990) use 
Monte Carlo simulation methods to model the spread of HIV among drug users. They 
use six compartments to model the progression of HIV, ranging from susceptible to 
death from AIDS. They also create a parallel system which describes the career 
progression of drug injectors. Figure 3, which is adapted from Peterson's paper, presents 
the compartments that are used to describe the career progression of drug users. 
Several things are worth noting from this diagram. Although Peterson goes on to model 
this scenario with stochastic methods, his compartmental framework can quite easily 
be modelled using deterministic methods. In the figure, he and his colleagues chose to 
present values for the probabilities instead of working with parameters such as β or γ. 
In the 'Daily IV user' compartment, the mean duration in months assumed for this 
compartment is 44.0. In other words, once a person begins injecting daily, they will, on 
average, remain injecting daily for 44 months. Certain events can happen to a daily 
drug injector: they can end up in jail; end up in a community treatment programme; 
cease injecting completely and therefore go back to being a member of the general 
population; or die from something unrelated to HIV. It should be remembered that a 
parallel compartmental modelling system describes the disease progression and this 
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Figure 3: Compartments used to model the 
career progression of drug users 
General population 
0.01 
1 
monthly intravenous user 
16.7 
0.32 
0.67 
0.01 weekly intravenous user 
16.7 
0.80 
0 .19 
daily Intravenous user 
44.0 
0.98 
0.02 10.05 0.02 
Τ T T T 
0.11 
community 
not using 
5.6 0.08 
non-HIV death 
Source: adapted from Peterson et al. (1990) 
system wou ld include death f rom AIDS. Each event has a probabil i ty attached; for 
example the probabil i ty that a daily drug injector wi l l go to jail is 0 . 6 1 . 
As can be seen f rom Figure 3, this compartmental system relies on probabilit ies that 
can perhaps be estimated f rom sociological research. For example, studies can look at 
the probabil i ty of drug injectors ceasing injecting and can also look at the non-HIV-
related mortal i ty of d rug injectors. In other compar tmenta l models, some of the 
probabil it ies are harder to estimate. For example in disease models very little is known 
about the probabil i ty of becoming infected w i th HIV after using a needle which is 
contaminated w i th the virus. 
Other compartmental models have been used to model the spread of HIV among drug 
injectors, either in isolation (Greenhalgh and Hay, 1997) or in conjunct ion wi th sexual-
spread models (Blower et al . , 1991 ; Arca et al., 1992). However, these models do not 
specifically look at changes in the size of the drug-inject ing populat ion. 
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Another type of stochastic model which has been used to model the spread of disease 
is the chain-binomial model. In this type of model, the number of new infections caused 
by an infected person is assumed to follow a binomial distribution. For example, an 
infective will infect one or more people with different probability and these people will 
then go on to form the next link in the chain by infecting other susceptibles. Mackintosh 
and Stewart (1979) use this technique to model a heroin epidemic, as did de Alarcón 
(1969), who demonstrated this technique using data collected from a community. This 
type of modelling assumes that heroin use follows contact with other users and can 
model the scenario in which drug use is introduced fairly rapidly into a community. 
Model development 
A good example of model development is that of the models to describe the homosexual 
spread of HIV. The initial models did not differ much from those which described the 
spread of diseases such as measles except that there was not a 'recovered' class in HIV 
models. However, it soon became clear that the transmission dynamics of this disease 
are more complex, particularly because a new infection results from a sexual act, and 
this could not be modelled in the same way as a disease like measles which is airborne. 
The probability of becoming infected would depend on how sexually active an individual 
was and thus the mass-action law may not be strictly relevant. The selection of sexual 
partners can also be included in these models as the probability of becoming infected 
would be greater for someone who has intercourse with many people than a person 
who is in a monogamous relationship. The use of condoms will also affect the spread of 
the disease, as would biological parameters such as the infectivity of the virus at different 
stages of the disease progression. Thus what originated as a very simple model quickly 
became a complex model which realistically described the transmission dynamics of a 
particular disease. 
It may therefore be possible to develop the basic SIR model to make it relevant to drug-
related areas. In order to model non-drug users as a susceptible compartment and drug 
users as an infective compartment, the process that makes someone begin using drugs 
must be examined. A rate which describes people starting to use drugs can be assigned, 
and this rate may depend on the number of others in the population using drugs as in 
the mass-action law, or it may depend on other factors. As in AIDS models, drug use 
can also be split into more than one compartment, either by severity of drug use or by 
type of drug use. 
It may be possible to develop models to describe the start of drug use by young people. 
Research by Barnard et al. (1996) shows increasing numbers of children smoking, 
drinking and abusing solvents as they progress through school. What is of interest from 
that research is that the number of children smokingatage 12 is similar to those drinking 
at 13, those using solvents at 14 and those using drugs at 15. Whether or not these 
activities are related is an exercise in sociological research; however, these different 
events and the processes linking them would be ¡deal to describe as a compartmental 
model, especially as research involving young people often examines the age at which 
children begin using licit or illicit substances. 
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Critical assessment of model types for future use 
Various types of mathematical models have been presented above which attempt to 
describe a sociologicalor medical process, such as the transmission dynamics of HIV in 
a population of drug injectors, by creating compartments. Some processes are more 
amenable to being described by compartments, such as the 'susceptible', 'infected' 
and 'removed' compartments which describe the spread of measles. Other processes, 
such as the more sociological process of a drug-using career, may be less suited to these 
techniques. 
For example, does the probability that someone begins using drugs depend on the 
number of others within the population who are using drugs, or is drug use a 
consequence of growing up such that a certain proportion of young people will begin 
using drugs regardless of others? Is drug use such a rare occurrence that it can only 
begin after contact with another drug user, thus making a chain-binomial model more 
relevant? 
There could be other influences on the number of people using drugs, such as the 
relative success or failure of a drug-prevention campaign, or the availability of drugs. 
The latter could be modelled as a separate compartmental system and this would raise 
questions relating to what factors affect availability, such as supply and demand or law-
enforcement activities. This type of modelling would perhaps then be more akin to 
economic models. Even if it was concluded that the number of people using drugs, or 
the number of people who begin using drugs, depends on availability, what would be 
the parameters in a compartmental system that would describe them and how would 
these values be measured? 
The perennial question of definitions may need to be raised in creating compartments 
to describe, for example, a drug-using career. It would be difficult to model the 
progression from user to problem user to addict without a clear consensus about these 
definitions. In assigning an 'addict' compartment it is easy to model some transitions 
out of this compartment such as death, but what would be the process undertaken by 
a person to move from 'addict' back to 'user'? An issue related to definitions would be 
the different drugs used. In some areas and at different times the use of stimulants may 
be seen as a serious problem and modelling the use of these drugs may be of interest, 
whereas in other areas or at other times the use of these drugs may be seen as a stage 
in a process that results in opiate addiction. 
Although compartmental models may be better thought of as tools to examine 'what if' 
scenarios, there is still a need to employ realistic data where available. Blower and 
Medley (1992) describe the application of mathematical modelling techniques, including 
compartmental models, to examining the spread of HIV among drug injectors. Instead 
of examining the advances in the methodology, they discuss the more relevant issue of 
the availability of data that would be of use in creating models and the usefulness of 
this data. They detail problems with existing data, for example questionnaires that 
code parameters of interest such as the number of people who have shared injecting 
equipment within the last six months into categories such as 0-5, 5-10. Such questions 
would not be sensitive to small behavioural changes, and as the responses to such 
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variables are usually very skewed, it would be of more use to have single numbers as 
categories at the lower end of the scale. 
Unlike mathematical models of infectious-disease spread which employ biological 
parameters, the sociological parameters that would be needed to model drug-related 
problems may be more transient. For example, the length of time that someone remains 
infectious with a certain disease can be documented and this infectious period, or 
even an age-specific infectious period, would be common throughout Europe. This 
would be in contrast to, for example the reasons for a person stopping using drugs in 
Athens or Rome which may be very different to those for someone in Helsinki or 
Stockholm. 
Recommendations 
Although existing research which does not specifically focus on disease spread is limited, 
compartmental models have an exciting potential for future development. Two main 
areas of future research are proposed. The first is one in which the 'drug-using career' 
is quantified and assessed, for example by looking at existing data sources which report 
the time between a drug user beginning to use drugs and presenting at services. The 
other main area of research would be to examine children's drug use, based on studies 
that show that young people may begin using drugs after they begin smoking or drinking. 
More specifically, the following is recommended. 
Examining the feasibility of using epidemic models to model drug use as a disease 
While it is relatively easy to create compartments with which to describe different 
stages, the more pertinent questions relate to the processes that link the compartments, 
such as the reason for someone who already uses drugs to begin injecting, and the 
estimation of such parameters. It may be possible to answer these questions by 
undertaking research into these processes; however, another approach would be to 
review the available data, such as those collected by the Pompidou Group of the Council 
of Europe, and seek to adapt them for inclusion in a mathematical model. Such a 
review may identify problems with the existing data, or with data that are not routinely 
collected but may be readily available. It may be possible to glean data from the existing 
literature; for example, models which describe the spread of HIV through shared injecting 
equipment require an estimate for the probability that injecting with an infected needle 
will result in a new infection. This probability is often estimated from studies of needle-
stick injuries; however, Kaplan (1992) demonstrated an interesting use of his 
mathematical models in which he estimated this parameter. 
Within the context of other drug-related problems, research may be able to provide an 
insight into parameters such as the average time people use drugs before contacting 
services. Such information would have a dual use in developing back-calculation methods 
(see Chapter 6) as well as in compartmental models. A review of the literature may also 
seek to answer some of the questions presented above, for example the progression 
from one type of drug use to another and the increasing severity of drug use. Where 
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available, it would be preferable to use comparable data from throughout Europe to 
ascertain which processes are common to different areas in the same way that biological 
processes would be, and which processes vary over space and time. 
Feasibility of modelling the processes leading up to young people using drugs 
The academic literature often suggests a link between young people's licit substance 
use, such as smoking or drinking, and their drug use such that those who begin drinking 
or smoking at a young age are more likely to take drugs at a later age. Thus there are at 
least four compartments with which the underlying processes could be modelled: 
drinking; smoking; solvent abuse; and drug misuse. The use of drugs other than cannabis 
may be assigned another compartment, as can a parallel system such as the availability 
of drugs or alcohol. 
As in the models that describe the spread of diseases, the propensity to begin using 
drugs may be related to the number of the children's peers that use drugs; however, 
sociological research is yet to confirm that this is a relevant factor. It may then be 
preferable to model the uptake of drug use as something that happens to a proportion 
of young people, unrelated to the number of other young people that are using drugs. 
The previous two scenarios can both be modelled using the formula proposed by 
Caulkins and Kaplan and, while it may not seem sensible to attempt to estimate the 
parameters employed in this formula by commissioning sociological research, it may 
be prudent to adapt the existing knowledge about the factors relating to someone's 
inititation into drug use to indicate the likely values of these parameters. 
Both these recommendations seek to explore sociological processes that have already 
been Identified and examined, and this is reflected in the academic literature, particularly 
in relation to longitudinal studies. Pertinent questions can therefore be raised about 
both the applicability and the 'added value' of these methods. To answer these questions 
requires a definition of epidemiological mathematical modelling, such as that offered 
by Blower and Medley (1992). Compartmental models, regardless of which theory is 
used to analyse them, cannot at this time give precise answers to some of the more 
pressing questions in the field of drug misuse. What they can do is to increase the 
understanding of the processes and, perhaps more interestingly, illustrate the interactions 
between processes which may previously have been examined separately. Commenting 
on some of the longitudinal studies which have examined the social processes described 
above, namely the factors which determine a young person's uptake of drugs and the 
switch from smoking to injecting, can demonstrate this point. 
In both these situations, examining people over a period of time can, for example, offer 
great insight into the reasons why that individual has changed their route of administration 
from smoking or 'chasing the dragon' to injecting. A good example of this research 
would be the drug transitions study at the UK National Addiction Centre (Strang et al., 
1997). As part of this study, the reasons why individuals switch from smoking to injecting 
was examined and valuable information gathered on an individual's reasons for 
behavioural change. Similarly, longitudinal studies have proposed reasons why young 
128 
CHAPTER 7 
people begin using drugs, particularly in the United States (see Newcomb and Bentler, 
1986). While these and other studies explore the reasons why individuals make choices 
related to their drug or substance use, their generality at population level has yet to be 
evaluated. Within a stochastic compartmental model the variability of a population 
can be assigned by attaching a distributional form to a parameter or process, although 
this is still in an attempt to improve the generalisation at population level rather than 
implicitly to describe each individual. Deterministic models seek to describe these 
processes by a parameter such as a rate. Moreover, compartmental models seek to 
simplify the individual's processes, perhaps even to over-simplify these processes. This, 
however, does not contradict the definitions of Blower and Medley. By describing these 
processes either by a rate, as in the deterministic models, or a distribution, as in the 
case of stochastic models, the advantage of compartmental models is their ability to 
understand the interaction between the different ongoing processes. Thus compartmental 
models use basic mathematical modelling techniques to describe, or simplify, the 
individual processes relating to drug misuse. However, the benefits of such simplifications 
are to enable the different processes to be joined together within a logical framework 
of compartments, to give an insight into the complete picture. This complete picture 
may then be the result of a 'thought experiment' as described by Blower and Medley 
(1992). 
Conclusions 
To conclude, compartmental models use mathematics to describe not only individual 
processes, but also how these processes join together or interact to present a more 
complete picture. The step from examining individual processes to examining the 
complete picture necessitates some simplification, and this is reflected in the difficulties 
in using compartmental models to provide precise predictions. Compartmental models 
can, however, offer great insights into the interaction between these processes, and 
indeed into situations which are often described as one process, such as the reasons 
why a young person would begin using drugs, but which may be better attributable to 
several underlying processes. 
Epidemiological drug researchers are aware that the science is necessarily vague. It 
may never be able to answer precisely questions such as how many people use drugs 
or how long a person will smoke heroin before moving on to injecting. This does not 
detract from researchers' interests in these questions; however, it should be recognised 
that compartmental models may be the best way to explore some of the underlying 
processes. Of course, compartmental models may not answer all questions about drug 
misuse as there can never be a single methodology which answers all questions. The 
uses of this methodology in the situations described above and also in the study of 
other drug-related problems, should, however, be explored thoroughly. 
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CHAPTER 8 
DYNAMIC MODELS IN DRUG EPIDEMIOLOGY 
Colin Taylor and Philip Young 
In this chapter the term 'dynamic model' is used to cover methods from system analysis 
and time-series modelling which are applied to drug-prevalence estimation, but which 
do not simply attempt to chart or measure prevalence, but rather attempt to model the 
underlying processes. A useful distinction among such methods is to categorise them as 
either dynamic or static models. Static methods evaluate a population at a single point 
in time, while dynamic methods are appropriate when a population is traced over 
time. 
Because of their simplicity, static models have found favour in prevalence estimation. 
The simplest static-estimation techniques are the synthetic-estimation techniques. These 
methods develop prevalence estimates for new populations using readily available data 
sources, or indicators, from known populations by matching various predictor variables, 
usually demographic characteristics (e.g. ethnicity, gender, age and regional location) 
and determining appropriate weighting schemes. The appropriate weights are typically 
determined by either projection models or principal-component analysis. 
Dynamic models differ from the static models in that they describe processes over 
time. The process examined may be the states of individual drug users via multiple-
capture models. Multiple-capture models are divided into two classes: open-population; 
and closed-population models. In a closed-population model it is assumed that the 
population remains the same throughout the time period, while in an open model 
adjustments are made for the fact that members of the original population may leave 
and new members may enter. Techniques for closed-population methods are much 
simpler, such as the truncated Poisson model, and other than the closed-population 
assumption make fewer additional assumptions. However, if the time period is sufficient, 
then closed-population methods will be biased and the more complex open-population 
models may provide a better estimate of prevalence. 
If only aggregate data are available, then a system-dynamic model may be used. Although 
such models only use aggregate data, they can provide fairly sensitive estimates of 
prevalence because they typically employ additional economic and social data in a 
feedback mechanism to adjust the crude aggregate data. 
The choice of model selected is largely dictated by the data that are available, and their 
interrelationships are summarised below in Figure 1. 
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Figure 1 : The inter-relationships of the various types of system-analysis model 
System-analysis models 
Dynamic models 
I 
Static models 
(e.g. projection models) 
(e.g. principal components) 
Closed-population capture models 
(e.g. truncated Poisson model) 
Open-population capture models 
(e.g. ecological models) 
(e.g. Markov recapture models) 
t 
System-dynamic models in which 
feedback mechanisms are used 
(e.g. social and economic data) 
Dynamic models 
The term 'dynamic model' appears to have no particular specific usage in the drug-
research field. Instead it would appear to be open very much to interpretation, carrying 
with it allusions and references from other disciplines where the usage is more specific. 
Broadly speaking, within the domain of general drug-prevalence research, it is a term 
found in discussions of systems analysis and time-series modelling. 
To give a more precise and narrower focus, the term 'dynamic model' will here cover 
methods that have all of the following characteristics: epidemiological macro-models; 
models that deal with transitions in time; models that move beyond formulating and 
formalising purely cross-sectional relationships; and models that look beyond analysis 
of time series to the mechanisms and dynamics behind the series. 
Domains of research that are excluded by these criteria, but which may have some 
claim to the term 'dynamic' in a very broad sense, are: simple charting of prevalence or 
incidence through time; predictive but non-explanatory models; analyses that model 
the levels of drug prevalence or incidence without reference to explanators, for example 
very simple auto-regressive or moving average (or Box-Jenkins) approaches; micro-
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models that study the progression of individual drug users through various stages of 
their drug careers, and the process of becoming addicted; micro-models that look at 
the psycho-dynamics within individuals and their motivations and structures in relation 
to changes in their drug-taking behaviours; and transmission models of the spread of 
infection amongst drug users 
Issues concerning dynamic modelling 
A central reference worth consulting for an overview of dynamic models of prevalence, 
which includes comparisons with static prevalence-estimation techniques, is the papers 
contained within the special issue of the Journal of Drug Issues on prevalence estimation 
(Hser and Anglin, 1993). There are, however, several issues concerning dynamic 
modelling that are worth mentioning specifically. 
First, on issues relating to measuring population coverage and classification it should be 
noted that such methods are mostly directly concerned with simply counting people. 
Prevalence estimation must also consider the time frame and geographic boundaries 
because drug use is a dynamic process. Non-users move into the actively using population 
while current users may cease use; or drug users sometimes move in and out of 
geographic areas. 
The types of drug used and levels of use often need to be considered for several reasons. 
First, multiple-drug use is common and estimates of users therefore need to take into 
consideration this overlap of individuals and multiple-consumption occasions in order 
to avoid repeated counts of the same people. Second, because of the associated severe 
social and health consequences, some prevalence estimation may focus on a particular 
type of drug user (e.g. intravenous drug users) or more severe levels of use (e.g. addicts). 
However, when prevalence estimation is approached from a view of total drug 
consumption, all categories of drug users must be considered since all levels of drug 
use contribute. Definitions are necessary to identify appropriate data sources and to 
provide valid prevalence estimates. 
The second point relates to the use of data from national surveys to estimate prevalence. 
Several national surveys and special-purpose federal data systems containing drug-
related information have been conventionally used for prevalence estimation. Major 
surveys in the United States include the National Household Survey on Drug Abuse, 
the High School Senior Survey, the National Ambulatory Medical Care Survey and the 
National Hospital Discharge Survey. Examples of federal data systems include the Drug 
Abuse Warning Network, the System to Retrieve Drug Evidence, the Uniform Crime 
Reports, the Drug Use Forecasting Program and the Client-Oriented Data Acquisition 
Process. These data sources have both strengths and weaknesses and several issues 
must be considered in assessing the utility of a particular data system for prevalence-
estimation purposes. In particular, all of the above data sets are American, and this may 
reduce generalisability of the published results for EU countries. However, recent 
initiatives by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 
may provide alternative European data sets which are suitable for these types of analyses. 
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Particular care should be taken over the issue of sampling. Most large-scale surveys of 
drug use are based on probability-sampling techniques. However, general surveys often 
undersample certain lower-risk groups because of non-response or non-coverage. If 
drug users are disproportionately over-represented among the sample population used 
in the survey then this will overestimate the prevalence of drug use. 
It is also worth noting whether the data-storage system is event-based or person-based. 
Event-based systems are those in which each record arises from a single event, such as 
emergency-room admission. Person-based systems are those that provide records 
corresponding to individuals or allow ways to link an individual's multiple records. 
Except for survey data, most federal monitoring systems are event-based recording 
systems. It is often the case that several records belong to one individual who has 
multiple treatment admissions or emergency-room episodes. Thus, the number of people 
actually responsible for the number of records in these data needs to be determined if 
the person-based prevalence estimate is desired. 
In addition to the availability of data, the description of trends in use over time also 
requires consistency in the reporting panel, a goal which is not often achieved in 
continuously reporting indicator systems over long periods of time, especially when 
reporting by the contributing agencies is voluntary. Inconsistencies in reporting standards 
and practices must also be considered. The various data systems may also not share 
standardised methods of data collection, so that the comparison of indicators and their 
interpretation must be carefully attended. 
Finally it should be well understood that prevalence-estimation methods differ in their 
data requirements and statistical properties and thus in their utility for providing certain 
types of prevalence estimates. Each of these methods has strengths and limitations, and 
none can provide estimates without knowledgeable and careful application. Some of 
these limitations are due to the necessary simplicity of the assumptions of the model, 
others are due to the demands for specific data of a certain quality. Therefore, in selecting 
a model, the user must consider the appropriate use of the data that are available and 
interpret estimates derived from these methods within the appropriate context. 
Types of prevalence-estimation methods 
The comments in this chapter describe several prevalence-estimation methods with 
either historical importance or promising future applications. These methods include: 
synthetic estimation (population-projection models and principal-component 
approaches); closed-population capture models (specifically the truncated Poisson 
estimation model); open-population models (specifically the ecological models and 
the Markov-based dynamic-recapture models); and system-dynamic modelling. 
The useful distinction among these methods is to categorise them as primarily dynamic 
versus static approaches. Static methods such as synthetic estimation or closed-population 
models evaluate a population at a single point in time. Dynamic methods such as 
open-population models or system-dynamic models are appropriate when a population 
is traced over time. The choice of model is largely dictated by the data that are available. 
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To highlight the contrast between these two broad approaches some brief description 
of the static approaches is appropriate. These are the least complex of the prevalence-
estimation models, describing the system at a single point in time. Because of their 
convenience, these models have been the most popular in drug-use-prevalence 
estimation. 
Synthetic estimation is the simplest of the static-estimation techniques and is the main 
category of static models that is used in practice. These methods develop prevalence 
estimates for new populations using readily available data sources or indicators from 
known populations by matching various predictor variables, usually demographic 
characteristics, and determining appropriate weighting schemes. The following two 
methods are used to determine the proper weights to be applied. 
Projection models are based on the logic that if the drug-use prevalence rates are 
known in a population with a known demographic distribution, then the relationships 
between prevalence and demographic characteristics can be transferred or projected 
to another population, either smaller or larger than the first. 
Principal-component-based approaches assess the relationships observed among 
multiple indicators in several geographic areas in an attempt to obtain a single composite 
and common indicator of drug use. By combining several indicators into a single 
composite index with the weights determined by the principal-components analysis, 
an index that is more reliable than any single indicator alone may be derived. 
Dynamic models differ from the static models in that they describe processes over 
time. The process examined may be the states of individual drug users, as in the open-
population multiple-capture models, or it may be a collection of aggregate societal 
states, as in system-dynamic models. Because these models can represent processes 
more accurately than static models, and because they typically incorporate more 
information, these models potentially result in more accurate estimates of prevalence. 
Synthetic-estimation techniques are clearly not dynamic and will not be discussed further. 
Yet, although closed-population capture models are strictly static models, they are of 
historical interest and will be considered further in the next section. The following 
sections will then respectively cover the open-population capture models and the system-
dynamic models. 
Closed-population capture models 
A major heading for prevalence estimation is closed-population multiple-capture 
methods. These techniques are not usually framed as dynamic models, in that they 
estimate a population at a single point in time, or at least a closed population assumed 
closed over a fixed time interval; as such they are usually categorised as a variety of 
static estimation. In these techniques, two or more surveys of different data sources, 
such as emergency-room and arrest records, are used to probe the given population 
during a single time frame. Each survey must be able to identify specific cases and 
determine which individuals have been detected in both of the surveys. Using the 
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information about the relative sizes of the samples and their overlaps, the number of 
individuals that have not been detected can be estimated. This procedure has also 
been referred to as dual-system estimation (Chandra-Sekar and Deming, 1949; Ericssen 
and Kadane, 1985). 
The population whose size is to be estimated here is said to be closed because the 
single sampling time implies necessarily that it cannot change and gives the appearance 
of a simple cross-sectional study. It is, however, likely that the capture points cannot all 
be considered as generating a sample simultaneously with unfettered potential for 
overlaps between these samples. In reality, a person appearing at one capture point 
can only appear at another after a time lag of a length that is dependent on the precise 
nature, physical or administrative, of the capture points. This consideration throws the 
multiple-capture process immediately into a dynamic framework even when the 
population being estimated is closed to change over a time period. It would appear, 
however, that no studies or methods have specifically focused on this structured capture 
process to date. This topic is not pursued further here. 
The truncated Poisson model 
The truncated Poisson estimation model is the simplest version of the multiple-
observation models. It can be applied in situations where only the frequency with 
which an individual appears in a data system is recorded. In this procedure, events, 
such as arrests for drug possession, that occur one or more times to individuals in a 
population during a specific interval of time are examined. The distribution of people 
experiencing various numbers of events is used to extrapolate the size of the population. 
In the population whose size is to be estimated, some individuals have no events and 
are never observed, some have one event, some have two, and so forth. The problem 
is that although the number of people with one, two, three or more events can be 
observed, the number with no events cannot be directly observed. However, by assuming 
a probability model, this can be used to extrapolate what the number of people with 
no events is, and hence estimate the total population. 
Now when the events are rare, as they usually are for drug-use incidents, then under 
the following two assumptions it can be deduced that a plausible distribution for the 
number of events ¡sa Poisson form, leading to truncated Poisson estimates (Blumenthal 
et al., 1978). The two assumptions about the events needed for it to be a Poisson 
distribution are: that they occur randomly over both individuals and times; and that 
their rate is homogeneous across the population. To estimate the size of the population, 
an incomplete Poisson distribution is fitted to the frequencies of the observed events, 
and the single-rate parameter of the distribution is estimated. Knowing this parameter, 
the size of the unobserved category is estimated and added to the observed count to 
obtain the final estimate. Once the data have been fitted to the Poisson distribution, 
the observed and expected frequencies for each number of events can then be compared 
via a chi-squared test, which will facilitate validation of these assumptions, or not, as 
the case may be. 
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The truncated Poisson models have been used for estimating the size of the criminal 
population from arrest history records (Greene and Stollmack, 1981) and the number 
of persons engaged in using or selling drugs from drug-related arrest data (Woodward 
et al., 1987). In these applications, an arrest distribution was constructed from the 
number of observed arrests and the number of arrestees responsible for them, then the 
truncated Poisson estimation procedure was applied to derive the population estimates. 
Based on a similar rationale, the Research Triangle Institute (1988) applied the model 
to estimate the size of the treatment-susceptible heroin population. Their model was 
unusual in that two separate sources of data were used to estimate the Poisson rate. 
The number of treatment admissions was available from one data source, while the 
distributional information was derived from a separate, non-linked source. In this two-
source implementation, the comparability of the two populations is critical to ensure 
that the assumed Poisson distribution is applicable. 
The strength of the truncated Poisson method lies in the simplicity of its data requirements 
and its straightforward statistical formulation. As long as the data can be consolidated 
into a frequency distribution of the number of people at each level of the repeated 
observation, an estimate is easily obtained. However, the quality of the estimates depends 
on the degree to which the Poisson model is an adequate description of the underlying 
distribution. In particular, the counts must be independent Poisson events. This 
assumption is frequently violated. For example, criminals are strongly motivated to 
avoid re-arrest and are, to some extent, quite successful in doing so. On the other 
hand, risk of arrest may increase as the offender becomes known to the police. The 
effects of such violations of independence on the truncated Poisson-derived estimates 
are often not calculable. 
Open-population capture models 
Data that are drawn from identifiable individuals in a system of successive surveys or 
censuses using the open-population multiple-capture method are similar to those 
obtained in the closed-population multiple-capture situation described above. These 
data also form an incomplete contingency table. The similarity is superficial, however, 
for the processes to which the models are applicable are quite different. In the closed-
population situation, every individual is at risk for every census, while in most longitudinal 
repeated censuses, some individuals leave the population before the final census while 
others enter after the first census is complete. Therefore, closed-population models 
trace and estimate the size of a single population, while open-population models keep 
track of population changes and provide estimates reflecting such time-related changes 
of in and out flows. The data from a longitudinal dynamic process thus require a different 
type of statistical model, based on some assumptions about the open population under 
consideration. 
Most applications of the multiple-capture methodology to longitudinally repeated drug-
use samples have used closed-population models (e.g. Doscher and Woodward, 1983; 
French, 1977; Greenwood, 1971 ; Woodward et al., 1985). Such estimates are potentially 
biased because some individuals may not be available throughout the entire sequence 
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of time sampling and the degree of bias may increase with longer intervals between 
samplings. The nature and magnitude of these biases have not been studied. However, 
the magnitude of the standard errors in these closed-population applications is usually 
quite large, ranging from 10 % to 80 % of the estimated population sizes. Such poor 
estimation is especially serious within geographical areas representing relatively small 
populations. Models that accommodate the more realistic open-population dynamics 
may be generally more appropriate for estimation purposes. 
A more sophisticated approach using repeated sampling that builds on the truncated 
Poisson model described above may provide a better estimation methodology. Ecological 
open-population models, which assess the size and character of a biological population 
based on repeated marked samples, have been developed and extensively analysed 
(for reviews see Seber, 1982, 1986). The most common class of ecological sampling 
models that are applicable to the estimation of the number of drug users is the capture-
recapture type. For an open population, the most recent models are the Jolly-Seber 
model Golly, 1965, 1982; Seber, 1965, 1982) and a related model by Cormack (1981, 
1985). However, a number of the assumptions of these models are unrealistic for drug-
using populations, and none of these models has yet been applied to drug-use prevalence 
estimation. For example, the Jolly-Seber model assumes that: all samples are of 
independent and identical capture probability and survival probability; samples are 
instantaneous and release is made immediately after each sampling; the drug user's 
behaviour is unaffected by the capture history; and there is no temporary emigration 
from the population. These assumptions can hardly be satisfied by existing data or by 
the population characteristics of drug abusers. 
Markov dynamic-recapture models 
Another variety of the open-population multiple-capture approach developed recently 
is a Markov-based dynamic-recapture model. Instead of counting the individuals 
captured in each sample, a longitudinal model is based on the variety of capture histories. 
The model characterises capture probabilities by a two-step sampling process. The 
initial sampling probability is governed by a stochastic process in which users are drawn 
from a large population of non-users. After this first observation, the balance of the 
process is governed by the dynamics of a state structure that represents the evolution of 
drug-consumption patterns and their repeated observations by some indicator system 
(e.g. treatment admissions). This process forms a Markov chain (Wickens, 1993). The 
full history probabilities are therefore the product of three terms: the size of the sample 
in which an individual is first observed; the probability of that observation; and the 
probability of the observation history subsequent to the initial observation, characterised 
by the full variety of such histories. This procedure generates estimates of the size of the 
population from which the observations are drawn. 
In this procedure, the data from a repeatedly observed population are treated as sampling 
histories of individuals. As in the closed-population multiple-capture models, a 
probabilistic model is fitted to the observed histories, then extrapolated to count the 
unobserved members of the population. The Markov and semi-Markov models describe 
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the way the individuals change between observations as transitions among a small set 
of discrete states. Individuals enter into the target population, pass through various 
states of observation and non-observation, and possibly may leave the target population. 
In a semi-Markov process, the individual's passage among the states is modelled in 
continuous time by a homogeneous transition process. For data from a series of samples, 
the transitions are only observed at the times of sampling, and a simpler discrete-step 
Markov chain is used. 
The essential feature of a Markovian process is the assumption that the current state of 
an individual provides all available information about his or her future behaviour. How 
the individual initially reached that state is irrelevant. This independence of history 
means that the properties of the process are summarised by a set of transition rules 
pertaining to the specific states. For example, individuals in the observed state are 
characterised by the three probabilities (or rates) that indicate how likely they are to 
pass to each of the three states to which the observed state is connected. 
The transition probabilities among the observation and post-observation states can be 
estimated from the observed histories and are used to infer the target population size. 
The crucial assumption underlying these methods is that the dynamics of unseen 
individuals match those of the individuals who have been observed. Moreover, the 
transition structure must adequately approximate the dynamics of real individuals. It 
should be recognised that these models impose a considerable structure on the data 
and cannot be accurately used without a history sequence of some length. 
The Markov estimation technique has the advantage of being able to provide a somewhat 
more realistic dynamic description of the drug-using process. Its weakness is that the 
model comes with some strong intrinsic statistical assumptions of homogeneity and 
independence of history. In addition, to be practically applied, the model can have 
only a minimal dynamic structure. The limitation on the complexity of the model is 
necessary if its parameters are to be identifiable and estimated. A rich data source is 
needed to identify any complex structure, and such comprehensive data are not usually 
available. 
Although the open-population models potentially allow a more realistic picture of drug-
using populations as they evolve over time than do closed-population models, such 
models still require certain restrictive assumptions. Some of these assumptions are 
particular to the specific models developed in ecological situations, and others serve to 
simplify the required statistical models so that parameters can be adequately estimated. 
The latter assumptions include the requirements that individuals behave independently 
of each other and that the model's parameters are homogeneous throughout the 
population. A number of applications have shown that these assumptions are often 
violated in biology and health sciences (e.g. Huber, 1962; Manly, 1971 ; Wittes, 1974), 
and simulation studies have shown potentially large biases in population estimates under 
such conditions (e.g. Carothers, 1973; Gilbert, 1973). 
Theoretically, surveys or other data sources used by multiple-capture methods (either 
closed or open) should be comprehensive in population coverage. In reality, data suitable 
for this type of application have been limited to treatment-admission records that do 
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not provide such comprehensive coverage, thus limiting the generalisability of the 
estimation results. One common difficulty in applying multiple-capture models is the 
necessity of matching individuals across observations. The data source must ensure 
that an individual captured in one sample is identifiable as the same person if captured 
in another sample. However, such information is usually difficult to obtain. 
Because the multiple-recapture models attempt only to estimate the number of 
unobserved individuals from the observed sample, they cannot extrapolate to completely 
unobserved sub-populations. Like any of the statistical methods, they cannot solve the 
hidden-population problem. However, open-population models generally are based 
on probability theory and have better-known statistical properties that allow estimates 
to be evaluated by standard methods such as confidence intervals. In addition, 
boundaries of generalisability can usually be inferred by data coverage and model 
specifications. 
System-dynamic modelling 
System dynamics is a general methodology, first developed in the late 1950s, for analysing 
dynamic phenomena through the use of simulation models based on information-
feedback-control theory. A system-dynamic model consists of an interconnected set of 
difference equations representing continuous time movement and accumulations of 
people, materials and information. After being assigned initial conditions consistent 
with historical data, this set of equations is used to generate output over time. If the 
model is a valid one, this output will closely mimic the true course of events, and the 
model may be used for prevalence estimation and for making conditional forecasts. 
An example of system-dynamic modelling studies of illicit drug use include the 'Persistent 
Poppy' model of Levin et al. (1975). The Persistent Poppy model examined heroin use 
in New York City from the standpoint of policy rather than prevalence estimation. 
Although the model contains several interesting endogenous factors, such as law-
enforcement activity and treatment programmes, it was developed at a time when the 
numerical data needed for its calibration and validation were lacking. 
Another example of a system-dynamic model was developed by Gardiner and 
Shreckengost (1985, 1987; Shreckengost, 1984, 1985). The models developed by 
Gardiner and Shreckengost address drug supply and demand on a national level, with 
specific application to heroin and cocaine. They have been used primarily to make 
inferences about drug-import levels, thus focusing on quantity measures rather than 
persons or events. The model developed for heroin was adapted to estimate the number 
of users, but such estimates were shown to be rather sensitive to uncertain assumptions 
about the number and type of drug-user categories (Shreckengost, 1984). The models 
of Gardiner and Shreckengost may also lack sufficient feedback structure and internally 
generated momentum to be useful for prevalence estimation and forecasting. 
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A recent model of cocaine use (Homer, 1990) was developed to make inferences about 
unobserved populations from available data sources related to drug-use prevalence. 
This model reproduces historical drug-indicator data from 1976 onwards and produces 
prevalence estimates and forecasts for several population categories, including casual 
and compulsive users. For this purpose, the model uses two sorts of information. First, 
it uses information about the logical relationships among various population categories. 
For example, the model depicts the escalation process by which casual users become 
compulsive users, and distinguishes the effects of powder cocaine from those of crack. 
Second, the model uses information about the logical relationships between the 
population categories and other indicators, including morbidity and mortality, drug-
crime arrests, retail price and purity, and so forth. For example, the model is calibrated 
to reflect the idea that compulsive users are more likely than casual users to show up in 
the Drug Abuse Warning Network (DAWN) data on cocaine-related morbidity and 
mortality. With sufficient numerical data and knowledge of a phenomenon's structure 
and dynamics, the range of estimates for the hidden populations may be narrowed to 
a considerable degree. This model has been further used by Everingham and Rydell 
(1994) and Rydell and Everingham (1994) to model the demand for cocaine and to 
explore various scenarios developed from current drug policies (see Figure 2). 
More technically in the system-dynamic technique, quantities such as the prevalence 
of drug use are measured by embedding them in a larger model that describes the 
feedback relationships among these quantities and other social and economic factors. 
A system-dynamic model describes continuous-time change in quantities and factors 
through an interconnected set of differential equations. System states, such as the number 
of individuals in a particular state of drug use, are represented by level variables L(i). 
The level variables are related to one another and change according to net-rate functions 
Figure 2: Logical structure of cocaine-control model 
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f; for each level L there is a single net-rate function fL. These net-rate functions use 
intermediate variables known as rates and auxiliaries. Rate variables define identifiable 
flows into and out of the levels, such as drug-use initiation, escalation, stopping and 
relapse. Auxiliary variables define other concepts that make the model more intuitive 
and natural, such as retail price and perceived health risk. The net-rate functions are 
parameterised by constants C, which include delay times and strength-of-response 
parameters, such as price elasticities. The net-rate functions may also be influenced by 
exogenous variables X(t) that change over time and are determined by external data, 
such as the baseline population growth rate and the fraction of drug imports that are 
seized. With the many level and exogenous variables, constants and net-rate functions 
written as vectors, a system-dynamic model is expressed as 
dL(t)/M - ψ = flL(i), X(t); C] 
When investigating the model, these differential equations are typically not solved 
analytically, but are expressed as difference equations, for small time intervals At. 
L(t) = L(t-At) +AtxfL(i), X(t-At); C) 
The variables are simulated starting at some initial time such as t = 1976 and stepping 
forward to subsequent times. The computation interval Δ has no real-world significance 
and is chosen to be sufficiently small such that the simulation output lies close to the 
true solution of the corresponding differential equations. 
The validation of a system-dynamic model, unlike that of the simpler probabilistic models 
described elsewhere, is an ongoing process of building confidence in the realism of the 
model's structure and behaviour, using a variety of largely qualitative tests (Forrester 
and Senge, 1980). The complexity of the models allows for similar observed behaviour 
to be generated by a variety of structures, which must be carefully chosen if unobserved 
dynamic quantities, such as prevalence, are to be accurately described. Confidence in 
the model and its estimates is enhanced when all equations have concrete real-life 
significance, are dimensionally correct and operate appropriately even under extreme 
conditions. Confidence is also enhanced when the model faithfully recreates the dynamic 
patterns and correlations observed in real life, and when it bring to light behaviour in 
the real system that has gone unrecognised or unexplained (Mass, 1991). 
System-dynamic models typically attempt to explain observed dynamics as being the 
consequence of endogenous feedback relationships among constituent variables. This 
endogenous perspective distinguishes the system-dynamic approach from other 
modelling methods, such as synthetic estimation, which depend heavily upon exogenous 
or independent predictors whose own behaviour over time is left unexplained by the 
model. The continuous-feedback perspective of system dynamics also leads to models 
that contain a greater variety of system variables than the multiple-capture or Markov-
type models, and tend to be larger in scope. This enlarged scope is rendered manageable 
by modelling flows as aggregate measures, rather than by keeping a unique record of 
every individual unit in the flow, as is done in the multiple-capture models. 
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System dynamics is an attractive approach for prevalence estimation largely because it 
can be used to explain past history, fill in the gaps in indicator data, and project outcomes 
under different assumed scenarios and policy interventions. In addition, a system-
dynamic model can often help detect certain flaws in existing indicator data sets, such 
as possible logical inconsistencies between incidence data and prevalence data. 
However, the very flexibility of system dynamics opens the door to potential model 
mis-specification, a danger that becomes greater as the number of variables and 
conceptual scope of the model increase relative to the quantity of relevant data. Also, 
like any method, the accuracy of a system-dynamic model is sensitive to the quality of 
the data used to calibrate it. Nevertheless, a well-specified system-dynamic model may 
be useful even if it falls short in numerical precision, because it reveals and anticipates 
trends that other methods may miss. 
Because of the complexity of system-dynamic models and the risks of mis-specification, 
a variety of tests for building confidence into such models have been offered that go 
well beyond the usual requirement that historical data be reproduced (Forrester and 
Senge, 1980). But these validation techniques are themselves subject to uneven 
application or improper interpretation. It must be recognised that system-dynamic 
modelling, despite its many attractions, is difficult to master, and there are pitfalls in its 
application that must be carefully avoided. 
Conclusions 
Techniques are already available for the dynamic system analysis of drug prevalence. 
The problem with such models is that their applicability is highly dependent on the 
level of data available. As better-quality and more comprehensive data become available 
it may be that more complex modelling techniques will also be proposed; however, at 
present there are already methods proposed which go beyond the available data. As 
such, the key priority in this area must be the implementation of better and more 
comprehensive methods of data collection. In addition, if these techniques are expected 
to be applied to the European drug market then it is also important that European data 
sources are developed. 
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CHAPTER 9 
STRUCTURAL EQUATIONS AND PATH ANALYSES: 
USING MULTIPLE INDICATORS OF DRUG PREVALENCE 
Colin Taylor and Philip Young 
In many areas of social research it is sometimes not possible to measure directly the 
concepts that are of major interest. The first distinction that researchers wish to make is 
that between frequency of drug-taking and the quantity of drugs taken. Distinguishing 
between frequency and quantity has important implications for recognising the presence 
of drug or alcohol problems by health-care professionals, employers or co-workers. 
Many studies combine frequency and quantity measures to assess drug and alcohol 
consumption (e.g. Makela and Simpura, 1985). 
However, frequency of drug use and quantity or amount of substance ingested per 
occasion may be differentially related to disruptive or 'problem' use of drugs. Thus, 
although frequency and quantity are typically correlated in a positive direction (Fitzgerald 
and Mulford, 1984; Huba et al., 1982), they may not be equally complicit in predicting 
general problems with drug use or use of drugs in inappropriate settings (i.e. disruptive 
use at work or school). Huba et al. (1982), in a study of 257 adolescents between 15 
and 18 years of age, found a correlation of 0.91 between quantity and frequency 
measures of use of alcohol, cannabis and hard drugs. In addition, researchers are often 
interested in the public's subjective perception of the drug problem. 
From the above, four underlying concepts related to drug use that may interest 
researchers can be identified: the frequency of drug use; the quantity of drug use; the 
amount of disruptive drug use; and the subjective perception of drug-use problems. 
Researchers may then be interested in the relationships between these concepts or 
factors. Specifically, researchers are often interested in modelling the correlations 
between them. The idea of using these underlying factors first appeared in the field of 
psychometric testing when researchers came to realise that the measurement of 
hypothesised constructs, such as personality traits and intelligence, could be improved 
by considering scores on a variety of indicators (Bentler, 1990). 
Unfortunately, although it is easy to discuss drug usage conceptually in terms of these 
factors, it is often difficult to measure these quantities directly. As a result, researchers 
often tend to collect information on variables which they believe will act as indicators 
of the underlying concepts. The most basic way of proceeding is to use a technique 
known as factor analysis. The basic factor-analysis model is essentially the same as 
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multiple regression, except that the observed multiple indicators are regressed on the 
unobserved underlying factors, which are often referred to as latent variables. 
When a specific number of factors are assumed to be involved, then the factor analysis 
really revolves around trying to justify, or confirm, that these are the correct factors to 
use, and is often called confirmatory-factor analysis. The use of multiple indicators has 
long been recommended as an alternative to counting actual prevalence or incidence, 
and at present the Pompidou Group of the Council of Europe is still making their use a 
central part of its recommended programme. The use of a multi-trait multi-method 
procedure (Campbell and Fiske, 1959) using latent-variable confirmatory-factor analyses 
is commonplace. 
The confirmatory-factor model has been described by Schmitt and Stults (1986) as the 
preferred method of analysing multi-trait multi-method matrices. Such procedures have 
been successfully used to demonstrate construct validity and to derive more accurate 
measures of drug use (Stacy et al., 1985), while Harvey et al. (1985) found it useful to 
incorporate method factors into their confirmatory-factor analysis of the job diagnostic 
survey. 
The above examples of latent variables are, of course, only some of the underlying 
constructs, or factors, that have been postulated. Another important aspect to recognise 
in researching drug prevalence is that poly-drug abuse is very common. In fact, most 
drug users do not limit themselves to a single substance and typically use two or more 
drugs as part of their lifestyle (Clayton and Ritter, 1985). In particular, those who use 
illicit drugs (i.e. cannabis, cocaine or other hard drugs) also tend to use alcohol (see 
Newcomb and Bentler, 1986a, 1986b). Thus, the general drug factors identified in 
these analyses reflect poly-drug use, a more realistic appraisal of drug involvement 
than studying single substances. 
However, most heavy users of drugs other than alcohol tend to be poly-drug users 
(Clayton and Ritter, 1985), with alcohol being one of the multiple substances. Alcohol 
use in a poly-drug-use context may have quite different consequences than when it is 
used in moderation. It is possible that moderate use of drugs other than alcohol may 
not invariably be associated with problem use of such substances by young adults. 
Another area where drug-prevalence research is concentrated is in the detailed 
relationship of drug use to personal behaviours and in particular to drug-related problems, 
expressed as underlying latent constructs. It is of particular interest to determine whether 
high levels of drug use are invariably associated with inappropriate or disruptive use of 
drugs on the job, or at school, or with other specific problems of use (e.g. car accidents 
and arrests) among adolescents. In the same way, many features of intravenous drug 
users' (IDUs) behaviour, such as sharing injecting equipment or sexual activity, may be 
considered latent variables with many partially correlated indicators. 
Sadava and Secord (1984) reported that consumption of alcohol and drugs was related 
to, but not equivalent to or redundant with, alcohol problems. Sadava (1985) also 
found that self-reported consumption and problems were largely independent among 
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adults. He argued that alcohol consumption and alcohol-related problems must be 
more clearly separated on conceptual and methodological bases. Survey studies typically 
have found an average correlation in the 0.3 to 0.4 range between measures of 
consumption and problems (Sadava and Secord, 1984). In a longitudinal study, Stein et 
al. (1987) found different prior determinants of use and problem use of drugs in young 
adulthood. General use was related to prior use and early adult models, whereas problem 
use was related to earlier rebelliousness. 
In their 1988 study, which is a good example of the genre and which touches on all 
three of these issues, Stein et al. examined the interrelations among different ways to 
assess drug use, self-reported problems with use and specific negative outcomes resulting 
from drug use. Specifically, the analyses concern the relation among self-reported use 
of drugs in the workplace; arrests for driving while intoxicated (DWI) and for other 
drug-law violations; having car accidents while drunk or stoned; general drug problems; 
and frequency and quantity of using alcohol, cannabis, cocaine and other hard drugs. 
Figure 1 depicts the hypothesised confirmatory-factor model and illustrates how the 
specific drug-use components (alcohol, cannabis, cocaine and hard drugs) are separated 
from poly-drug-use tendencies (frequency and quantity), disruptive use and subjective 
problem-use factors. These constructs are identified by 13 measured or observed 
variables. Latent variables are depicted as circles, and manifest variables are represented 
as rectangles. On the left-hand side of Figure 1, a general alcohol-use latent variable is 
hypothesised to generate measures of alcohol frequency, alcohol quantity, disruptive 
alcohol use, subjective problems with alcohol, and trouble with alcohol or drugs. 
Similarly, the other measured variables of drug use are assumed to reflect specific 
tendencies to use cannabis, hard drugs and cocaine. On the right-hand side of Figure 
1, a substantive general latent variable of drug-use frequency (i.e. frequency of poly-
drug use) is assumed to generate manifest measures of frequency of alcohol, cannabis, 
hard drug and cocaine use. Drug-use quantity is identified by quantity measures of 
alcohol and cannabis use. The tendency to use a range of drugs on the job or in school 
is called disruptive drug use and is reflected in four measures of disruptive alcohol, 
cannabis, cocaine and hard-drug use. Three measures of subjectively perceived problems 
with drugs or alcohol, both long-term and more recent, are reflected in a latent variable 
of subjective problem drug use. The lines with double-headed arrows indicate co-
variances allowed between the latent variables. Correlations between the substantive 
latent variables and the specific drug-use latent variables were set at zero. 
The report examined relations among self-report measures and outcomes of drug use 
among 739 young adults. It is worth noting that the usual factor-analysis model assumes 
normality of the indicators. However, the indicators used by Stein et al. (1988) were 
screened for appropriate distributional properties, such as skewness and kurtosis. Most 
of the indicators were found to have distributions quite far from normality. Fortunately, 
confirmatory-factor analysis is known to be fairly robust to departures from normality. 
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Figure 1 : Confirmatory-factor model of multi-trait multi-method 
assessment of drug use 
Source: Stein et al. (1994) 
Predicting single traits from multiple indicators 
Confirmatory-factor analysis considers a number of latent variables as the underlying factors 
that explain the correlations between the observed multiple indicators, so that if the value 
of the latent variables were known there would be no partial correlations between the 
indicators. Although such a model is useful in understanding the associations between the 
various factors and indicators, it is not intended to provide predictive estimates. 
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One advance would be to form a predictive equation for one of the observed indicators, 
for example overall drug use, and predict this using the other indicators through the 
latent variables. One major line of development in this area has been the study of 
geographic variation in prevalence levels, derived from national, or rather sub-national, 
official data sources. Multiple-indicator methods that use a combined multivariate 
analysis in deriving a single prevalence figure have been used extensively in the United 
States to chart geographic variation in opiate abuse, particularly at the level of the small 
metropolitan statistical area (SMSA) in conjunction with the Drug Abuse Warning 
Network (DAWN) which produces data at this level of aggregation for 24 areas. 
Indirect estimation has progressed from simple use of hepatitis indicators (Minichiello, 
1974) and national estimates of prevalence (Greenwood and Crider, 1978) to multiple-
indicator approaches at both SMSA (Person et al., 1977; Riley et al., 1981 ) and county 
level (French, 1977). 
Historically, these methods have often gone under the name of 'multi-method single-
trait' modelling and more recent methods have grown from the initial models of 
confirmatory-factor analysis (Joreskog, 1971) developed in psychological research 
methodology. Additionally, a variety of demographic models of ¡nter-SMSA variation in 
indicator-derived prevalence (Schlenger and Greenberg, 1978) have been employed 
to investigate inter-metropolitan correlates of drug use, and demographic models of 
census-tract variation in drug-abuse prevalence have been tested by Demaree et al. 
(1978). 
More recently interest has focused specifically on questions of validity and reliability. 
Beginning with Person et al. (1977), the conceptual problems of estimating heroin-
abuse prevalence from indicators have been discussed. Because of definitional 
difficulties, they use the term 'heroin abuse' rather than 'heroin prevalence' and consider 
the use of the term 'heroin problem index'. Earlier papers had assessed the internal 
consistency of such multi-method single-trait estimates, for example Person et al. (1976) 
for a set of heroin-abuse indicators drawn from medical, treatment and law-enforcement 
sources for the 24 DAWN SMSAs. 
Indirect support for face validity of the procedure has in the past been demonstrated. 
Woodward (1978) fitted a single-factor model simultaneously at two time periods 
separated by a single quarter (three months). Not only could the longitudinal model be 
accepted as plausible, but the estimated correlation between the heroin-abuse constructs 
across time was high, indicating the expected high degree of stability across the three-
month time period; similar relationships were found by Stoloff et al. (1975) in a 
longitudinal study carried out within a single SMSA. Moreover, the two-point longitudinal 
model was fitted in the context of two drug-abuse-related demographic characteristics 
of the communities - urbanicity and employment. Again, the model showed adequate 
fit, and the significant coefficients of the model were consistent with the interpretation 
that the single factor underlying the indicators is a measure of the intensity of heroin 
abuse: that is, the heroin-abuse construct was positively related to urbanicity and 
negatively related to employment. 
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Structural-equation modelling 
With the availablity of more powerful analysis programmes (e.g. LISREL, EQS) the trend 
is now to place such analyses within the currently popular format of structural-equation 
modelling (SEM). The model used, for example, by Woodward et al. (see Figure 2), can 
be fitted with a confirmatory-factor-analysis procedure. In that all links between 
constructs or traits have to be bi-directional and can be regarded as partial correlations, 
and all links from constructs are unidirectional towards the observed data or methods, 
the model is restricted to being a confirmatory-factor-analysis model. However, 
Woodward et al. (1984) used a more versatile structural-equation programme to fit the 
confirmatory factor-analysis model. 
Figure 2: Standardised maximum-likelihood estimates and goodness-of-fit test 
for the log-rate three-construct model 
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The model used by Woodward et al. (1984) was constructed with multiple traits, the 
constructs of heroin abuse and heroin availability. With the recognition that the central 
construct in these indirect indicator models, even if called heroin-use prevalence, is 
actually a more general and broader concept than simple head-counting and deserving 
of a different name (Woodward et al., 1984), it becomes useful to have more than one 
such unobserved construct incorporated into the analysis in order to account for the 
different indicators, hence the two nodes on the right of Figure 2 called prevalence (1) 
and availability (2). 
The use of SEM procedures has a number of advantages. Not only does it allow the 
identification of multiple constructs, it also allows models to be specified in terms of 
causal paths, as represented by estimating regression coefficients, between the constructs. 
Further, it considerably extends the ability to specify error structures and correlations 
between not only error terms, but also error variables and constructs themselves. 
The structural component of the analysis involves path analysis, which may be defined 
as the process of estimating the coefficients of a set of linear structural equations (i.e. 
regressions) representing the predictive relationships hypothesised by the investigator. 
Rather than estimating each equation separately, the SEM approach considers the model 
as a system of equations and estimates all the structural coefficients simultaneously. 
The ability of the model to estimate parameters simultaneously represents a considerable 
advance over earlier types of path analysis in which it was only possible to estimate 
parameters sequentially. 
This greater modelling potential represents the use of data other than official statistics 
to derive drug-prevalence information, and to model behaviour in relation to drugs 
generally. The shift is driven by the recognition that prevalence per se is not precisely 
what is at the heart of drug addiction. Studies of personal behaviour allow a better 
description of many important facets of addiction prevalence. 
An example of EQS 
In a EQS structural-equation model every variable, be it latent or manifest, is defined as 
either independent or dependent. Dependent variables are those that can be expressed 
as a structural regression function of other variables. Independent variables are never 
regressed on each other. The two types of variables are then related by a set of structural 
equations. The analysis is usually conducted using the EQS structural-equation 
programme (Bentler, 1986). 
The Stein et al. (1994) study illustrates the use of structural-equation modelling as a 
complex multi-step procedure. A stable, well-fitting and plausible factor structure was 
established from preliminary confirmatory-factor analyses. Here the 13 measured 
variables used in the initial analysis reflected the eight hypothesised latent variables in 
a reliable manner (see Figure 3). Further analyses were then undertaken using chi-
square difference tests on various more restricted models. Specifically, the concordance, 
or similarity, among the substantive latent variables, once specific drugs have been 
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Figure 3: Significant regression paths among latent and manifest 
variables in the structural-equation model 
► I Abortion 1 
Notes: ^Regression coefficients are standardised, and residual variances are in circles 
bp <0.01 
cp <0.001 
Source: Steinetal. (1994) 
partialled out, are tested by setting restrictions on the general model by constraining 
pairs of correlations between latent variables at 1.00. These analyses are performed 
separately for each pair of constructs to test whether they are assessing identical traits. 
In other words, even though it is hypothesised on conceptual grounds that four 
substantive factors will be found, it is possible that fewer factors may account for the 
data. For instance, frequency and quantity factors may be measuring an identical 
tendency to use drugs. 
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The goodness-of-fit of the models is assessed in two ways: through use of a chi-square 
test of the overall fit of the model; and through use of the Bentler-Bonett normed fit 
index (NFI) statistic, which takes sample size into account. Acceptable values of the NFI 
should equal at least 0.90 (Bentler and Bonett, 1980). 
Second-order factors are also tested. A second-order factor is a latent variable that is 
assumed to reflect an underlying relation or commonality among the primary latent 
variables. In particular, it is of interest to determine if the frequency and quantity latent 
variables may themselves result from a general drug-use second-order factor. 
Furthermore, another second-order general factor of drug-use and abuse is hypothesised 
and tested to account for all four of the substantive latent variables. If such a general, 
second-order factor were supported by the data, this would indicate that all types of 
drug-using behaviours, as well as negative consequences of drug-use, are generated by 
a pervasive disposition for drug involvement spanning both use and abuse. 
After completion of the preliminary assessments of the factor structure, regression effects 
among the latent variables are examined. In particular, drug-use frequency and drug-
use quantity are used to predict disruptive drug use and subjective problem drug use in 
order to assess the relative contribution of each predictor variable to these negative or 
adverse outcomes. These relations represent one of the main focal points of interest in 
the study because they represent associations among general drug factors after the 
influence of using specific drugs has been controlled. Finally, a model is tested that 
includes the negative drug consequences latent variable as part of the confirmatory-
factor analysis. Then the negative drug consequences latent variable are included as a 
consequent variable in the regression model. 
Specific problems arising from drug use are reflected in actual adverse consequences 
reported by the subjects. These variables include car accidents while under the influence 
of alcohol or other drugs, arrests or convictions for driving while intoxicated from alcohol 
or other drugs, and drug-law violations for selling or possessing drugs. The prediction of 
these specific drug-related behaviours is then based on the substantive latent variables 
identified in previous analyses. These problem variables are not included in the original 
multi-trait multi-method assessment because they do not relate specifically to separate 
drugs. 
Both normal-theory maximum-likelihood (ML) and arbitrary-distribution theory 
(asymptotically distribution free; Browne, 1984) generalised least-squares (AGLS) 
estimation methods were used to estimate preliminary solutions for the model. Because 
many of the variables were non-normally distributed (normalised multivariate kurtosis 
estimate for the 13 variables = 319.75), the linearised AGLS (Bentler, 1983; Bentler 
and Dijkstra, 1985) solution was used in all subsequent analyses. 
Results supported the construct validity of the hypothesised latent factors. Although 
highly correlated, drug-use frequency and drug-use quantity were not interchangeable: 
quantity was a more powerful predictor of disruptive and problem drug use. A second-
order factor of general drug use and abuse accounted for these first-order constructs. 
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LISREL example 
In contrast to an EQS model, a linear structural-relations (LISREL) model defines a set of 
latent response variables. These latent response variables depend on a set of latent 
explanatory variables. The relationship between the latent response and explanatory 
variables is defined in what is known as the structural model. The latent explanatory 
variables cannot be observed directly. However, some manifest response variables and 
manifest explanatory variables are observed. These are linked to the latent variables, 
both response and explanatory, through what is known as the measurement model. 
The specification of both the structural and measurement models is left to the user, and 
care must be taken to define an overall model which is both plausible and calculable. 
This approach formally develops a model in which the measurement model is separate 
from the structural relations between the constructs or latent variables. 
Specifically using the idea that latent variables could be used generally for all constructs 
required by the models, Frischer et al. (1991 ) used two indicator, or manifest, variables for 
each of the latent variables of interest. Frischer et al. (1991 ) used data obtained as part of 
a cross-national study sponsored by the World Health Organisation, and a representative 
sample of current Glasgow IDUs were recruited from 'in-treatment' and 'out-of-treatment' 
sites. For the purposes of this study, in-treatment sites were defined as agencies whose 
principal aim is to modify drug-taking behaviour. A total of 536 IDUs were eligible for 
participation in the study. The LISREL programme was used to construct measurement 
and structural models relating to injecting drug use (Joreskog and Sorbom, 1989). 
Subjects were included in the Frischer et al. (1991 ) analysis who had injected drugs In 
the two months prior to interview and had not already been interviewed for the study 
in the current calendar year. In addition, those recruited from in-treatment sites were 
only eligible if their current episode of treatment had begun within the previous four 
weeks. Each participant joining the study was told the name of the interviewer and the 
purpose of the study - t o improve understanding of the drug-taking and sexual behaviour 
of IDUs in relation to their HIV seroprevalence. They were informed of the confidentiality 
of information to be obtained and the voluntary nature of the study. One hundred and 
seventy IDUs were recruited to the 'in-treatment' subset from 13 different agencies 
which together represent most of the drug-treatment capacity in Glasgow. The remaining 
333 IDUs were recruited from 12 'out-of-treatment' settings, selected both to provide 
geographic spread and to maximise the likelihood that a proportion of the sub-set 
would include drug injectors who had no contact with drug-user treatment or harm-
reduction agencies. The majority of respondents (84 %, N = 423) had injected in all of 
the six months prior to interview. The mean age of first drug use (by injection) was 17.3 
years, and the mean length of drug-use injection was 6.8 years. The three drugs most 
commonly injected by respondents were buprenorphine, heroin and temazepam. 
Sample characteristics used as control variables in the analysis are described in the 
section on the measurement model below and shown in Table 1. 
For the measurement model, ten features of injecting drug use were identified as being 
the most frequent topics of research (see Table 1 ) from a literature search which focused 
on injecting drug use and HIV-related risk practices. The measurement component of 
a SEM model consists of a number of underlying or latent variables that account for the 
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Table 1: Variables in a LISREL measurement model 
Indicators Correlation 
Injecting drug use 
Sharing of injecting 
equipment 
Sexual activity (not 
prostitution) 
Prostitution 
(Current) awareness 
of AIDS 
Harm reduction 
(sexual activity and 
drug use) 
Travel 
(12 years prior to 
interview) 
Prison experience 
Income 
Treatment (lifetime) 
A. Number of drugs injected 
B. Frequency of injection of all drugs 
A. Frequency of equipment given by other 
B. Frequency of equipment given to others 
A. Number of sexual partners 
B. Frequency of sex 
A. Number of clients 
B. Frequency of all sex 
A. Frequency of talking about AIDS 
B. Number of routes of infection mentioned 
A. Number of changes made 
B. Number of changes maintained 
A. Number of places injected outside Glasgow 
B. Number of places had sex outside Glasgow 
A. Frequency of injecting/sharing in prison 
B. How many nights spent in prison 
A. Scale of main source of legal income 
B. Percentage of income from illegal sources 
A. Number of types of treatment 
B. Frequency of treatment 
0.728 
0.443 
0.318 
0.711 
0.270 
0.777 
0.381 
0.275 
0.295 
0.852 
Note: except where noted, indicators refer to behaviour in the six months prior to interview 
c o m m o n relat ionship among a number of observed variables. Previous work has 
indicated that it is inappropriate to interpret a latent construct as a measure of substantive 
importance in relation to its indicators where all its squared mult iple correlations are 
less than 0.55 (Cuttance, 1987). These parameters are a measure of the validity of the 
measurement model . 
For the structural model , all paths from all to all constructs were included in this particular 
model , an at tempt was made not to pre-judge any issue of cause or effect, and the 
model was subsequently ' t r immed ' of non-significant links (bi-directionally). As in all 
regression analyses, the effect of any independent variable on any dependent variable 
is tested independent ly of the variance shared wi th other variables. All parameters 
were estimated using the method of max imum l ikel ihood. 
Addit ionally, seven exogenous variables were included in the model . Each of these 
variables was measured by a single indicator and was constrained in the model to be 
predictive of, but not predicted by, the latent variables. These variables were socio-
demographic in nature. Again fo l lowing a global strategy, all relationships between the 
constructs and the exogeneous variables were control led when estimating the path 
coefficients between the set of constructs. 
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Conclusions 
The structural-equation-model procedures when brought to bear on very complex 
behaviours such as drug-addiction prevalence, intensity and problems can afford a 
richness of models to supply answers that are over-powering. The multiplicity of causal 
link paths between constructs that can only be loosely related to their manifest indicator 
measures, coupled with the ability to allow for measurement models that have correlated 
error variables, can generate models that are far from parsimonious (see e.g. Figure 2 
from Stein et al., 1994). Such models tackle a particularly complex set of inter­
relationships. It is not clear that such extensive modelling actually clarifies the relationships 
between the observed phenomena. 
Frischer et al. (1991) report on a study that carries the idea of estimating structural 
paths to a logical conclusion, implying that any regression-analysis model could be in 
fact replaced by a path analysis between latent variables within a structural-equation 
model. A study that assesses relationships using several regression models (as did the 
original path models) could take advantage of the larger structural-equation model by 
incorporating all such analyses, if using a common or overlapping set of variables, into 
a single model. 
Stein et al. (1988) report a study that uses structural-equation modelling extensively, 
with the frequency/quantity issue as central. The study was designed to ascertain whether 
measures of frequency and quantity are essentially interchangeable as predictors of 
problem or disruptive use of drugs in an older sample. They further examined the 
interrelations among different ways to assess drug use, self-reported problems with use, 
and specific negative outcomes resulting from drug use. 
An explicit measurement model was developed by Person et al. (1977) in which it was 
hypothesised that each indicator, regardless of the method of measurement, was a 
monotone function of heroin abuse and an error term unique to the indicator. Tests of 
the measurement model, which derive from non-metric confirmatory-factor analysis, 
using non-metric statistics (McDonald, 1967) revealed an adequate fit of the model to 
data collected at four different time periods. 
Subsequently, Woodward (1978) applied linear structural-equation models to test 
statistically a variety of measurement models of heroin-abuse indicators drawn from 
medical treatment and law-enforcement domains, addressing a variety of reliability/ 
validity issues. Within a given quarter of the year, two alternative measurement models 
were contrasted. The first model allowed for factors defined by variables having a 
common method of measurement, and the second model postulated a single heroin-
abuse construct underlying all indicators. The single-construct model could be accepted 
as plausible while the method-factor model could not. 
While these early studies of the reliability and validity of indicator-based estimates of 
heroin abuse are important, they can be considered as only an initial step in the right 
direction. Because indirect methods such as factor analysis involve so many untenable 
assumptions, inaccuracies and influences beyond the control of the researcher, their 
practical utility remains constantly in doubt. In theory, the factor-analytic method works 
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well (for a simulation, see Person et al., 1976), but application to SMSA aggregate data 
remains a problem because of potent ial ly shift ing report ing bases under ly ing the 
indicators, d ist r ibut ional problems of the data, and other pract ical v iolat ions of 
assumptions. The same, however, can be conc luded of the other major indirect 
estimation procedure, the capture-recapture method. 
In conclusion, SEM models have been used successfully and have great potential to be 
used again in helping researchers to understand the complex relationships between various 
factors and in understanding how underlying theoretical concepts can be fitted into models 
of drug prevalence. As such, these methods are excellent tools for model generation and 
for stimulating discussion. That said, care should be taken not to take the results of such 
models too literally: these methods should always be viewed as powerful explorative tools. 
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MODELLING THE HEALTH 
CONSEQUENCES OF 
DRUG USE 

INTRODUCTION 
T his part concentrates on modelling adverse health consequences of problem drug use, possibly the main reason for policy and intervention in the field of drug use. One of the most important health consequences of illicit drug use is infectious 
diseases such as AIDS. At the same time the field of infectious-diseases epidemiology is 
one of the public-health areas that may have benefited most from modelling studies and 
may therefore serve as an example for approaches that could be applied to the drugs 
field. 
In Chapter 10, Kretzschmar follows a different approach from the chapters in Part III In 
starting from an explicit problem to be solved rather than from the methods to be used. 
She discusses the main disease-specific parameters that have been much used in models 
of the sexual transmission of HIV, but less so in models of injecting drug use or other 
drug-related infections. Kretzschmar defines dynamic models and introduces the concepts 
of a core group and a mixing matrix before considering the influence of partnership 
duration in pair-formation models and network models, where each individual and each 
contact between two individuals are modelled explicitly. The author argues that these 
models can easily be adjusted for hepatitis Β and C. Techniques discussed in the chapter 
could be used to answer questions such as how well the future course of these drug-
related disease epidemics can be predicted, what the effects of behaviour change would 
be on these diseases, and what prevention strategies are to be recommended. 
Jager and his colleagues give a structured overview of developing multinational scenario 
analyses in Chapter 11. The authors argue that the drug problem is well suited to this 
form of analysis as the issue is serious and important, complex, multinational, multi-
disciplinary and in need of information to inform policy decisions. The main elements of 
a scenario study are the development of a conceptual model, the translation into 
mathematical models, the performance of a basic analysis and the construction of 
scenarios. A preliminary conceptual model for the drugs field is presented, besides 
examples of conceptual models for AIDS and blood supply that have already been applied 
at EU level. 
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CHAPTER 10 
MODELLING INFECTIOUS DISEASES AND OTHER 
HEALTH CONSEQUENCES: PREDICTING FUTURE 
MORBIDITY CONSEQUENCES AND SPREAD OF HIV, 
H E P A T I T I S Β A N D H E P A T I T I S C 
Mirjam Kretzschmar 
A very high prevalence of HIV, hepatitis Β virus (HBV) and hepatitis C virus (HCV) is 
found in populations of injecting drug users (IDUs) due to a combination of high-risk 
behaviour and high transmission rates via sharing of contaminated injection equipment. 
In many European countries, HIV incidence among IDUs is alarmingly high and 
prevalence is rising explosively. In southern European countries, the largest fraction of 
new HIV infections is among IDUs. While the incidence among homosexual men has 
stabilised and prevalence seems no longer to be rising, among IDUs prevalence is still 
increasing. For HBV and HCV prevalence is even higher. Although hepatitis may not be 
as serious an illness as AIDS, it can nevertheless lead to major health problems and in a 
small fraction of cases can lead to liver cancer. A sustained prevalence of carriers of the 
hepatitis virus also constitutes a source of infection for the entire population. These 
infectious diseases are therefore important consequences of drug misuse. 
Mathematical models are used to attempt to understand the quantitative relationships 
between the characteristics of a specific disease, the contact patterns in the population 
within which it is transmitted, and the resulting incidence and prevalence of the disease. 
These insights can then be used to support the interpretation of epidemiological data, 
help decide which data are needed to be able to assess an epidemiological situation, 
and help design effective prevention measures. To extend disease modelling in this 
way requires further steps and information. This could, for example, include costs of 
prevention programmes, or the quality of life for given levels of prevalence and incidence 
over a certain time period. It is clear that the time scale in which the spread of the 
epidemic takes place, and the time scale in which prevention programmes are designed, 
play an important role in the outcome of the evaluation of prevention programmes. 
The disease-specific parameters of importance for modelling are, among others, the 
probability of transmission per contact, where a contact is defined as an event in which 
transmission can possibly take place; the duration of the latent period and the infectious 
period; the fraction of infections that are asymptomatic, but are infectious to others; 
the recovery rate. Which of these parameters are incorporated into the model depends 
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on the characteristics of the disease being modelled and on the level of detail that is 
needed to properly describe transmission and the required outcome variables. For 
example, in modelling the spread of HIV it might be useful to take a number of stages 
of infection into account distinguished by their CD4 + counts, even if these stages do 
not play distinct roles in the transmission process. Concerning the contact patterns that 
underlie transmission, these are obviously determined by the transmission route of the 
disease in question. For a sexually transmitted disease it matters whether spread is to 
be modelled by homosexual or heterosexual contact; furthermore, the number of sexual 
partners per time unit (e.g. year), the duration of the sexual partnerships, the overlap in 
time of partnerships or 'concurrency', and the heterogeneity with respect to these 
variables in the population are determinants of the contact patterns. Similarly, for IDUs 
the contact structure is constituted by the social contacts of drug users within which 
injecting equipment is shared, such as anonymous contacts in shooting galleries, or 
longer-lasting relationships with friends and sexual partners. In this case, the existence 
of two different transmission routes for the infection, namely the needle-sharing and 
the sexual routes, makes the contact patterns even more complex. 
The aim of this chapter is to give an overview of the work that has been done in the 
area of infectious-disease modelling, and more specifically in modelling the spread of 
HIV via sexual contact and needle sharing. The relevant questions and approaches are 
identified and the implications for future work to investigate the spread of HIV, HBV 
and HCV in populations of IDUs are summarised. Finally, the findings are evaluated in 
the light of questions posed at EU level in the context of this monograph. The focus is 
on so-called dynamic models, that is, models that explicitly describe the transmission 
process and the resulting dynamics of the spread of an infection, as opposed to statistical 
models, such as the back-calculation method, that are used for data-based projections. 
For an application of the latter methodology to data from the European Union, see 
Downs et al. (1997) and for a fuller description of this method, see Chapter 6. 
Models for HIV, HBV and HCV 
Since the beginning of the AIDS pandemic in the early 1980s, an enormous effort has 
been made in devising mathematical models to predict the further spread of HIV. Rather 
than attempting to give a complete overview of the existing models, this chapter focuses 
on the relevant modelling questions that have been discussed and that are essential not 
only for HIV, but for any infectious disease that spreads via sexual contact or via shared 
injecting equipment. It should be said that the large majority of all models investigated 
so far have focused on the former transmission route, and many of these have dealt 
specifically with the transmission group of homosexual men. Only very few models 
have addressed questions pertaining to transmission via needle sharing. These models 
will be discussed in the following section. For the spread of HBV and HCV, to the 
author's knowledge only very few models exist and will be mentioned briefly at the 
end of this section. 
Even before AIDS had become the dominant problem in the area of sexually transmitted 
diseases (STDs) it was recognised that the heterogeneity in sexual behaviour of a 
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population plays an important role in determining the patterns of spread of an STD. In 
modelling prevention strategies for gonorrhea, Hethcote and Yorke (1984) introduced 
the concept of a 'core group', a small sub-group of the population engaging in very 
high levels of sexual activity, in other words, a high rate of partner change. With the 
advent of AIDS, attention to the incorporation of a detailed description of sexual 
behaviour increased greatly, and a number of modelling approaches developed. The 
basic idea was to distinguish different activity levels in the population and to define a 
'mixing matrix' describing the contact rates within and among sub-groups of different 
sexual activity (see e.g. Anderson and May, 1991; Blythe and Castillo-Chavez, 1989; 
Jacquez et al., 1989). It was then possible to investigate how mixing between sub­
groups determines the epidemic spread, and how prevention focused on specific sub­
groups affects incidence and prevalence. However, it turned out to be very difficult to 
collect reliable data with which to estimate the parameters of the mixing matrix. 
A different approach in modelling focused on the influence of partnership duration on 
the epidemic spread. In the above-mentioned mixing models, it is implicitly assumed 
that every contact is with a new individual and there are no longer-lasting partnerships. 
In contrast, in the so-called 'pair-formation models', first introduced in the context of 
STDs by Dietz and Hadeler (1988), the formation and separation of possibly long-
lasting partnerships between pairs of individuals is explicitly taken into account. Especially 
for the spread of STDs in heterosexual populations, partnership duration cannot be 
neglected as a determining parameter. Although conceptually pair-formation models 
are very appealing, they have the disadvantage that including more structure into the 
model, such as sub-groups with different levels of sexual activity or the possibility to 
have more than one partnership at a time, rapidly increases the complexity of the 
model. 
A further step towards a detailed description of sexual behaviour is made by 'network 
models' (Kretzschmar et al., 1994). These are models that try to capture the essential 
features of sexual networks by describing the population explicitly as a collection of 
individuals and their relationships. In contrast to the types of models discussed above, 
which are implemented as systems of differential equations, network models are 
inherently stochastic and require simulation by Monte Carlo methods for obtaining 
results. In other words, except in very simple cases, it is not possible to derive analytic 
'parameter-value-independent' results, but it is necessary to run and analyse large 
numbers of simulations and to apply statistical techniques as if analysing real data. The 
advantage of this procedure is that the simulations are easily comparable with 
epidemiological data and data obtained by sexual-behaviour surveys. It has been shown 
(Morris and Kretzschmar, 1997) that a description of sexual partnerships in terms of 
numbers per year and duration is not sufficient to predict the spread of an STD, but 
also that the possible overlap and therefore concurrency has a large effect on the speed 
and size of an epidemic. Simultaneous, longer-lasting partnerships cannot be modelled 
with mixing models and only in a very limited degree with pair-formation models; they 
arise naturally, however, in network models. 
Although these modelling approaches were developed with the aim of describing the 
sexual-contact structure in a population, it is obvious that the same questions will play 
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a role when describing the transmission of a disease via sharing injection equipment. In 
that case an important determinant of the spread of an infectious disease is the 
heterogeneity in behaviour, that is, the possible existence of sub­groups of the population 
with high­risk behaviour and their mixing patterns with the rest of the population with 
lower­risk behaviour. It is important to consider whether the sharing of needles takes 
place within long­lasting relationships, that is, with friends or sexual partners, or whether 
it takes place more or less randomly as is the case in shooting galleries. If longer­lasting 
relationships are the basis for risk behaviour and disease transmission, the question will 
be how best to describe the networks these contacts constitute. In short, modelling 
techniques that have been developed to describe the spread of an infection via sexual 
contacts, can ­ with the proper adjustments ­ be used for modelling transmission via 
needle sharing. Of course there are additional factors to be considered that will be 
discussed in the following section. 
To describe a specific disease in terms of model variables and parameters the relevant 
disease stages, their duration and the transmission probabilities related to those stages 
must be specified. With respect to HIV/AIDS the discussion has focused on its long 
incubation period and the varying ¡nfectivity during that period. Using statistical models, 
Longini et al. (1989a), Longini et al. (1996) and Hendriks et al. (1998) have estimated 
the time from infection to development of AIDS for homosexual men and IDUs, 
respectively. For the transmission of the infection and therefore its epidemiology, the 
probability of transmission per contact in the various stages of infection is important. As 
Longini et al. (1989b) and Jacquez et al. (1994) have argued convincingly, data and 
modelling results support the idea that ¡nfectivity is very high in the first acute phase of 
infection, very low during the long asymptomatic phase, and higher again when the 
first symptoms of AIDS become manifest. Blythe and Anderson (1988) have investigated 
how variable ¡nfectivity affects the spread of the epidemic in a mixing model; Kretzschmar 
and Dietz (1998) have investigated the effects of variable ¡nfectivity in models with 
long­lasting partnerships. 
Although the prevalence of hepatitis Β and C is extremely high in some risk groups, 
there has been surprisingly little work done on modelling the spread of those diseases. 
The only work to the author's knowledge is by McLean and Blumberg (1994) and by 
Williams et al. (1996a, 1996b). Both models are mixing models, as described above, 
and incorporate features specific to hepatitis B, such as the existence of an asymptomatic 
carrier stage. While the former focuses on modelling countries with high transmission 
rates, the latter investigates the cost effectiveness of immunisation programmes against 
hepatitis Β in the UK. Furthermore, the latter model makes a distinction between 
transmission in the heterosexual and the homosexual populations, respectively, 
characterised by different values of the parameters describing sexual activity. The 
vaccination strategies discussed are antenatal screening, mass infant and adolescent 
vaccination programmes with different coverages, and vaccination targeted at genito 
urinary (GU) clinic attenders with various coverages. 
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Models for HIV in injecting drug users 
Models that have been designed to describe the spread of HIV specifically in populations 
of IDUs are summarised in Table 1. The transmission via needle sharing adds a 
complication that is not present with sexual transmission, namely that transmission 
takes place via a 'vector', the infected needle. As a result, contacts can be directed in 
the sense that if a susceptible borrows a contaminated needle from an infected person, 
transmission can take place, while if an infected person borrows from a susceptible, 
transmission is impossible. Of course, there are also less clearly defined situations, for 
example when a group of IDUs successively uses the same injecting equipment, which 
is even more complex to incorporate explicitly into a model. 
The first model for the spread of HIV in IDUs was introduced by Kaplan (1989). In this 
model the complications of the transmission route were taken into account by explicitly 
describing the fraction of infected needles that circulated in the IDU community (see 
Figure 1). The risk of an IDU becoming infected depended on the fraction of infected 
needles, which in turn could be influenced by increasing the inflow of clean needles 
via a needle-exchange programme. It was possible to evaluate the effects of such a 
programme in a very short time and to show that needle exchange significantly reduced 
the risk of new infections. The Kaplan model has been extended to include a more 
complex description of transmission probabilities (Greenhalgh and Hay, 1996) and 
heterogeneity in the risk behaviour of IDUs (Greenhalgh, 1996, 1997). 
Figure 1 : Kaplan model 
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Source: Kaplan (1989) 
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Table 1 : Summary of models and their data needs and possible application 
Model 
Kaplan (1989) 
Greenhalgh and 
Hay (1996) 
Blower et al. 
(1991) 
Capasse et al. 
(1995) 
Gani and 
Yakowitz(1993) 
Peterson et al. 
(1990) 
Kretzschmar and 
Wiessing (1998) 
lannelli et al. 
(1997) 
Output 
estimate of 
effectiveness of needle­
exchange programmes 
in reducing HIV 
incidence 
as above 
HIV prevalence for 
different transmission 
groups 
threshold theorem 
(R0) 
expected number 
HIV infected as 
function of time 
HIV prevalence 
yearly HIV incidence 
under various 
prevention scenarios, 
HIV prevalence 
projections of HIV 
and AIDS incidences 
Applicability 
applicable to cities 
with homogeneous 
mixing (shooting 
galleries or similar 
settings) 
homogeneous 
mixing, but different 
risk levels 
cities with large IDU 
populations 
? 
small groups of IDUs 
cities 
small populations 
(cities) with small­
scale mixing (sharing 
with friends/partners) 
countries, split up by 
transmission groups 
Data demands 
HIV prevalence, 
needle­exchange 
rates, fraction of 
infected needles 
circulating 
differences in risk 
behaviour, probabilities 
of needles being 
infected 
needle­sharing 
behaviour, sexual­
behaviour data 
? 
detailed data on 
needle­sharing 
behaviour 
detailed data on 
needle­sharing 
behaviour, HIV 
progression 
detailed behavioural 
data (rate of needle 
sharing, fraction of 
sharing from friends 
or strangers, etc.) 
AIDS incidence 
among IDUs 
Why not applied more? Added value 
only useful in 
combination with 
needle testing 
only theoretical 
results 
many parameters to 
be estimated 
only theoretical 
results 
too complex, too 
many assumptions 
very complex, 
detailed data not 
available 
very complex, 
detailed data not 
available 
similar models applied 
for HIV in other 
transmission groups 
objective tool for 
evaluating needle­
exchange 
programmes, easy 
implementation 
refinement of Kaplan 
model for 
heterogeneous 
populations 
implementation not 
too difficult, includes 
sexual transmission 
? 
submodel for local 
spread of infection 
tool for evaluation of 
behaviour changes and 
targeted prevention 
programmes 
tool for evaluation of 
behaviour changes 
and targeted 
prevention 
programmes 
mathematical theory 
about this type of 
model available 
Geographic area 
New Haven, CT 
not specified 
New York City, NY 
not specified 
not specified 
not specified 
Arnhem, Rotterdam, 
the Netherlands 
Italy, especially 
tatium region 
2 o o m Γ­η 
ζ Ο 
Η Ι 
χ 
ο ο 
ζ 
ín 
Ο c 
ΓΠ 
ζ π m in 
O 
­η 
α 
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Note: ? indicates unknown 
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Blower et al. (1991 ) designed a model to describe the situation of IDUs in New York City. 
The model incorporated transmission via needle sharing, via heterosexual contact and via 
vertical transmission from mother to unborn child. Furthermore, differences in risk levels 
were taken into account by distinguishing between IDUs who share needles with strangers 
and others who share with 'buddies'. The model consisted of a system of 34 ordinary 
differential equations with a large number of parameters. One of the results obtained was 
that the stabilisation of prevalence that had been observed in New York City could be 
explained as the natural course of the epidemic without any behaviour changes. Also, the 
stabilisation of prevalence in the model was only temporary and was followed by a renewed 
increase in prevalence that was driven by heterosexual transmission. An important 
conclusion is that the stabilisation of prevalence may not be interpreted as being the 
consequence of behaviour changes without having more information about population 
structure and mixing parameters (Blower, 1991 ). This information, however, is very difficult 
to collect and the uncertainty in these parameters leads to extremely wide confidence 
intervals in the predictions of future incidence and prevalence. 
The existence of groups of IDUs which exhibit risk behaviour is included in a deterministic 
model by Capasso et al. (1995) and in a stochastic model by Gani and Yakowitz (1993) 
and Yakowitz (1994). While the description of the group-forming process in a 
deterministic setting is questionable, in the stochastic setting it quickly leads to a very 
complex model. Thus as yet there appear to be few epidemiologically relevant results 
and future research remains to be done. 
Peterson et al. (1990) and Kretzschmar and Wiessing (1998) investigated stochastic, 
individual-based models in which the contact patterns of IDUs can be described in 
much detail. The model of Peterson et al. consists of three sub-models: one is a model 
of HIV progression in an infected individual that distinguishes five stages of infection; 
the second describes the heterogeneity of injecting drug use within the population, 
distinguishing monthly, weekly and daily injectors and drug users in jail or in treatment 
programmes; the third sub-model describes the contact patterns in the IDU community 
and distinguishes between the acquaintance network of an IDU, individual strangers 
and shooting galleries. Transition probabilities are then defined for the various states an 
individual can be in and Monte Carlo simulations are performed. The authors investigated 
the effect of the social-network structure on the epidemic and found a far slower increase 
in prevalence in populations where sharing took place in acquaintance networks as 
opposed to random mixing in shooting galleries. Again, the prediction for prevalence 
in all cases displayed a wide variability, here as a consequence of the stochastic nature 
of the processes. Finally, the authors showed that the effectiveness of intervention is 
highly dependent on the prevalence level of the population; in a low-prevalence setting 
prevention can potentially be much more effective because it begins before the start of 
the epidemic. 
In Kretzschmar and Wiessing (1998) the effect of different prevention strategies on the 
incidence of HIV in IDU populations is compared. The model distinguishes between needle 
sharing within long-lasting relationships (friends/partners) and sharing with individual 
strangers (see Figure 2). Furthermore, it is assumed thatthe ¡nfectivity of an infected individual 
is very high during the first six weeks of infection and very low during the long asymptomatic 
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Figure 2: Network of IDUs 
Notes: Individuals 1, 4, 5 and 7 are susceptible; individuals 2, 3 and 6 are infected. 
= steady, long-term relationships (buddies) 
= incidental borrowing from strangers 
Arrows show the direction of passing on a needle. Transmission can only take place if the 
individual at the base of the arrow is infected and the individual at the point of the arrow is 
susceptible. 
Individuals 1 and 4 have a long-term relationship in which they regularly share needles. They 
are both uninfected, so cannot infect each other. Individual 4 also regularly lends needles to 
individual 3, but does not borrow any from individual 3. Therefore individual 4 cannot get 
infected by individual 3. However, individual 1 borrows a needle in an incidental contact from 
individual 2, and could get infected in that way. Individual 5 does not borrow needles at all and 
is not at risk of getting infected. Individual 7 borrows regularly from his infected partner 
(individual 6) and has a large risk of eventually becoming infected. 
Source: Kretzschmar and Wiessing (1998) 
phase afterwards. Values for behavioural parameters were estimated from surveys in two 
cities in the Netherlands. Analysing the results obtained with Monte Carlo simulations the 
authors investigated the effects of various contact patterns on the prevalence and incidence 
of HIV. They found that there was a clear threshold phenomenon for the sharing frequency, 
that is, that below a certain average sharing frequency the epidemic never takes off while 
above the threshold it quickly reaches high levels of prevalence. Also, the variability in the 
course of an epidemic as a consequence of the stochastic nature of events and the 
transmission via a contact network is large, which means that predictions about the future 
course of an epidemic are uncertain. In the comparison of prevention strategies, the authors 
concluded that focusing prevention on new injectors can possibly have a large effect on 
HIV incidence, while behaviour change of IDUs after a positive HIV test has no significant 
effect at a testing rate of 50 % per year. Finally, reducing the sharing frequency with strangers 
has a larger impact on the epidemic than the same reduction in the sharing within the 
stable buddy network. 
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lannelli et al. (1997) examined several hypotheses about the dynamics of the HIV 
epidemic among injecting drug users in Italy by fitting a model to the existing data and 
using a least­squares approach to determine the best fit. The model is a variant of the 
classical susceptible, infected, removed (SIR) model, but includes variable ¡nfectivity 
depending on the time since infection. The authors conclude that the fit of the model 
to AIDS­incidence data can be improved with respect to a simple reference model by 
either assuming a reduction in risk behaviour over time, or assuming that there is a 
small sub­group in the population with high­risk behaviour. Furthermore, the assumption 
of constant ¡nfectivity turned out to be untenable, while variable ¡nfectivity seemed to 
be in agreement with the data, thus confirming earlier empirical findings and theoretical 
results. 
Although none of the models discussed in this section is designed to describe the spread 
of hepatitis Β and C, most models can be adjusted fairly easily to account for the 
specific properties of those diseases. 
Future role of modelling 
Many problems remain to be solved in appropriately modelling the social structure 
underlying the transmission of infectious diseases via needle sharing, and collecting data 
that will provide more quantitative information about contact patterns and risk behaviour 
is essential. In addition, little work has been done on analysing the interaction between 
needle­sharing networks and sexual networks. This section examines what is needed to 
make modelling successful, and discusses some research topics in which modelling can 
play a key role in investigating hypotheses and interpreting data. 
A prerequisite in making any modelling effort successful will be the understanding of 
the contact patterns of IDUs, of their essential featuresand how these are related to the 
spread of an infectious disease. 'Contact pattern' here means a quantitative description 
of behaviour that relates to possible transmission events. For the sharing of injection 
equipment the following needs to be known: techniques of sharing such as borrowing 
used syringes, backloading; with whom this behaviour takes place, whether steady 
groups of IDUs, changing groups, steady sexual partners or strangers; how often risk 
behaviour takes place, that is, borrowing rates per month; the typical 'life history'of an 
IDU, in other words, how risk behaviour changes during an IDU's injecting career, how 
long do IDUs on average stay in the population of drug users. An important aspect of all 
these variables will be their heterogeneity: a population of IDUs is probably not 
homogeneous in its behaviour, but will contain sub­groups of individuals with very 
different behaviour. For example, there is a small core group of IDUs with high­risk 
behaviour including: high rates of injecting, high rates of sharing used equipment possibly 
in settings that encourage sharing with strangers. Other IDUs, who restrict themselves 
to sharing with their steady sexual partner, contribute much less to the spread of the 
epidemic. Similar aspects are important for the sexual transmission route. While for 
sexual behaviour large surveys have been conducted, the information about behavioural 
aspects of sharing injection equipment is still scarce. 
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A task for the modeller is to identify those aspects of risk behaviour that can be quantified 
and that determine the epidemiology of the disease in question. The aim is therefore to 
find a (preferably small) number of aggregated variables that satisfactorily describe risk 
behaviour, that are possible to measure in the field and that are sufficient for explaining 
epidemiological phenomena or even predicting the qualitative and quantitative 
development of an epidemic, although the latter might only be a theoretical possibility. 
It immediately follows that this information can be used to design prevention programmes 
because knowledge of the risk factors that have the largest influence on, for example, 
the incidence of a disease indicates which prevention measures will have the largest 
effect on incidence. 
Furthermore, modelling can be used to test hypotheses about the parameters describing 
the course of an infection. Comparable to the discussion about the variable ¡nfectivity 
in HIV-infected persons, there might be questions related to the natural course of a 
hepatitis infection which could be investigated in a model. Reliable epidemiological or 
microbiological data are then needed in order to compare the fit of model results 
under different hypotheses with the data and then decide on which hypothesis produces 
the best fit with observations. 
A very interesting study will be the comparison of the way different infectious diseases 
spread in the same population. In a population of IDUs, in which needle sharing and 
sexual behaviour are the transmission routes, how on the basis of disease-specific 
parameter values an epidemic of HIV, HBV and HCV proceeds can be compared. 
What is the equilibrium prevalence and incidence for these diseases in the same 
population? What degree of co-morbidity can be expected? How do similarities and 
differences depend on the underlying contact parameters? If good information were 
available about the prevalence and/or incidence of these three diseases, could 
conclusions be drawn about the underlying levels of risk behaviour? It is expected that 
there will be differences in the effectiveness of a given prevention strategy as a 
consequence of differences in disease-specific parameters such as transmission rates 
and the resulting variations in prevalence. 
It has been shown that HCV is transmitted mainly via needle sharing (or more generally 
blood-to-blood contact), while HBV spreads via sexual contact and via needle sharing 
(van Ameijden et al., 1993). A comparison of prevalence and incidence of these two 
viruses in a population of drug users can therefore give some information about the 
interaction of the two transmission networks. This in turn would be very valuable 
information for the design of prevention measures. A certain fraction of new infections 
could be attributed to the two transmission routes, possibly depending on the risk 
behaviour with respect to these transmission routes, and prevention could be focused 
on the dominating form of transmission. For example, how important are prostitutes 
who inject drugs as bridges between the IDU network and the core group with high 
sexual activity? 
It is also possible to link the incidence of HBV and HCV to the prevalence of injecting 
drug use. If the fraction of infections due to transmission via needle sharing, the fraction 
of asymptomatically infected persons or chronic carriers, and the prevalence of HBV 
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and HCV in IDU populations were known, then the number of IDUs in a country 
could be estimated. An assumption here would have to be that there was a stable 
endemic situation and that there was sufficient knowledge of the risk behaviour among 
IDUs to estimate the equilibrium prevalence. 
In the context of a World Health Organisation (WHO) programme promoting vaccination 
against HBV infection, all countries are advised to vaccinate all newborns against hepatitis 
Β from the year 1997 on. As in many European countries, prevalence is very low and 
restricted mainly to some high-risk groups, the cost-effectiveness of such a vaccination 
programme is questionable (cf. Williams et al. 1996a, 1996b). However, vaccination 
focused on risk groups such as IDUs may be very effective in reducing incidence as 
well as the prevalence of chronic carriers. In view of the fact that a female IDU who is 
infected with HBV might pass the virus on via vertical transmission, screening of pregnant 
women within that risk group is especially important. However, it is known that IDUs 
are a group that is difficult to reach so the effectiveness of vaccination will be limited by 
its coverage. Modelling can help to quantify the dependence of cost-effectiveness 
measures on coverage and other parameters of a vaccination programme. 
Conclusions 
The use of specific models by an organisation such as the European Monitoring Centre 
for Drugs and Drug Addiction (EMCDDA) or in the context of a concerted action of the 
European Union depends very much on the types of questions being investigated and 
possibly answered. Types of questions could be: how well can the future course of the 
HIV epidemic be predicted in different Member States of the EU? What are the effects 
of behaviour change on the prevalence of HIV, HBV and HCV in different European 
countries? Which prevention strategies are recommended for a country given the 
dominant type of risk behaviour in that country? What conclusions can be drawn about 
the prevalence and incidence of injecting drug use from the prevalence of HIV, HBV 
and HCV in different European countries? 
Predictions about the future course of the HIV epidemic among IDUs in Europe have 
been made via the back-calculation method (Downs et al., 1997). That method has 
some shortcomings, however, that makes its results unreliable. Predictions are made 
on the basis of AIDS incidence, and HIV incidence can be estimated using knowledge 
about the incubation time distribution. It is not possible to incorporate effects of 
behaviour change explicitly into the model. Also, as the effects of treatment on the 
incubation time are not known, the estimates will in the future become even more 
uncertain than they are now. 
Dynamic models, which explicitly model the transmission process, can be used to 
evaluate the effects of behaviour change and other prevention measures. However, 
dynamic models require much more detailed data for describing the transmission 
process, mainly data about risk behaviour (Blower and Medley, 1992). A start at collecting 
such data at European level has been made by Papaevangelou and Richardson (1995) 
and Richardson et al. (1993). Using dynamic models it is often advisable to begin with 
a very simple structure even if many simplifying assumptions have to be made, because 
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the results will usually allow a clear interpretation. A very good example is the model 
by Kaplan and Heimer (1992), which consisted only of two differential equations and 
did not take any of the complications of the contact structure into account. Nevertheless, 
Kaplan demonstrated the positive effects of a needle-exchange programme on HIV 
incidence so clearly that the programme was continued and new needle-exchange 
programmes were established in different cities in the United States. A summary of the 
models discussed above, their data needs and possible applications is shown in Table 1, 
above. 
If more detailed questions about the effects of behaviour changes are to be answered, 
more complex models are needed that allow the implementation of a relevant contact 
structure. In this respect, individual-based simulation models seem to be the best choice 
at present. However, if modelling is to be closely related to empirical findings it will be 
necessary to collect detailed behavioural data. It is very important that modellers and 
epidemiologists work together from the start to avoid large gaps between model design 
and data format. 
In conclusion, regardless of the amount of work that has been done in modelling the 
spread of HIV/AIDS, modelling the spread of infectious diseases via needle sharing and 
the specific problems connected with the spread of hepatitis Β and C is still in its 
infancy. If models are to be used in an EU context, they should be developed according 
to the questions they are supposed to answer and in close interaction with social scientists 
and epidemiologists. 
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DEVELOPING MULTINATIONAL SCENARIO ANALYSES 
OF HEALTH IMPACTS OF DRUG USE 
Johannes C. Jager, Maarten J. Postma and Peter W. Achterberg 
The issue of drug use and its health-related consequences represents a complicated 
and multifarious scientific and societal problem. This chapter explores how scenario 
analysis may be used to investigate the actual situation, possible future developments 
and potential effects of policy measures in Europe. 
Since the early 1980s, considerable experience with future research on public health 
and health-care problems has been built up in the Netherlands. The Dutch Steering 
Committee on Future Health Scenarios (STG) commissioned about 20 scenario studies 
on diseases and their consequences for public-health-strategy development, including 
on chronic diseases such as diabetes mellitus, chronic non-specific lung disease, 
rheumatoid arthritis (Casparie and Verkleij, 1991-94), mental health care (Idenburget 
al., 1991; Bijl, 1991) and HIV/AIDS (van den Boometal., 1992). The methodological 
accomplishments from these STG studies have been summarised and translated into 
practical guidelines for scenario research (Genügten et al., 1996). On a broader scale, 
covering many diseases and determinants (risk factors) which affect health, the 
Department for Public Health Forecasting of the National Institute of Public Health and 
the Environment (RIVM), Bilthoven, established, in cooperation with several other 
institutes, a detailed description including forecasts of the health status of the Dutch 
population (Ruwaard et al., 1994; Ruwaard and Kramers, 1997). Further, in two specific 
research projects, the scenario-analytic approach was extended to the multinational 
(European Union) level, with the European Commission Concerted action on 
multinational AIDS scenarios examining the epidemiological, economic and socio-
cultural impact of AIDS on society (Jageretal., 1995; Downs et al., 1997; Postma et al., 
1997) and another project on the attainment of blood self-sufficiency in the EU (Van 
Aken et al., 1997). 
These multinational EU-directed studies have developed and implemented an integrated 
application of mathematical modelling, epidemiology and health economics within a 
scenario-analytic framework. This chapter builds on the experience acquired through 
the studies with respect to their relevance for the scenario research process. The second 
section characterises essential features of the scenario-analytic approach while the third 
section motivates the application of scenario analysis to the drug issue. The following 
section gives a concise overview of the multinational scenario projects mentioned above 
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and their generalisable methodological accomplishments, and the fifth section offers a 
preliminary approach to scenario-building in modellingdruguseand related problems. 
The last section contains some conclusions and recommendations for potential policy-
oriented research on drug use and related problems. 
The scenario-analytic approach 
Scenario analysis is a form of research that makes use of a variety of techniques, such as 
mathematical modelling and statistical analysis, brain-storming techniques, meta-analysis 
and cost-effectiveness analysis. Its main power lies in structuring a joint study involving 
participants from different disciplines, interests and countries. It differs from empirical 
research in its strong dependence on secondary data (data not collected according to a 
strict study design and sampling plan), incomplete and heterogeneous data and its 
meta-analytic approach. Methodological weakness has to be remedied by extensive 
consultation of experts. 
Essential elements of a scenario research are the conceptual approach, the use of 
mathematical models, departure from a basic analysis and the development of scenarios. 
Conceptual model 
A scenario study starts with the construction of a conceptual model. This construction 
should be a joint activity of all participants involved in the project. The conceptual 
model is a schematic representation of the field under study in terms of components 
and their main relations. As stated in Ruwaard et al. (1994), it has the following functions: 
to provide a structure for the development of ideas; to define the boundaries; to offer 
a structure for orderly handling of the subject matter; and to serve as a basis for producing 
a formal model in mathematical terms. 
Mathematical model 
Ideally, the conceptual model is elaborated as a mathematical model, which can be 
used to describe the past, to predict the future and to perform 'what if' analyses. 
Modelling results represent the quantitative backbone of the scenario development. 
The role of modelling and the interaction of modellers and other researchers has been 
discussed in Jagerand van den Boom (1994). For a discussion of the interdependences 
of quantitative and qualitative procedures in scenario research, see Bijl (1991). 
Basic analysis 
The basic analysis (or baseline analysis) comprises the identification of data sources and 
the collection of available, primary and secondary data on all the components taken up in 
the conceptual model. These are subject to data analysis and meta-analysis, and form the 
basis for the application of scenarios. The evaluation of data availability and quality 
(comparability, completeness, potential for generalisation) is important here. Another 
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important aspect of scenario analysis is to specify data needs. The basic analysis also 
comprises the selection and specification of key variables and impact indicators to be 
handled in the construction of scenarios (and the mathematical model). The data play a 
role in the validation of models. Often modelling detects essential data gaps. Key variables 
represent factors which may significantly influence the system understudy. Impact indicators 
describe the most interesting aspects of the performance of the system. 
Scenario development 
The construction of scenarios starts from the conceptual model, the mathematical model 
(where possible) and the results of the basic analysis. A reference scenario builds on the 
assumption that the present situation and recent trends will continue in the future, and 
describes the surprise-free continuation of the past. Alternative scenarios may be 
elaborated on the basis of 'what if' questions. 
Why apply a multinational scenario approach to drugs? 
Generally, the scenario-analytic approach to problems within the domains of public 
health and health care is motivated by its expected contribution to policy-making, to 
long-term planning and to strategy development. Effective analyses supporting these 
activities require a methodology which deals coherently with epidemiological analyses 
of the current situation and its projection into the future based on explicit assumptions. 
Mathematical modelling techniques and linking epidemiology to insights in costs related 
to care and prevention from health-services research are essential (Jager and van den 
Boom, 1994). 
Thus, a scenario study requires cooperation between specific experts such as modellers, 
epidemiologists and economists. The following issues will particularly influence the 
choice of a scenario approach: 
the weight, scope and complexity of the problem (only important and complex 
problems require a scenario approach; there is a demand for interdisciplinary 
approach); 
the need to make decisions and launch interventions, which may be confronted 
with great uncertainty (an interest in the future; the wish to make predictions and 
plans/interventions, which are extremely difficult in view of great uncertainty); 
the potential impact on decision-making by elucidating alternative developments 
in quantitative terms; 
the involvement of different groups (patients, care providers, public-health officials, 
community, government, countries) with diverging interests and the inherent 
invitation to discuss these alternatives in a coherent and rational way (potential 
consensus as a result of discussion between interested parties and relevant 
disciplines). 
To conduct a successful scenario analysis it should be possible to distinguish key variables 
and impact indicators that are sensitive to policies. 
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It is easy to show that the drug issue fulfils the above characteristics of a problem which 
should be investigated with the help of scenario analysis. The drug problem is worldwide, 
it depends on widely different socio-cultural conditions/factors, it is being addressed 
by different policies in different countries, it is in urgent need of effective interventions 
and is a 'hot topic' politically. It involves drug users, their partners and families, the 
health and legal systems, health and various other officials and it causes discussions 
between countries and between disciplines such as medicine, epidemiology, the 
economy and law, the study of social problems including ethics and the methodological 
disciplines (mathematics and statistics). 
Experiences from multinational and multidisciplinary scenario studies 
Conceptual modelling 
A conceptual model designed for public-health-status assessment and forecasts comprises 
five basic components: health status; determinants of health status; health policy; use 
of care (and costs) and autonomous developments; and their interrelationships (Ruwaard 
and Kramers, 1997) (see Figure 1 ). For further elaborations of the separate components, 
see Ruwaard et al. (1994) and Ruwaard and Kramers (1997). Specific health problems 
which have already been analysed have been modelled in an analogous way. The 
conceptual model underlying the EU Concerted action on multinational AIDS scenarios 
(Jager et al., 1995) is presented in Figure 2. The scenario study on the attainment of 
blood self-sufficiency in the EU (van Aken et al., 1997) has been based on a conceptual 
model of a national blood-supply system, incorporating policies, population 
characteristics, donors, the production methods of blood products, the product-specific 
market, the recipients and the medical methods and performance (see Figure 3). In all 
studies, the construction of the conceptual scheme stimulated enthusiastic discussions 
and resulted in a clear delineation of the subject under study, the specification of relations 
which should be studied and corresponding appointments for the division of tasks 
among the research teams involved and their prioritisation. In this way, conceptual 
Figure 1 : Conceptual basic model of public-health status and forecasts, 1997 
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Figure 2: Conceptual model for the European Commission Concerted action on 
multinational AIDS scenarios 
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Figure 3: Conceptual model for national blood supply 
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modelling stimulates and facilitates interdisciplinary discussion and provides the 
mathematicians with starting points for elaborating the conceptual model in 
mathematical terms. This process can also highlight specific data needs. 
Mathematical modelling 
Mathematical modelling provides several functions: quantitative description of the 
phenomenon understudy; insight into the causal relations involved; detection of crucial 
data needs; parameter estimation starting from empirical information; projection into 
the future under specified conditions; and prediction. In the study concerning AIDS-
impact scenarios, several models have been developed which pertain to parts of the 
conceptual model (e.g. concerning the effects of medical treatment, behavioural change 
and the organisation of health-care provisions) (Bailey and Heisterkamp, 1995). It would 
be unrealistic to try to encompass the whole area under study in one, necessarily very 
complicated, mathematical model. However, the specifications for different models 
were similar enough to warrant comparability of the outcomes. Much attention was 
paid to the development and application of a common methodology to describe the 
baseline situation (Downs et al., 1997; Heisterkamp, 1995). The blood-supply problem 
(van Aken et al., 1997) has been represented by a single model with sub-systems which 
may be activated as desired. 
The overall experience is that mathematical modelling is essential in scenario analysis, 
but it should be applied flexibly (several models using the same specifications; 
simultaneous use of simple descriptive (trend analyses) and more complex dynamic 
models) and results should be supplemented by qualitative considerations, discussions 
and comments. 
In AIDS-scenario studies, several models have been developed which incorporate 
intravenous drug use (IDU) as a determinant in the spread of HIV. For the Dutch AIDS 
scenario study (van den Boom et al., 1992) a multi-group transmission model was 
developed (van Drutenetal., 1990,1992) which represents the HIV epidemic as resulting 
from overlapping sub-epidemics in six groups (among which are IDU men and women). 
The contacts between and within these groups occur via several transmission routes: 
unprotected anal intercourse; unprotected vaginal intercourse; and the shared use of 
needles. The model enables the simulation of the effects of preventive interventions 
targeted to behavioural change (see Chapter 7 in van den Boom et al., 1992). Another 
mathematical technique, which also concerns the spread of HIV in several risk groups, 
including IDUs, is the so-called back calculation (BC) (Heisterkamp, 1995, and Chapter 
6, above). Back calculation makes it possible to estimate past and to project future 
incidence and prevalence of HIV infection based on reported AIDS surveillance data. 
In the EC project on multinational AIDS scenarios, these estimates were obtained for 
the 15 European Member States (Downs et al., 1997). Recently, this BC has been 
extended to include age effects (report of EC Concerted action on multinational AIDS 
scenarios, in preparation). This advancement is important because it supports the results 
of analysis of the AIDS epidemic in birth cohorts of separate risk groups such as IDUs 
(Houweling et al., 1998) for public-health-strategy development. Recent estimates of 
HIV infections in IDUs in Europe by BC are available. 
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Basic analysis (key variables and impact indicators) 
Basic analysis involves the collection of available data, which can be specified according 
to variables associated with the components in the conceptual model. It has been 
found profitable to devise a table which presents relevant variables according to the 
components of the conceptual model and/or according to the disciplines involved (van 
den Boom et al., 1992; Jager et al., 1995; van Aken et al., 1997). The correspondence 
to related impact indicators should be given. This table concerning the AIDS-scenario 
study is structured according to disciplines such as epidemiology, economy and sociology 
(see Figure 4) (Jager et al., 1995). In the blood-supply study (van Aken et al., 1997) the 
impact indicators were explicitly developed by considering each component in the 
model (see Figure 5). 
Scenario development 
In most previous scenario studies (van den Boom et al., 1992; Jager et al., 1995; van Aken 
et al., 1997), the construction of the reference scenario generally took a major part of the 
available time. In an initial planning meeting for the project on multinational AIDS scenarios, 
four working groups were formed on modelling support, on epidemiological impact, on 
economic impact and on social impact, respectively. The mathematicians started to devise 
an overview of available mathematical models (Heisterkamp, 1995) and decided to develop 
a common methodology which could be applied to European AIDS surveillance data. The 
epidemiologists needed several sessions to specify - in cooperation with the modellers -
the epidemiological starting points for the reference scenario (Houweling et al., 1996). 
They also had to collect additional country-specific HIV/AIDS surveillance data to underpin 
their specifications (Roosmalen et al., 1996). Thus, rather late during the course of the 
project, alternatives to the reference scenario were eventually specified, though in principle, 
at the beginning of the project, available mathematical models could handle them very 
well. This shows that a reference scenario should be developed as soon as possible in the 
execution of a scenario project. 
Apparently, a detailed elaboration of a reference is a satisfactory foundation for 
formulating themes for alternative scenarios and further scenario-building. Another 
aspect of multidisciplinary scenario construction refers to levels, for example the 
extension of the epidemiological level to the economic level by linking epidemiological 
variables to economic information (see Figure 4, and Leidl, 1994). The mathematicians 
should keep in mind which level is an endpoint (in terms of impact indicators) for their 
modelling activity, because it will determine the set-up of their models. 
Some notes on economic aspects 
Classification of costs and definition of economic-impact indicators 
Essential dichotomies regarding the classification of costs suitable for scenario analyses 
of costs and effects are: 'costs within the health-care system' versus 'costs outside the 
health-care system'; and 'direct costs' versus 'indirect costs' (van Genügten et al., 
1996, and Chapter 12, below). 
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Figure 4: Key variables and impact indicators (epidemiological and economic level) 
for the EC Concerted action on multinational AIDS scenarios 
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Figure 5: Key variables and impact indicators for blood self-sufficiency in the 
European Community, classified according to the components of the conceptual 
model 
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Linking epidemiology and health economy 
In linking epidemiology and health economy the following notions are important for 
constructing scenarios concerning the economic consequences of health problems: 
'incidence-based indicators' versus 'prevalence-based indicators'; the connection of 
these indicators to successive economically relevant disease stages or longitudinal profiles 
of care (Dijkgraaf et al., 1996; Postma et al., 1995); and resource use 'per patient' 
versus resource use 'per person-year'. These issues are illustrated in detail in Chapter 
12 (see also Scitovsky and Over, 1988). 
Scenario analysis versus cost-effectiveness analysis 
There is great similarity between guidelines for scenario analysis and for the conduct of 
cost-effectiveness analyses (CEA) for the allocation of health-care resources. Recent 
guidelines for CEA (Russell et al., 1996) stress the importance of a reference case with 
a broad perspective, as a point of comparison for specific alternatives. In addition, the 
crucial role of conceptual modelling and its relation to mathematical modelling are 
recognised (Gold et al., 1996). Thus, on the one hand, any CEA should include structured 
scenarios and, on the other hand, CEAs can easily be incorporated into scenario analyses. 
CEAs and scenario analyses can thus be mutually linked. 
Conceptual model for drug use and health-related consequences 
The basic conceptual model underlying the Dutch public-health status and forecasts 
effort in 1997 (Ruwaard and Kramers, 1997) is given in Figure 1, above. It comprises 
five coherent components or blocks: health policy; determinants; health status; use of 
care; and autonomous developments. Health status takes a central position and is 
affected by the determinants of health, which in turn can be affected by health policy. 
The health status of the population leads to the use of care. Health policy is designed 
in response to developments concerning determinants, health status and use of care. 
Autonomous developments affect this system. The arrows represent the main 
interrelations of interest. The determinants comprise somatic and mental health care 
and different components of prevention such as health protection, disease prevention 
and health promotion, which together with exogenous factors (physical environment, 
lifestyle, social environment) and endogenous (hereditary, acquired) factors influence 
health status. Departing from such representations as developed in Ruwaard et al. 
(1994) and Ruwaard and Kramers (1997), a preliminary conceptual model for the 
health-related consequences of drug use in the EU has been drafted (Figure 6). 
Table 1 lists suggested components for a preliminary conceptual model for drug use and 
(health-related) consequences. Figure 6 shows the complicated position of drug use as an 
element of lifestyle affecting health and affected by many other factors as indicated by the 
arrows in the figure. Here drug use is placed within the context of' public health. The 
conceptual model can be adapted to other relevant contexts. A study focusing on the 
impact of one determinant or on a specific health condition should start with the quantitative 
assessment of (trends in) incidence, prevalence and (geographic) spread, as indicated in 
the table. Thus the quantitative measurement of the impact of drug use starts with the 
assessment of incidence, prevalence, trends and geographic spread of drug use. 
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Figure 6: Preliminary conceptual model for drug use and health-related consequences 
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Table 1 : Components for conceptual modelling of drug use and its consequences 
Health policy (and intersectoral policy) 
Supranational strategies/policies 
United Nations conventions and organisations (WHO) 
European Action Plan on Drugs (EU) 
Treaty on European Union 1993 
Coordination of research activities 
National strategies/policies 
Drug-specific strategies 
Research (national focal points) 
Determinants (risk factors) affecting health 
Health care and prevention 
Somatic care 
Substitute prescribing (methadone) 
Detoxification 
Pharmaceuticals 
Prevention 
Health protection 
Syringe and needle exchange 
Disease prevention 
Vaccination 
Screening for drug-related infectious diseases 
Health promotion 
Education (safe sex/needle hygiene) 
Targeted programmes 
Professional training 
Mass-media campaigns 
Telephone help-lines 
Mental care 
Counselling 
Exogenous factors 
Physical environment 
Biological agents 
HIV/HVB/HVC/M. tuberculosis 
Resistance to antibiotics 
Physical factors 
Housing 
Chemical factors 
Quality of drugs 
Lifestyle (quantitative assessment of incidence/prevalence/ 
trends/spread) 
continued 
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Drug use 
Type of use 
Hard/soft drugs 
Route of administration (by mouth, 
smoking, injecting, sniffed) 
Needle sharing 
Frequency/prevalence/patterns of use 
Sexual behaviour/prostitution 
Alcohol 
Lack of hygiene/dental care 
Social environment 
Sub-populations (sub-cultures/social profiles of users) 
General population 
Ethnic minorities 
School children 
Young people outside school 
Students and intellectual circles 
Geographic patterns/urbanisation 
Availability and supply of drugs 
Attitudes/public opinion 
Endogenous factors 
Genetic factors 
Gender differences 
Acquired attributes 
Ageing 
Immunodeficiency 
Malnutrition 
Health status (quantitative assessment of health impact: incidence, 
prevalence of disease/disease stages, mortality, trends, spread, transmission) 
Drug addiction (dependence, poly-drug dependence)/overdose/ 
accidents/suicides 
Drug-related diseases and conditions 
HIV/hepatitis (B/C)/endocarditis/tuberculosis 
Injection-related abscesses/malnutrition/weight loss/ 
respiratory problems/nasal damage/sleep disturbance/chest 
pain 
Neurological/psychiatric disorders 
Comorbidity 
Use of care/costs 
Formal/informal care 
Need 
People needing help 
Objective versus subjective need 
Denial , 
continued 
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Supply 
Hospital beds 
Budget 
Availability of doctors 
Demand 
People seeking help 
Supplier-induced demand 
(Un)satisfied 
Indication/use 
Hospital 
GP 
Medication 
Related costs 
Direct costs 
Patient-related 
General programme 
Indirect costs 
Lost productivity 
Employment 
Potential years of life lost 
Autonomous developments 
Demography 
Mobility/immigration 
Macro-economic developments 
Geopolitics of supply/control of trade 
Socio-cultural/legai developments 
Criminal-justice systems/national drug laws (legal versus illegal 
drugs) 
Accessibility (prohibiting/punishing possession/arrests and drug seizures) 
Reduction in demand/supply of drugs 
Rehabilitation of drug users 
Medical technology 
Vaccine development 
Conclusions 
Scenario analysis offers an appropriate methodological context for approaching the 
drug problem in a pol icy-oriented mult inational sphere of interest. It can stimulate 
various research efforts in important interdisciplinary areas related to the drug-use 
problem in the EU Member States, so as to al low for best practices and best research to 
disseminate throughout the EU. This wil l guide individual States towards optimal strategies 
for combat ing the drug problem. 
Four (general) aspects of scenario analysis should be emphasised: conceptual model l ing; 
its relation to data-gathering (basic analysis); its relation to mathematical model l ing; 
and its potential for orderly and creative scenario construction. 
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Conceptual modelling stimulates and facilitates interdisciplinary discussions and provides 
mathematicians with starting points for elaborating the conceptual model in 
mathematical terms. A multinational approach will allow for a much broader and 
divergent input to conceptual modelling, with a greater chance of high-quality expert 
input in all relevant areas. The process of conceptualisation stimulates causative and 
associative thinking and may identify priorities for data collection and analysis. 
The drug problem should be delineated in a conceptual model. A preliminary conceptual 
model has been suggested as a starting point for further discussion on refinements and 
further elaboration. Parts of the conceptual model and associated specific questions 
may be selected for mathematical modelling. The development of scenarios should 
also build on a conceptual model. 
Mathematical modelling should be applied in a flexible way within a scenario analysis, 
for example, by using several models simultaneously, such as simple, descriptive models 
and more complex, dynamic models. Modelling results should be supplemented by 
qualitative considerations to guide further discussions and comments, possibly resulting 
in new and better model input. Again, the multinational approach will give access to 
increasingly diverse mathematical models and expertise. Mathematical models should 
be classified in relation to the components and relations indicated in the conceptual 
model. The potential of mathematical models with respect to the construction of a 
reference scenario and alternative scenarios should be made explicit. 
There are several other advantages of, and opportunities to be gained from, a 
multinational approach. Assessing variations within and between countries broadens 
the view of different policy options. A multinational approach may provide what might 
be called a 'natural' set of experiments as a disease may express itself differently in 
different countries. It can thereby also provide a first realistic estimate of the variability 
of certain outcomes. A good example, again, is the AIDS epidemic, where the 
development of an epidemic in a particular country is highly dependent upon the 
magnitude and characteristics of the sub-epidemics. 
A multinational approach will thus give rise to an optimally balanced scenario analysis 
with regard to expertise in the areas relevant to the analysis, that is, epidemiology, 
mathematical modelling, economic analysis, and medical and sociological expertise. 
Moreover, policy-makers from different countries may in certain stages also be involved 
and contribute to the variety in policy options. 
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INTRODUCTION 
E conomic models are often directly translatable to decisions on budget allocation, which is of primary importance for policy-makers. In Chapter 12, Postma and his colleagues elaborate on estimating drug-related HIV/AIDS costs as an example 
for extending to other drug-related health-care costs. HIV/AIDS health-care costs include 
costs for resources such as hospital beds, nursing care, specialist consultations, day care 
and GP visits. Costing studies have been used to assess and project national health-care 
use and costs for HIV/AIDS and the economic impact of different intervention scenarios 
has also been explored. A set of methods thus exists that can be applied to other drug-
related diseases. To date, studies have used different methods, and the authors argue 
that greater standardisation is necessary. They recommend extending the work on HIV/ 
AIDS to hepatitis as a first step, collecting country-specific information needs on health-
care use and costs by drug users, and developing future costing scenarios for all relevant 
drug-related diseases. 
Sutton describes the potential for modelling economic drug markets in Chapter 13. He 
distinguishes three levels of analysis: picoeconomics (individual level); microeconomics 
(areas or markets); and macroeconomics (across areas or markets). Studies at individual 
level have the greatest potential, but the macro level is what policy-makers are most 
interested in and where by far most data are available. The author suggests that price 
and income elasticities of demand are currently unclear from existing published studies, 
and that essential issues to explore are individual health perception and education, 
individual preferences, habit formation, time preference and peer effects. Sutton concludes 
that individual-level analysis by a multi-disciplinary team is probably the most promising 
modelling approach for understanding interactions between policy interventions and 
markets. 
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CHAPTER 12 
MODELLING THE HEALTH-CARE COSTS OF 
DRUG-USE-RELATED DISEASE 
Maarten J. Postma, Keith Tolley and Johannes C. Jager 
Different types of costs, such as health-care costs, the social costs of dependency and 
costs associated with criminal activity, can be related to drug use. In general, drug users 
are at increased risk of various types of infectious diseases, such as HIV/AIDS and 
hepatitis (Haverkos and Lange, 1990). Furthermore, some non-infectious diseases have 
also been associated with drug use, in particular with the use of crack cocaine (Umbricht-
Schneiter et al.,1994; Kaku and Lowenstein, 1990; Dinwiddie et al., 1992). An overview 
of drug-related diseases is provided in Table 1. 
At society level, the epidemiology of drug-use-related disease imposes a relevant public-
health problem for many countries (Schlenger et al., 1992). For example, almost 40 % 
Table 1 : Diseases and conditions related to drug use 
Anaemia 
Bone infections 
Central nervous system infections (tetanus, meningitis) 
Chronic liver disease 
Endocarditis 
Heart disease (hypertension, heart attack, stroke) 
Hepatitis 
Human Immunodeficiency Virus (HIV) 
Mental disorders (schizophrenia) 
Other retroviruses (HTLV) 
Pneumococcal bacteremia 
Respiratory diseases 
Sexually transmitted diseases (gonorrhea, syphilis) 
Skin infections 
Tuberculosis 
Sources: adapted from Haverkos and Lange (1990), Umbricht-Schnelter et al. (1994), Kaku and 
Lowenstein (1990) 
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of reported AIDS cases in the European Union are related to the intravenous use of 
drugs (European Centre for the Epidemiological Monitoring of AIDS, 1994). 
This chapter focuses on the health-care costs of drug-use-related diseases. The treatment 
and care of these-mostly infectious-diseases require the input of various health-care 
resources such as hospital beds, nursing care, specialist consultations, day care and GP 
visits, corresponding to financial budgets and expenditures. Since 1990, research into 
the spread of HIV/AIDS in groups of intravenous drug users has increased the awareness 
of these type of costs (Rice et al., 1991 ). For example, an overview of hospital costing 
studies of HIV/AIDS was published in 1993 (Postma et al., 1993). In addition, quality 
standards for these type of costing studies were defined (Tolley and Gyldmark, 1993). 
As a next step, these studies have been used to assess and project national totals for the 
use of health-care resource and costs for HIV/AIDS (Rovira and Leidl, 1995; Postma et 
al., 1995; Kyriopoulos et al., 1992). Furthermore, in scenario analysis, the epidemiological 
and economic impact of different future courses of the epidemic and different treatment 
and prevention options are explored (Postma et al., 1993; Rovira and Leidl, 1995). 
Obviously, in the field of quantitative AIDS research and scenario analysis in particular, 
a set of new methods has been developed that might be applicable to problems of 
health-care costs of other drug-use-related infectious diseases (see Chapter 11). This 
chapter investigates this applicability, and reviews some previous and ongoing research 
into the health-care costing of drug-use-related diseases. 
Chapter 11 also explains the basic framework for scenario analysis. The steps taken 
are: to construct a conceptual model; to go from a conceptual model to a mathematical 
model; to integrate into the model epidemiological and health-care information from a 
structured review; and to construct a reference and several alternative scenarios (Van 
Genügten et a!., 1996). Whereas for non-infectious diseases assessment of health-care 
burdens can sometimes do without an actual epidemiological model, the nature of 
infectious diseases necessitates the use of a sometimes complex mathematical model 
for the spread and progression of the disease (see Chapter 10). The methodological 
parts of this chapter focus on approaches for linking epidemiological models with health­
care information, preferably specified for drug users. To enable specific estimates for 
drug users, this chapter emphasises the need for patient-based data on health-care use. 
Several detailed examples are presented here, including one that addresses some of 
the problems that arise when different costing studies for one disease are reviewed and 
compared, focusing on hepatitis costs. A second example illustrates the use of patient-
based data for estimating health-care impacts for drug users. The final example specifies 
the drug-use-related hospital care in the reference scenario for AIDS hospital care in 
EU countries (Postma et al., 1997). 
Linking epidemiological models to health-care information 
The objective of modelling the health-care impact of drug use is to assess current and 
project future health-care needs and financial requirements. The general design of the 
model links an epidemiological sub-model to formatted information on health-care 
needs. The epidemiological sub-model can be any type that assesses and projects the 
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burden of disease at national or multinational (for example, EU) level. A common 
distinction in infectious-disease modelling is between population-dynamic models and 
empirical models (Bailey and Heisterkamp, 1995). Empirical models draw on surveillance 
data or counted new cases of a disease. Population-dynamic models explicitly 
incorporate some of the transmission dynamics of the infectious agent. To enable detailed 
country-specific impact assessments, the generalisability of the epidemiological model 
to various country contexts has become an important prerequisite. In particular, the 
model should enable the provision of standardised epidemiological information of 
comparable quality for all EU countries. 
The format of the information on health-care needs should be in line with the type of 
output of the epidemiological model. The format of health-care-needs information will 
be addressed in the next section. Generally, the impact calculus is based on incidence 
or prevalence output figures. The methods are respectively labelled as incidence-based 
and prevalence-based (Hartunian and Smart, 1981). The first concerns accounting 
lifetime health-care resources to the year of incidence of disease. The second method 
concerns an annualisation of these lifetime health-care resources. To cover the full 
economic impact of a health-care measure, it is necessary to analyse the lifetime 
consequences for resource needs incurred by a representative case. This incidence-
based approach does, however, assume that future health-care technologies will remain 
the same as in the analysis, and also extends all other assumptions up to the time until 
the last incident case has been dealt with. If the assumption of everything staying equal 
holds true for the period of analysis, and if the full economic impact is what is being 
referred to in a decision-making context (for example, in decisions on research budgets), 
the incidence-based approach is the more appropriate one. If, on the other hand, the 
budget impact of a health-care technology is the focus of analysis, and if this impact is 
expected to change with new treatment technologies, then the prevalence-based 
approach, applied over a well-defined period of time, will be the more appropriate 
approach. Obviously, the incidence- and prevalence-based approaches may differ when 
applied to the same epidemiological situation. Ideally, a modelling approach can deal 
with both incidence- and prevalence-based assessments. 
Model development 
Besides the availability of an appropriate epidemiological sub-model, a full model for 
the health-care impact of drug use requires a sound procedure for incorporating reliable 
estimates of health-care needs and costs. This procedure should take into account a 
disease-staging that distinguishes stages that differ significantly with respect to resource 
needs. Neglecting to take account of such stages can introduce serious biases in future 
projections, in particular in situations with non-stable epidemiology and changing 
treatment patterns (Postma et al., 1998). This staging may or may not overlap with 
clinically relevant stages. For example, for chronic diseases a useful staging has proved 
to be one that distinguishes a late or terminal phase from one or several other stages 
(Scitovsky, 1984). In particular, this concept has been of value in modelling the costs of 
a disease as clinically diverse and complex as HIV/AIDS. For a clinically clearer-cut 
disease progression, the use of a progression tree is a good alternative. Antoñanzas et 
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al. (1995) present a progression tree for the clinical evolution of hepatitis. Hepatitis 
infection has an acute symptomatic manifestation and may result in chronic carriership. 
The symptomatic form is often mild, but can be severe or fulminant in some cases with 
serious associated liver disease possibly requiring transplantation. The chronic carrier 
might develop active hepatitis, associated with cirrhosis, heptocellular carcinoma and 
again possibly requiring liver transplantation. In the next step, reliable parameter 
estimates for resource use and financial costs for the distinguished stages in the 
progression tree have to be specified. 
In health economics, several classifications are used for expressing the consequences 
of disease on resource use and costs: direct versus indirect; patient-related versus general 
programme; and health-care versus non-health-care costs (Rovira, 1990). Direct costs 
arise from the treatment and care of patients in different health-care settings and from 
research, public-information, prevention and media campaigns. Indirect costs relate to 
production losses as a result of premature death (potential years of life lost or PYLL) or 
illness (sickness absence). Patient-related costs are directly associated with the individual 
person at a certain disease stage (Johnson, 1988). These costs comprise direct costs of 
treatment and care as well as indirect costs. General programme costs are the costs of 
research, prevention, public information and the maintenance of services for the benefit 
of the entire population. In particular, patient-related costs are very suitable for linking 
to epidemiology in an incidence- or prevalence-based assessment. 
Drug use involves a range of clinical and public-health problems with alleged cost 
implications. Costing implications will vary from country to country and from health­
care sector to health-care sector. Drug-use-related disease, such as HIV/AIDS and 
hepatitis, involves hospital care, home care, medication, and so on. Furthermore, non-
patient-related costs arise from providing information programmes for drug users, 
providing appropriate protection from infection for health-care workers, screening 
pregnant women for HIV and hepatitis, and screening and heat treating blood and 
blood products. Finally, mortality due to AIDS and hepatitis complications gives rise to 
life years lost and corresponding production losses. In this chapter, the main focus is on 
the patient-related direct costs of drug-use-related disease in the hospital sector. 
As both HIV/AIDS and hepatitis involve serious complications and complex health­
care interventions that take place several years after the actual infection with the virus, 
the concept of discounting future costs is important. Discounting reflects a weighting 
procedure, where costs are weighted less the farther in the future they accrue. The 
discounting procedure reflects time preference: most people would rather get 100 
Euros now than, for example, next year. First, 100 Euros acquired now can be invested 
and hence grow to an amount that is more than 100 Euros next year. Second, there is 
uncertainty with regard to future happenings, namely, will it be possible to benefit from 
the 100 Euros next year as now? There is widespread consensus among health economists 
on the discounting of costs (Drummond et al., 1987; Gold étal., 1996) and the rationale 
for the procedure can be found in the existence of 'time preference', opportunity cost 
of investment and economic growth. There is less agreement on the choice of the 
appropriate value of the discount rate, although it should clearly be related to the 
marginal rates of return on investment and market interest. Discount rates varying from 
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zero to 20 % have been reported (Petrou et al., 1993). Furthermore, discounting should 
not be confused with correcting costs for inflation rates. In addition to discounting, 
costing studies should apply a deflator to express costs in different years in a currency 
of constant price level. It should be noted that there is less consensus on discounting 
health benefits, such as PYLL and quality-adjusted life years (Mooney and Olsen, 1994; 
Parsonage and Neuberger, 1992; Keeler and Scretin, 1983). A full discussion of the 
controversy is beyond the scope of this chpater, but the general recommendation is to 
include in the model calculation options with and without discounting future health 
benefits. 
The reliability of the parameter estimates of the direct health-care costs depends on 
the quality and representativeness of the data that are used for estimation. Specific 
criteria for the data can refer to the number of patients in the database/costing study 
(also in relevant sub-groups, for example drug users), the number of health-care centres 
involved, their distribution throughout the country and a set up of the data-gathering 
allowing in-depth analysis for fine-tuning information to the epidemiological model's 
design. To enhance comparability of HIV/AIDS costing, a standardised approach has 
been developed (Tolley and Gyldmark, 1993; Tolley et al., 1998), identifying five specific 
fields for standardisation. 
• First, information should be detectable from a sufficiently large patient sample size 
in the relevant disease stages and sufficient patient follow-up for recording resource 
use and costs to be ensured. 
• To produce representative estimates for national and regional planning purposes a 
sufficient number of the main treatment sites covering the country/region needs to 
be included. 
• It should be possible to break down aggregates so as to identify the contribution of 
different components in the care and cost totals. 
• The possibility should be built in to produce homogeneous cost groups, for example 
using several classifications for HIV/AIDS as defined by the Centres for Disease 
Control in Atlanta, Georgia, the international classification of diseases (ICD) codes, 
the Turner stages (Turner et al., 1991 ) or specific disease-staging definitions, such as 
terminal/late versus chronic. 
• Finally, a standardised methodology for approach and presentation should be 
followed to enable the effect of 'true factors' to be identified (differences in epidemics, 
health-care structure and practice, pricing structures and local health-care labour 
markets). The standardised approach is intended to provide guidelines in these five 
areas and could possibly serve as a clearing house for studies of resource use and 
costs for HIV/AIDS and other diseases, such as hepatitis. 
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Model applications 
Reviewing costing studies 
The standardised approach for costing studies is in essence a hierarchy of technical 
'accounting' steps associated with estimating mean resource use and costs per person-
year for disease stages, specific episodes and lifetime resources and costs. The accounting 
framework is based on a number of elements of standard economic costing practice, 
and can be applied to any disease. Five main standards were used to develop the 
approach. 
• As a starting point, the perspective of the evaluation should be clarified, in other 
words, the hospital or the health-services planner at the national or multi-national 
(e.g. EU) level. 
• Next, cost components and resource-use units should be identified according to 
the perspective adopted. The framework covers four standard cost components: 
inpatient; out-patient; day care (inpatient for several days with no overnight stay); 
and day case (admitted and discharged in one day). For specific purposes the last 
two or three components are taken together as day care and out-patient care 
respectively. 
• To measure physical resource use, rigorous methods of study design and data 
collection are essential, such as a predominantly patient-based (bottom-up) 
assessment of resources. 
• Resources should be valued using appropriate methods of unit-cost (or price) 
estimation that best reflect opportunity cost. Therefore, caution must be exercised 
in using health-service charges, tariffs or prices. 
• Mean resource and cost estimates should be presented according to the decision­
making context for which they areto be applied (total, disease-stage, clinical condition 
or transmission group such as drug users). Together, the accounting framework and 
the standard principles on which it is based, if adopted in new cost studies, should 
produce cost estimates that meet the normative criteria of good quality and 
comparability better than do previous studies. 
The health-care impact of hepatitis has primarily been modelled for the purpose of 
evaluating the costs and benefits of vaccination programmes. Since both plasma-derived 
and recombinant-DNA-produced vaccines have become available, many studies in 
this field have been performed. In this framework several costing studies for hepatitis 
were conducted in the 1990s (Jefferson and Demicheli, 1994; Badia étal. , 1997). In 
general, concern has been expressed about the quality and comparability of such disease-
specific health-care costing studies (Drummond et al., 1993). This concern is reinforced 
by Jefferson and Demicheli (1994) who indicate a wide range for direct health care 
(25th percentile US$ 650, 75th percentile US$ 3 768) and indirect costs (25th percentile 
US$ 14 164, 75th percentile US$ 127 592) in different hepatitis-costing studies. The 
high level of the indirect costs can be explained by the use of the human-capital method 
for valuing years of life lost to hepatitis. This section provides some of the costing details 
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of selected cost­effectiveness analyses of hepatitis Β vaccination in EU countries published 
in international health­economics journals (Table 2; Antoñanzas et al., 1995; Beutels et 
al., 1996; Kerleau et al., 1995). In this study, cost figures were converted into US$ using 
the exchange rates for the local currencies as reported in the publications. Obviously, 
for better comparison, health­care­specific purchasing­power parities could be 
considered (OECD, 1993). Costs were not deflated, but cost estimates refer to different 
price years. Already this limited selection of three studies indicates major differences in 
the way the various cost categories are conceived. For example, the Spanish study 
(Antoñanzas et al., 1995) calculates significant costs for the stage of chronic infection, 
in other words, healthy carriership versus active carriership. The costs for assessing 
active chronic infection include those for a physician's visit, liver biopsy, interferon 
treatment, eight­day hospitalisation, six follow­up visits and a final follow­up visit with 
testing for hepatitis Β markers. The other two studies neglect or assign lower cost figures 
to these stages. Furthermore, the Belgian (Bentels et al., 1996) and French (Kerleau et 
al., 1996) studies apply much higher cost estimates for the follow­up and long­term 
complications of active chronicity. The higher estimate for Belgium compared to France 
can partly be explained by the higher discount rate in the latter study. 
Table 2: Reference, country of study, price level, discount rate and costs 
in US$ for various hepatitis stages 
Reference 
Country 
Price level 
Discount rate 
Antoñanzas et al. (1995) 
Spain 
1990 
5 % 
Beutelsetal. (1996) 
Belgium 
1995 
5 % 
Kerleau et al. (1996) 
France 
1990 
8 % 
Costs per stage 
ia 
ii 
iii 
iv 
ν 
vi 
vii 
viii 
ix 
χ 
xi 
560 
3 660 
1 510 
6310 
115 000e 
510 
8 080 
210 
420 
1 470 
-
420 
2 990 
3 560b 
4 870b 
83 000 
310 
1 230 
130 
1 430 
11 100 
15 300 
1 150 
5 400 
-
-
80 000 
-
-
150 
5 000 
4 600 
10 000 
Notes: I­vü are expressed per stage; v¡ü­x¡ are expressed per full year of follow­up 
a ¡: acute, non­fulminant mild; ii: acute, non­fulminant severe; iii: acute, fulminant fatal; iv: 
acute fulminant fatal; v: liver transplant; vi: assessment of healthy chronicity; vii: assessment 
of active chronicity; viii: healthy carrier; ix: active carrier; x: cirrhosis; xi: cancer 
b own estimates 
c including the present value of future follow­up of liver­transplant patients 
­ indicates not reported 
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A standardised approach to cost estimation would help explain such differences in cost 
estimates, maximising the usefulness of the estimates for a range of policy purposes at 
various decision-making levels. Obviously, there is a need for a standardised approach 
to estimate the per-patient, per-stage and total costs of hepatitis treatment and care. 
The development of this approach should follow principles outlined in earlier work on 
costing standardisation of HIV/AIDS hospital care (Tolley and Gyldmark, 1993; Tolley 
et al., 1998). Kerleau étal. (1995) pays special attention to hepatitis Β cost-effectiveness 
for interventions among drug users. In particular, the authors estimate benefit-to-costs 
ratios of 3.5 and 5.7 for respectively vaccinating all drug users and vaccinating only 
those drug users found susceptible to hepatitis (after screening). 
Selecting cost studies for scenario analysis 
As mentioned above, the standardised approach to health-care costing has been applied 
to HIV/AIDS. For the purpose of linking epidemiology and health care in future scenarios, 
specific databases on AIDS hospital care in the EU have been selected. Three criteria 
were applied. First, information should be recent (1990 or later), reflecting current 
efficiency of practices in hospital care. During the 1980s and into the 1990s, efficiency 
changed due to increasing experience with managing people with AIDS (PWAs). 
Furthermore, resource use has been controlled by more (cost-)effective use; for example, 
the substitution of less expensive out-patient care for hospital inpatient care. Second, 
selected studies should include data that can be assumed to be representative of the 
national situations. The representativeness was considered safeguarded in multi-centre 
studies. Third, the resource-use data should be patient-based, enabling resource use to 
be linked to individual patients, patient groups and disease stages, such as HIV infection 
and specific opportunistic illnesses. Six studies - most of them designed as databases -
satisfied most of these criteria (individual studies are listed in Postma et al., 1997), and 
are theoretically able to specify separate estimates for drug-use-related HIV/AIDS. In a 
previous application no distinction between different risk groups was made (Postma et 
al., 1997). For this chaper, it was possible to specify estimates for drug users from Dutch 
(four hospitals) and Italian databases (ten hospitals). 
It is well known that hospital-resource needs incurred by AIDS vary in the different 
stages of the disease. In particular, the terminal phase of AIDS entails a relatively high 
intensity of resource needs and costs. Therefore, two stages are differentiated for PWAs: 
a final stage of six months (maximum) before death (late stage: LS); and a stage for the 
foregoing period (chronic stage: CS). It has been argued that neglecting this concept 
threatens the validity and comparability of estimates derived from different studies of 
use and introduces significant biases in consequent future projections (Postma et al., 
1998). Applying the staging concept to Greece, Spain, France, Italy, the Netherlands 
and the UK has shown that per-person-year (ppy) inpatient days in LS are at least twice 
those in CS. For example, in Italy and the Netherlands ppy inpatient days in LS are, 
respectively, 60 and 80, whereas the respective CS figures are 24 and 33 inpatient 
days. 
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Table 3 shows the Italian and Dutch figures, specified according to drug-use-related 
and non-drug-use-related AIDS. Italy and the Netherlands show opposite patterns. In 
Italy, total hospital contacts are higher for drug-related AIDS in both stages. In particular, 
late-stage inpatient-day needs are relatively high. Obviously, the late stage of drug-
related AIDS in Italy involves a relatively frequent occurrence of inpatient-day-intensive 
complications, such as AIDS dementia. In the Netherlands, the figures illustrate a different 
pattern; LS inpatient-day needs are relatively low. This is consistent with a previous 
Dutch study (Postma et al., 1995) showing relatively low use of ppy inpatient days for 
drug users (16.1 versus 47.9 for homosexual men). However, in this study no correction 
for chronic and late stage could be made. Furthermore, both the current and the previous 
Dutch studies involve small sample sizes for drug users. 
AIDS scenarios 
In a mixed ¡ncidence/prevalence-based approach, epidemiological information (Postma 
et al., 1997) is linked with the per-person-year hospital-resource needs of PWAs. 
Estimated ppy hospital-resource use is used as a proxy for resource needs, implicitly 
assuming that recorded resource use reflects actual care needs. Annual resource needs 
for CS are estimated by multiplying the annual period-prevalence in CS by the 
appropriate ppy resource-need parameters for CS. Annual resource needs for LS are 
estimated by multiplying annual mortality, the duration of stay in LS (six months or less) 
and the appropriate ppy resource-need parameters. It is assumed that ppy resource 
Table 3: Hospital resource use per person-year of AIDS, A IDS stage and risk group, 
Italy and the Netherlands 
Country 
Italy 
Nether lands 
Risk group 
all 
drug-use^lated 
χ^^\ 
noni l rug-useJre la ted 
all β 
y drug-Ce- re la ted ^ * 
^ ^ ■ * ^ 
non-drug-use-related 
Stage 
CS1' 
LS 
CS 
LS I 
r 
(r 
r 
LSC 
es 
LS 
IPDa 
33 
60 
€ 68^^ 
3 ^ ^ 
24^S 
80 
27 ^ 
30 
23 
82 
OPC 
44 
28 
46 
1 30 
39 
26 
W 21 
^ 2 3 
^ 1 9 
33 
21 
22 
THC 
77 
88 
78 
98 
73 
66 
45 
103 
46 
63 
44 
104 
Notes: ' IPD: inpatient days; OPC: out-patient contacts; THC: total hospital contacts 
b CS: chronic stage; LS: late stage 
c This figure was derived from only three patients 
Source: Postma et al. (1997) 
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needs remain stable over calendar time in each stage so that the effect of changes in 
epidemiology can be isolated. Finally, a generalisation had to be chosen to extrapolate 
the approach from the six countries with high-quality hospital-resource-use studies to 
those lacking these studies. This generalisation specifies the calculation of average ppy 
resource needs in CS and LS for the countries with the information, and these are 
applied to the countries with missing information. 
Figure 1 presents period prevalence-based estimates of needs for hospital beds and out­
patient hospital contacts (including day-care treatment) in the reference scenario. The 
crucial epidemiological assumption in the reference scenario specifies that the future level 
of annual HIV incidence equals the level estimated for 1993. Other scenarios are presented 
elsewhere (Postma et al., 1997). Figure 1 indicates that less than 40 % of EU hospital-bed 
needs concern drug users, whereas they are responsible for over 40 % of the need for out­
patient contacts. This gives rise to the hypothesis that the share of out-patient treatment in 
total hospital care is relatively high for drug users. Overall, however, the share of drug-user-
related hospital care is below what might be expected on the basis of their share in incidence. 
This share rises to more than 50 % in 1999. The difference between the shares in hospital 
care and incidence can be explained by the fact that drug-use-related AIDS is primarily 
Figure 1: Reference scenario for drug-use-related hospital-resource needs 
15-1 Γ 1.50 
^r 10 
1990 1995 1999 
Note: Hospital-bed needs and outpatient contacts indicated as parts of 
totals for all risk groups 
Source for totals: Postma et al. (1997) 
214 
CHAPTER 12 
located in the southern European countries (for example, almost 70 % of the new AIDS 
cases in Spain in 1999 were drug users, compared to just over 60 % in 1995). These 
countries show on average lower estimates of ppy inpatient days and out-patient contact 
needs than the EU averages of 54 days and 22 contacts. For example, in Italy estimated 
ppy inpatient-day needs are 38.5 for 1995 and the need for out-patient contacts in Spain 
amounts to 15.6 ppy of AIDS in 1995. 
As Italy is one of the EU countries with a large share of drug-use-related AIDS in the 
total epidemic, Figure 2 specifies the 1995 needs for total hospital contacts (inpatient 
days, day-care days and out-patient contacts) of drug users in this country (incidence-
based calculations) (Postma et al., 2000). Furthermore, total hospital contacts are shown 
taking the relatively high resource needs of drug-related AIDS cases into account (Table 
3). Finally, the total estimate for all risk groups is shown (including homosexual men 
and heterosexuals). The figure indicates that approximately 60% of all hospital contacts 
in 1995 are estimated to have been for drug users. 
Figure 2: Total hospital contacts (inpatient days, out-patient 
contacts and day-care days), Italy, 1995 
70-1 
6 5 -
% 6 0 -
5 5 -
50- Reference Alternative 
Scenario 
Notes: ■'percentage related to drug use in total for all risk groups. The dark blue band 
indicates the range between lower and upper 95% confidence limits 
•■reference: see Figure 1 ; alternative: taking into account relatively high resource 
needs for drug-related AIDS cases 
Source: Postma et al. (1997, 2000) 
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Critical assessment of models 
Obviously, this type of costing analysis requires a rather detailed patient-based registration 
that is ideally set up to provide information for cost-of-illness and future projections. 
Furthermore, the type of information required can only be retrieved from bottom-up, 
patient-based data on health-care resource use and costs in cases of time-related staging 
of disease with documentation over the full life span of a specific patient. This detailed 
information enables estimates to be provided of drug-use-related disease in the present 
and in future projections to support health-policy decisions. They provide a quantitative 
order of magnitude for health-care resources in this area. They specify the patient mix, 
for example in terms of drug user versus non-drug user and chronic versus late, which 
are important indicators for planning hospital staff, capacity and support. 
A standardised approach to costing health care has helped in designing bottom-up, 
patient-based costing studies for HIV/AIDS that can render the appropriate information. 
If such an approach is followed, the information that is necessary for cost assessment 
and projection is identifiable. Further application of the standardised approach could 
involve the examination of local, national and multinational variations in cost estimates 
for drug-use-related diseases such as HIV/AIDS and hepatitis. If bias due to 
methodological differences is minimised, cost variations due to differences in clinical 
practice, health-care structure and organisation and epidemiology can be more readily 
identified. In addition, the standards should improve investigation of resource-use 
variations over time in one or more sites. Furthermore, detailed analysis in specific 
areas of treatment and care could facilitate investigation of the cost-effectiveness of 
alternative policy and care options in these areas (for example, screening for HIV and 
hepatitis, HIV combination triple therapy and hepatitis vaccination). Finally, the 
standardised approach could provide a starting point for further development to cover 
non-hospital care and social care. 
The focus of the models and model applications discussed above is mainly on the 
direct health-care costs. One study attempts to estimate the indirect costs of drug use 
(French et al., 1996). Using a quality-adjusted life-year methodology (French et al., 
1992), the value of avoiding drug-use-related morbidity and mortality is estimated. As 
a common unit of well-being applicable to all illnesses and diseases, quality-adjusted 
life years are calculated using the Rosser/Kind index (Rosser and Kind, 1978). The 
Rosser/Kind index uses eight disability levels and four distress levels to define 29 health 
states. Perfect health corresponds to a value of 1, death corresponds to a value of 0. For 
example, a moderately acute case of hepatitis Β corresponds to a value of 0.956 (severe 
social and slight work disabilities and moderate distress). These life years are valued by 
means of the 'US dollar value' for human life. In this particular case, a 'dollar value' of 
human life of US $5 million is applied (Viscusi, 1993). Different from the human capital 
method that only values the present value of future earnings, the value of pain and 
suffering is included in the calculations. For example, the dollar values for AIDS, severe 
hypertension and ten weeks of severe pneumonia are estimated at respectively 
US $115 000, US $75 000 and US $58 000 (Viscusi, 1993). The total lifetime value for 
HIV/AIDS amounts to US $158 000 (including pre-AIDS stages). Furthermore, including 
mortality costs, the estimated full dollar value of avoiding a single case of HIV equals 
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US $2 655 000. For comparison, lifetime health-care costs for HIV/AIDS in the United 
States have been estimated at US $119 000 (Hellinger, 1993), which obviously only 
reflects a small part of all the costs of a drug-related HIV/AIDS case. 
Costing impact by scenario analysis as outlined above represents an exercise that should 
potentially underpin health-care policy for drug users. However, due to differences in 
patient group, type of hospital care provided, and stage of disease dealt with, the 
quantification of current and future costing impact is quite a complex task. By integrating 
recent and detailed data, important steps can be made in improving the current state 
of information. Nonetheless, uncertainty will remain, leaving issues of availability of 
representative data on drug-use-related health-care costs, impact on non-hospital care 
sectors and dynamic integration of treatment technology for future work. In the short 
term, however, an indication of the order of magnitude of the impact of drug-use-
related disease on EU health-care systems can be provided, probably indicating that 
drug use should be an important issue on the agendas of health-care policy-makers in 
the coming years. 
Conclusions 
Essentially, this chapter argues that future costing scenarios for drug-use-related health­
care costs can be built by applying sound costing principles and by standardised 
epidemiological modelling using relevant disease-staging. 
As a first step, standardised gathering of health-care and costing information is crucial. 
This involves applying classifications of health-care costs, breaking down aggregate cost 
figures in line with conceptual models of the disease and recalculations for standard 
discount rates, price levels and currencies. It is therefore recommended that the 
standardisation of costing data collection as developed for HIV/AIDS is extended to 
other drug-related diseases, in other words hepatitis as the next step. 
For hepatitis, this chapter summarises some of the work that has been undertaken on 
costing the disease, in particular regarding the framework of cost-effectiveness analyses 
of vaccination strategies. As a logical start, it is recommended that existing databases 
for hepatitis care and costing be reviewed, in particular their appropriateness for 
application in drug-use-related costing scenarios should be evaluated. For example, 
the French AIDS-care database (Postma et al., 1997) includes hepatitis care, and could 
potentially be used for French drug-use-related hepatitis costs. 
Future scenario analysis of health-care and costing impacts requires the application of 
epidemiological models - primarily of infectious diseases - in combination with health-
economic information as indicated above. An appropriate choice for disease staging is 
important to avert structural biases in health-care needs assessments and projections. 
This has been argued for HIV/AIDS above, and has recently been illustrated for chronic 
diseases as well (Postma et al., 1998). In combination with major differences in resource 
needs and associated costs between these stages, epidemiological dynamics have major 
implications for resource needs and costs. In consequence, any application of costing 
approaches and scenario analysis should control for this disease staging. Again, it is 
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recommended to extend methods developed for HIV/AIDS ­ in particular the disease­
staging approach ­ to other drug­use­related disease costing (Postma, 1998). 
Furthermore, this chapter illustrates that detailed information on drug­use­related health­
care needs and costs for HIV/AIDS is potentially available by citing some detailed 
information for drug­use­related AIDS in Italy and the Netherlands. It is recommended 
that for other countries the acquisition of this type of information be pursued. For 
example, Spanish, English and French AIDS­care databases (Postma et al., 1997) allow 
the extraction of this information. This information will enable the estimation of drug­
use­related health­care costs in the EU at present and in future scenarios. As a result it 
is recommended that ultimately future costing scenarios are developed for all relevant 
drug­use­related diseases. 
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ECONOMIC MARKET MODELS 
Matthew Sutton 
Economists study behaviour in terms of markets or trading situations. In general, that 
study is divided between the analysis of demand or consumer behaviour and that of 
supply or producer and distributor behaviour. A fundamental distinction in the economics 
literature is the level of analysis. There are broadly three levels of analysis: 
• picoeconomics: the study of behaviour within individuals (often across time); 
• microeconomics: the study of behaviour across individuals within areas (or markets); 
• macroeconomics: the study of behaviour across areas (or markets). 
An interestin the dynamics of consumption suggests that picoeconomic analysis would 
be particularly pertinent in the case of illicit drugs, and much of the economic literature 
on addictive substances concerns picoeconomic relationships. However, whilst 
theoretical developments in the economics of addiction (and demand for addictive 
substances) have been more extensive at the picoeconomic level, it is macroeconomic 
outcomes which command the most policy attention. Much of the existing data on 
market outcomes and prices/purities are at the aggregate market level (e.g. Pompidou 
Group, 1994). The lack of conceptual guidance at this level tends to make interpretation 
of trends in these data precarious and the evaluation of policy interventions rather 
depressing (Caulkins and Reuter, 1996; Weatherburn and Lind, 1997). 
One of the central premises of economics is that market prices will change to ensure 
that the supply of, and demand for, commodities reaches equilibrium. Therefore, much 
applied work in economics focuses on the relationship between quantities traded and 
market prices. The other fundamental lesson from economics is that choices are made 
within a budget constraint and therefore income levels will affect quantities purchased 
in the market. 
Economic-market models can be used to generate estimates of the determinants of 
dynamic patterns of drug prevalence/incidence. There are very few applications of 
these models either within or outside Europe. The demand-side aspects of the models 
are based on theoretical models of individual behaviour which easily incorporate 
contextual/environmental factors. However, preferences play a major role in the 
determination of demand and there has been relatively little economic work on the 
formation of preferences. 
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The supply side of drug markets is known to vary substantially between areas, even 
within countries. It would therefore be difficult to extrapolate results to other areas 
(particularly between.the United States and Europe) because of the differences in the 
supply sides of markets. A study of how drug markets are formed and how their structure 
develops would aid the generalisability of any economic-market applications. 
Economic-market models require good-quality data on levels of consumption or 
expenditure, prices, purities and total income. The analysis can either be at individual 
or market level. At individual level, there are considerable problems in the collection of 
consumption data, and measures of market prices and purities may have little explanatory 
power for individual outcomes because of wide variability between individuals in prices 
paid and purities received. Moreover, recent developments in dynamic modelling of 
individual consumption require panel data on quantities consumed and/or prices paid. 
Despite the obvious difficulty with the feasibility of such data collection, recent attempts 
to collect economic data at individual level are encouraging. 
At a market level, the vast majority of economic data are derived from enforcement-
agency reports. Price data often rely on reports from undercover buys and purities 
relate to drugs seized. Neither data source has been established to be representative. 
Moreover, the problems with inferences about levels of consumption based on 'market 
indicators' such as seizures, drug-related deaths or registrations for treatment are well 
known. Based on such data, applied studies have found little link between economic 
factors, enforcement activity and market outcomes. 
This chapter contains an overview of the existing theoretical and applied economic 
analysis of drug markets. Available studies on demand are considered, followed by a 
limited analysis of the supply side of the market, a review of addiction models and 
finally some comments on market equilibrium. Some conclusions are drawn on the 
feasibility of further research across Europe. 
Analysis of the demand for drugs 
The extent to which demands respond to changes in price and income are termed the 
price elasticity and income elasticity of demand, respectively. The majority of applied-
economics work on addictive substances therefore attempts to estimate price and income 
elasticities (Leung and Phelps, 1993; Godfrey, 1994). The study of illicit drugs has focused 
to a greater degree on the price elasticity of demand, and particularly on the way in 
which addiction may influence the nature of the relationship between prices and demand 
(Wagstaff and Maynard, 1988; Beckeretal., 1992). 
However, there is more to economic models of demand and supply than price analysis 
and it is important to remember that the traditional study of market equilibrium (the 
downward-sloping demand curve and upward-sloping supply curve) is based on the 
ceteris paribus assumption (everything else held constant). Before reviewing the literature 
on price effects, a summary of economic work on the other determinants of demand 
and supply will be presented. Throughout the review, reference is made to applications 
of new models to the analysis of tobacco and alcohol consumption. Whilst simple 
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extrapolation of these results to the consumption of illicit drugs is not appropriate, 
these studies demonstrate the potential for economic methods. Fuller reviews of the 
economic literature on addictive goods can be found in Godfrey (1994), Leung and 
Phelps (1993) and Buck et al. (1996). 
Non-price determinants of demand 
Various drug-using behaviours have been analysed in demand studies. For the 
consumption of legal addictive substances, applied-economic analyses have focused 
on the separation of decisions about whether to consume and, given the choice to 
consume, how much to consume (Atkinson et al., 1984; Jones, 1989). At the macro 
level, this can be analysed as the percentage of individuals participating in the market 
and the total level of consumption Cones, 1989). More recently, Jones (1995) has focused 
on the determinants of the decision to quit smoking. He finds that individuals with 
higher potential benefits from quitting (i.e. heavier consumers) are more likely to attempt 
to quit. 
Analyses of the consumption of health-damaging commodities should be set within the 
context of individuals' decisions about their level of health (Birch and Stoddart, 1990). 
Grossman's (1972) model of individual health production dominated the early economic 
literature on individuals' choices about health and lifestyles. Grossman conceptualised 
health as being a stock variable which depreciates through time and can be replenished 
with health investments. Inputs into the health-production process include medical 
care and lifestyle variables, such as exercise and consumption of health-affecting 
commodities, for example, food and addictive substances. Grossman suggested that 
individuals with a higher level of education would have better knowledge of the 
production process and would therefore make more appropriate decisions about health 
inputs. Education may also affect individuals' knowledge of the health risks of addictive 
goods. Viscusi's (1992) empirical results suggest that, if anything, smokers overestimate 
the risks posed to their health by smoking. Viscusi's results have been challenged by 
Schoenbaum (1997), who found that heavysmokers, in particular, underestimated the 
risks they were taking with their future health. 
Differences in levels of demand between individuals which cannot be explained by 
these factors are often attributed to differences in preferences. Despite the importance 
of such considerations, there has been relatively little focus within economics on the 
ways in which such preferences are formed (Pollak, 1976). Within the study of health-
damaging and addictive goods there are some notable exceptions. There has been 
interest in the effect of habit formation on intertemporal consumption patterns (Alessie 
and Kapteyn, 1991 ) and the development of rational addiction models can be seen as 
a refinement of this broad approach (Becker and Murphy, 1988). Moreover, in the 
addiction area, there have been developments in the ways in which time preference is 
formed and manipulated (Becker and Mulligan, 1993). Finally, the effects of peer 
behaviour on consumption patterns have also received prominence in the area of 
addiction (Norton et al., 1997). Each of these three developments will be discussed in 
turn. 
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Habit formation 
Becker and Murphy (1988), for example, propose a theoretical model of addiction 
which emphasises the time-dependence of consumption levels. Previous theories had 
incorporated the effect of previous consumption on current consumption, but Becker 
and Murphy's theory predicted that individuals would be rational, in the sense that 
they would consider the consequences of current consumption decisions on future 
time periods. Becker and Murphy's model of rational addiction has been applied to US 
cocaine-consumption data by Grossman and Chaloupka (1998). Despite the limitations 
of the data set and the way in which the consumption-level data were collected, 
Grossman and Chaloupka did find some evidence to support Becker and Murphy's 
predictions. 
Time preference 
One of the other central areas of interest in economics has been the way in which 
individuals discount future occurrences (Buck et al., 1996). Many theoretical models of 
dynamic behaviour have been based on stable models of intertemporal behaviour (such 
as constant exponential discounting). Differences in time preference between individuals 
was one of the main explanations given by Becker and Murphy (1988) for why some 
individuals would begin an addiction career whilst others would not. Bretteville-Jensen 
(1997), however, presents empirical estimates of the time preferences of current users, 
ex-users and never-users. Her results do not suggest that ever-users (i.e. current and ex-
users) have systematically different (higher) time-discount rates. An alternative 
explanation for why current users do display higher time-preference rates as expected, 
but that ex-users have similar rates to never-users, is that of endogenous time-preference 
(Becker and Mulligan, 1993). If consumption of certain commodities (such as addictive 
goods) influences an individual's valuation of the future, drug users may be expected to 
have shorter planning horizons. 
Peer effects 
Most economic applications have included peer behaviour as an exogenous determinant 
of individual behaviour (Lewit et al., 1981; Jones, 1995; Sutton and Godfrey, 1995). 
Manski (1993) distinguishes between three different causal mechanisms which would 
give rise to similar patterns of behaviour within groups. Correlated effects arise when 
individuals form groups on the basis of common characteristics or attitudes. Exogenous 
effects relate to environmental or group factors which have a common effect on members 
of the same group. Endogenous effects, on the other hand, pertain to situations in 
which one individual's behaviour has a direct causal influence on the behaviours of 
others within the same group. It is only this latter effect which gives rise to the social 
multiplier which lies behind much of the policy concern with peer effects on behaviour. 
Having distinguished between these three types of effect, Manski (1993) demonstrates 
the difficulty of separating out these effects in cross-sectional data. Rice and Sutton 
(1997) categorise various economic theories of why individuals' preferences and 
224 
CHAPTER 13 
behaviours tend to conform in terms of whether they describe endogenous, exogenous 
or correlated effects. They apply Manski's (1993) framework to the analysis of alcohol-
consumption patterns within households and find significant evidence of correlated (or 
group-selection) effects. They also find evidence of endogenous and/or exogenous effects 
within households, but are unable to distinguish between them. In a US setting, Norton 
et al. (1997) find no evidence of correlated effects in groups defined by school 
attendance. 
Analysis of the supply side of the market 
Applied analyses of the supply side of illicit drug markets have been almost exclusively 
linked to the effectiveness of enforcement interventions in the market. Grizzle (1979) 
did find some evidence of the effectiveness of enforcement. Weatherburn and Lind 
(1997) attempted to link enforcement activity with market outcomes. They correlated 
levels of enforcement seizures with price data in the Sydney heroin market. Allowing 
for time lags between seizures and market outcomes, they found no evidence of an 
effect of enforcement on market conditions. Apart from being rather depressing for 
enforcement agencies, it is rather unclear what can be done with these findings. It 
could be, of course, that the results are a consequence of the data-collection procedure 
(i.e. enforcement is effective but its effectiveness was not measured) or the level of 
aggregation at which the analysis was performed (i.e. enforcement is effective but its 
effectiveness is unmeasurable at this level). More importantly, however, if the results 
are to be trusted, the study gives no guidance as to why enforcement is not effective at 
the margin. This would require a more detailed understanding of the operation of the 
supply side of the market. 
Wagstaff and Maynard (1988) illustrated the potential effectiveness of enforcement 
activity in the UK heroin market using Lewis et al.'s (1985) description of the structure 
of the London heroin market and Polich et al.'s (1984) model of the way in which 
enforcement activity impacts on the market. There were no real estimates available of 
the important parameters in the model and therefore the study became a way to generate 
data demands rather than an applied study of the effectiveness of enforcement. 
Subsequent studies in the US and the UK (Cave and Reuter, 1988; Crawford et al., 
1988; Rydell and Everingham, 1994; Sutton and Maynard, 1994) suffer from similar 
requirements to base effectiveness estimates on a number of parameter assumptions. 
Other studies of the supply side of the market have been broadly descriptive. Dorn et 
al. (1992), for example, provide a taxonomy of supply organisations which is impossible 
to operationalise in an economic model of the market. Chatterton et al. (1995) set out 
to characterise existing descriptions of trading organisations along a number of 
dimensions. An attempt was made to develop measures for some of these dimensions 
and to pilot data collection. Based on self-completion questionnaires from individuals 
attending treatment, an idea of the relative importance of different geographical market 
areas was sought. Respondents were also asked about the nature of trading relationships 
between themselves and the next level up in the supply chain. The vast majority of 
respondents reported using the same dealer either always or usually. Such a pilot exercise 
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indicates that at least at the lowest level, collection of quantitative data on market 
structure is feasible, although no tests of validity, reliability or representativeness were 
attempted. 
Addiction and the effect of price on demand 
Wagstaff and Maynard (1988) reviewed the pre-rational-addiction literature on models 
of the effect of addiction on the price elasticity of demand for addictive goods. In the 
late 1960s and early 1970s, it was widely believed that demand curves for addictive 
goods were perfectly inelastic, in other words that the quantity demanded by an 
individual did not respond in any way to changes in price. 
However, later additions to the debate proposed a range of options that were available 
to drug users in the face of changes (particularly increases) in price: switching to close 
substitutes; entry into treatment; quitting drug use altogether; or reducing consumption 
through decreasing frequency of use and tolerating withdrawal effects (Holahan, 1973; 
Bernard, 1983). Blair and Vogel (1983) suggested that demand may be responsive to 
price at low prices, but that once addicted individuals had reduced their consumption 
to maintenance doses, further price increases would not decrease consumption any 
more. Alternatively, White and Luksetich (1983) proposed that demand would become 
price-responsive at high prices because of difficulties with raising sufficient funds, changes 
in the relative attractiveness of treatment and increased risks of detection by enforcement 
agents. Wagstaff and Maynard (1988) suggested that these arguments related to different 
segments of the demand curve and suggested that this curve may be kinked, with 
elastic segments at the top and bottom and a perfectly inelastic segment in the middle 
price range. 
However, it was not clear whether this hypothesis referred to individuals or the market 
as a whole. The inelastic segment referred to individuals on maintenance doses and 
there was no discussion of whether this range would be common across individuals. 
Recent empirical work by Bretteville-Jensen and Sutton (1996b) failed to find evidence 
of changes in price-responsiveness along the market-demand curve. However their 
results, in common with those of van Ours (1995), suggested that the demand for 
heroin may be considerably more price-elastic than previously thought. The debate 
about the price-responsiveness of different groups of users is mirrored in the economic 
literature on alcohol consumption (Manningetal., 1995; Sutton and Godfrey, 1995). 
The level of analysis remains particularly important in analysing the economic 
determinants of demand patterns. Several studies have demonstrated the wide variability 
in prices paid by individuals within the same market (Bretteville-Jensen and Sutton, 
1996b; Caulkins and Reuter, 1996; Weatherburn and Lind, 1997). Collection of data 
from individual drug users has been shown to be feasible (Johnson et al., 1985; 
Grapendaal, 1992; Chatterton étal., 1995; Bretteville-Jensen and Sutton, 1996b) and 
offers far greater scope than simple analyses of unreliable indicators of market quantities 
and prices. 
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Demand, supply and market equilibrium 
Many studies of the price responsiveness of the consumption of addictive commodities 
refer to the price elasticity of demand rather than consumption. However, economic 
models emphasise that demand remains unobserved in most applications and all that 
is recorded is the quantity traded between demanders and suppliers. In markets where 
the price mechanism operates as assumed (i.e. it brings about equilibrium between 
supply and demand), the relationship between price and quantity traded can be assumed 
to relate to demand if supply is either held constant or controlled for using supply 
variables in the analysis. Where prices do not move to give equilibrium, more complex 
analysis is required such as disequilibrium models (Maddala, 1983; Chapter 10, above). 
Only structural relationships between market variables can be assumed to be 
generalisable between areas, and therefore careful consideration must be given to the 
relationship between demand, supply, prices and market equilibrium. The nature of 
these problems will differ considerably depending on whether the analysis is at the 
market or individual level. 
Analysis of the supply and demand sides of the illicit drug market is further complicated 
by the fact that many users are also small-scale dealers. Bretteville-Jensen and Sutton 
(1996a) found significant differences between dealers and non-dealers in their levels of 
consumption and the ways in which they generated income. In further analysis, they 
found that the ways in which market factors affected the behaviour of these two groups 
also differed markedly. At this level, they found significant effects of prices, income 
levels and potential profit opportunities on individual behaviour. The structural 
relationship between supply and demand decisions by individuals has also been 
discussed by Sommers et al. (1996). 
Conclusions 
Paucity of data is one of the principal reasons why economic-market models have not 
been extensively applied in Europe. However, there are other contributory factors. 
Compared to other disciplines, economists have had relatively little involvement in the 
analysis of drug use and related problems. Economists' involvement in illicit-drug debates 
has been primarily to contribute semantically to the libertarian debate about drug 
legalisation. It is probably fair also to suggest that the credibility or' economic market 
models suffers from both over-simplification by many commentators and the 'non-
results' found in the applied analyses undertaken at market level. 
Given the lack of applications of these models, it is tempting to propose that any research 
project in this area would have considerable 'added value'. However, to be worthwhile, 
an economic analysis of illicit drug markets would require considerable investment and 
a particular blend of researchers. The economic input should be firmly grounded in 
theory, but its thrust should be the application of existing concepts. The 'added value' 
of market analysis would primarily be a better understanding of interactions between 
policy interventions and market outcomes, since existing policy evaluations either ignore 
the role of markets in dictating outcomes (particularly in the context of treatment) or 
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adopt extremely simplistic notions of the market (in the field of enforcement). Economic 
analysis is required to identify structural relationships between different aspects of the 
market. 
There is no restriction on economic-market models as to the size of geographic area at 
which the analysis can be performed. However, individual-level analysis is the most 
clearly formulated and aggregate-level analysis may suffer from aggregation problems, 
such as the ecological fallacy or inappropriate aggregation of non-linear relationships at 
individual level. There is economic literature on the definitions of market areas and 
market segmentation which could be used to define the pertinent geographic area for 
analysis. 
A successful research project in this area would require a substantial amount of resources 
to ensure sufficient data of good quality on levels of consumption, prices and purities. 
This would require economic input into the design of the data collection, but also 
fieldwork by interviewers sympathetic to economic methods and concepts. The 
subsequent analysis and interpretation of the data would need an economist conscious 
of the special (illicit) nature of the phenomenon under study and the consequently 
inevitable trade-off between the importance of academic rigour and the need to obtain 
policy-relevant results. At this time, it would be unlikely that an economist with sufficient 
specialist knowledge could be found and the project would therefore need to be 
multidisciplinar/. 
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G E N E R A L C O N C L U S I O N S 
Richard Hartnoll and Lucas Wiessing 
Modelling has played and continues to play a principal role in various research fields 
such as the economy and public health, especially where macro-level decision-making 
is concerned. Scenario analyses of future trends in demography, AIDS cases or pension 
costs, for example, help to foresee future needs for services and financial reserves. 
Cost-benefit and cost-effectiveness analyses of alternative interventions help to decide 
whether procedures such as hepatitis vaccination or breast-cancer screening are best 
carried out for the general population or best limited to high-risk groups. 
In the drugs field, only a limited amount of such work has been carried out, even 
though the potential for some basic approaches had already been demonstrated in the 
1970s and earlier. It seems almost paradoxical that techniques that are meant to make 
sense of scarce data have rarely been applied in Europe because of a lack of data. An 
additional reason may be that European drugs research and social sciences in general 
have put stronger emphasis on historical or qualitative approaches than, for example, 
in the United States. Also, the European field of drugs research itself was very limited in 
size and resources until quite recently and is still under-funded. However, in recent 
years, the field has been developing rapidly and opening up to other disciplines including 
mathematics, statistics and economics. Data availability and quality are improving and 
the potential to use models to forecast future trends or to estimate hidden processes, 
such as initiation of drug use, has consequently been increasing. 
Quantitative techniques such as modelling should not be applied in isolation. A 
multidisciplinary approach is essential, especially for modellers, who are often highly 
expert in mathematics or statistics but may sometimes have less 'field knowledge' of 
drug use. As the projects that led to this monograph, and their ongoing follow-ups have 
shown, the most useful results of modelling are derived by inter-disciplinary teams of 
mathematicians, statisticians, epidemiologists, economists, sociologists and the medical 
doctors who see addicted patients every day. 
At the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), the 
most obvious complementary element to the European modelling network, of which 
this monograph isan important output, is the European network of qualitative researchers 
(see http://www.qed.org.uk and Understanding and responding to drug use: the role of 
qualitative research. EMCDDA Scientific Monograph No. 4. Lisbon: European Monitoring 
Centre for Drugsand Drug Addiction, 2000). Like the modelling network, this qualitative 
network aims to promote tools and methods to improve understanding of processes, 
hidden populations and usefulness of responses, be it using totally different and highly 
complementary approaches to mathematical and statistical modelling. It is very 
important, both for qualitative and quantitative drug-use researchers in Europe, that 
closer collaboration and mutual understanding of each other's approaches develops. 
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Future directions 
The EMCDDA has already embarked on a cluster of modelling projects as a follow-up 
to the initial reviewing project that resulted in this monograph. These activities are 
centred on three broad aims: 
» bringing together and consolidating European research infrastructure by forming 
networks of researchers, funding meetings for exchange of results and stimulating 
collaborations and joint publications; 
developing priority themes on quantitative epidemiological research of drug use by 
funding small pilot or 'seed' studies meant to be continued by national and more 
robust EU research funding; 
linking the results of the networks and pilot projects to the needs of policy-makers 
by holding joint seminars, focusing research objectives around policy relevant 
questions and presenting results in formats that are understandable by non-specialists. 
Bringing together and consolidating European research infrastructure 
This includes stimulating research initiatives such as writing proposals for larger research 
funding, holding meetings where experts can exchange results and keeping the research 
community informed of new initiatives through presentations at scientific meetings 
and conferences and publication in the EMCDDA Annual report on the state of the 
drugs problem in the European Union, its newsletter Drugnet Europe and its website, 
http://www.emcdda.org. The EMCDDA-funded European modelling network, that 
started with the reviewing project which resulted in this monograph, was consolidated 
at the end of 1998 through a research grant from the EU Commission under the fourth 
framework programme of former Directorate-General XII, Targeted socio-economic 
research (TSER). The EMCDDA took the initiative for writing the research proposal and 
is coordinating the project. This is a so-called 'network project' where funding is mainly 
for regular meetings to exchange results on ongoing work. Six working groups are active 
on the following topics: national prevalence estimation; local prevalence estimation; 
geographic spread; time trends and incidence; costs and cost-effectiveness; and drug 
markets and policy options. The EMCDDA/TSER project has resulted in a series of 
meetings on different themes with participation from over 40 experts in modelling and 
other disciplines. Outcomes to date include more than 30 scientific publications that 
have directly benefited from the project (see http://www.emcdda.org/activities/ 
epidem_tser.shr.ml). 
Developing priority themes on quantitative epidemiological research 
From the 1997 review meetings in York and the May 1998 Lisbon seminar, a number of 
themes emerged that appeared the most relevant to policy-making in the short term as 
well as feasible given the data and expertise available. Given the lack of an overall macro 
picture of drug use in Europe in 1998, the main emphasis was placed on descriptive 
epidemiology. Already in 1996 a seminar held in Strasbourg had highlighted the importance 
of improving methods for estimating the prevalence of problem drug use, using separate 
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approaches for the local and the national levels (see Estimating the prevalence of problem 
drug use in Europe. EMCDDA Scientific Monograph No. 1. Lisbon: European Monitoring 
Centre for Drugs and Drug Addiction, 1997). Additional themes that emerged from the 
modelling meetings in York and Lisbon were: estimation of the incidence of problem drug 
use using back-calculation methods and drug-treatment data; linking geographic information 
systems to forecasting models to investigate and map the geographic spread of problem 
drug use; using economic methods to calculate the health-care and social costs of drug-
related infections and the cost-effectiveness of interventions; modelling drug markets and 
supply-side factors to gauge the potential for policy options aimed, for example, at increasing 
the price of drugs. As descriptive epidemiology improves and more data become available, 
new themes can concentrate further on understanding mechanisms and interrelationships 
at a more detailed level and in a more fundamental way. At the initial meetings, modelling 
micro-diffusion processes was not recommended as it was seen as too difficult to find 
appropriate data. However, more basic analyses are already proving important, as a 
prerequisite for understanding developments at macro level. 
Linking the results of the networks and pilot projects to the needs of policy-makers 
Even if there is an obvious need for a centre such as the EMCDDA, it has been challenging 
to make the link between the interests and priorities of quantitative researchers and policy­
makers. This was related to the themes themselves, the nature of the methods used, the 
types of participants in different meetings and their interests and 'languages', and also to 
the difficult)' of clearly defining the needs of policy-makers and the concept of 'policy­
maker' itself. While the importance of prevalence estimation of problem drug use seemed 
obvious from the beginning and never raised many questions as to its relevance, the wider 
concept of 'modelling' has not always been fully understood by non-modellers in the 
drugs field. Most of the methods that underlie the work of estimating prevalence, incidence 
or cost-effectiveness are hard to understand for non-specialists while the experts themselves 
may often not be used to writing for an audience other than expert readers. Mixing specialists 
and non-specialists at larger meetings proved important but not easy, as the different jargons 
used in some cases resulted in Babylonian discussions. On the other hand, in both York 
meetings, which were held mostly among modellers, discussions often converged on the 
working of different techniques rather than on the highest priorities in drugs policy, reflecting 
the methodological interests of the experts involved. 
In conclusion, it is clear that work remains to be done in explaining the importance of 
using quantitative methods to estimate prevalence, incidence, spread, costs and cost-
effectiveness and the interplay of supply factors in drug markets to non-specialist decision­
makers. It may sometimes be difficult to understand that to obtain a sound evidence base 
in the longer term, some patience is necessary and funding is needed to develop 
methodological infrastructure. It bodes well for the future, however, that despite these 
difficulties a strong network of European modellers has been formed. Results are improving 
quickly in relevance and quality, in parallel to the increasing access to data sources among 
networks of other experts. It is also encouraging that European drug-strategy documents 
are increasingly based on setting quantitative and measurable goals. It is only a matter of 
time before the drugs field will be using these techniques as if they had always been there. 
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